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ABSTRACT OF DISSERTATION 
 
 
TOWARDS AN UNDERSTANDING OF PHARMACOLOGICALLY INDUCED 
INTRACELLULAR CHANGES IN NICOTINIC ACETYLCHOLINE RECEPTORS: 
A FLUORESCENCE MICROSCOPY APPROACH 
 
Upregulation of nicotinic acetylcholine receptors (nAChRs) is a well-documented 
response to chronic nicotine exposure.  Nicotinic acetylcholine receptors are pentameric 
ligand-gated ion channels consisting of alpha (α2-10) and beta (β2-4) subunits.  Nicotine, 
an agonist of nAChRs, alters trafficking and assembly of some subtypes of nAChRs, 
leading to an increase in expression of high sensitivity receptors on the plasma membrane.  
These physiological changes in nAChRs are believed to contribute to nicotine addiction, 
although the mechanism of these processes has not been resolved.  Recently, many studies 
have converged on the idea that nicotine induces upregulation by an intracellular 
mechanism.  In this dissertation, expression levels of nAChRs were quantified upon 
exposure to nicotine and its primary metabolite, cotinine.  A pH sensitive variant of GFP, 
super ecliptic pHluorin (SEP), was integrated with a nAChR subunit to study expression 
and trafficking of nAChRs by differentiating intracellular and plasma membrane inserted 
receptors.  In this work, cotinine is shown to increase the number of α4β2 nAChRs within 
a cell.  Cotinine also affects trafficking of α4β2, evident by a redistribution of intracellular 
receptors and an increase in single vesicle insertion events on the plasma membrane.  This 
work shows both nicotine and cotinine alter the overall assembly of α4β2 to favor the high 
sensitivity (α4)2(β2)3 version.  Since cotinine and nicotine induce similar physiological 
changes in nAChRs, the metabolite potentially plays a role in the mechanism of nicotine 
addiction. 
Although an intracellular mechanism for upregulation has been supported, a shift 
in assembly to the high sensitivity (α4)2(β2)3 version exclusively in the endoplasmic 
reticulum has not previously been detected.  In order to study organelle specific changes in 
stoichiometry, a novel method was developed to isolate single nAChRs in nanovesicles 
derived from native cell membranes.   Separation of nanovesicles originating from the 
   
endoplasmic reticulum and plasma membrane, encompassing isolated nAChRs, allows 
precise changes in stoichiometry to be monitored in subcellular regions.  In this work, 
single molecule bleaching steps of green fluorescent protein (GFP) encoded in each alpha 
subunit of the pentamer are detected.  The number of bleaching steps, or transitions to a 
nonfluorescent state upon continuous excitation, corresponds to the number of GFP-
labeled alpha subunits present.  Therefore, the stoichiometry can be deduced by detection 
of two bleaching steps, as in (α4)2(β2)3, or three bleaching steps, seen in (α4)3(β2)2.  Using 
this method on isolated nAChRs, a shift to assembly of high sensitivity (α4)2(β2)3 receptors 
is detected definitively within the endoplasmic reticulum.  In addition, an increase in 
(α4)2(β2)3 receptors located on the plasma membrane is shown when nicotine is present.  
This work provides convincing evidence that nicotine acts intracellularly, within the 
endoplasmic reticulum, to alter stoichiometry of nAChRs. 
 
KEYWORDS: nicotinic acetylcholine receptors, nicotine, cotinine, fluorescence 
microscopy, total internal reflection fluorescence microscopy, single molecule 
photobleaching 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
1.1   Nicotine History and Usage  
1.1.1   Tobacco Consumption  
 Smoking harms almost every organ in the body, making tobacco consumption the 
leading preventable cause of death [1, 2]. The use of tobacco products began as early as 
5000-3000 BC [3], and, despite health warnings, still affects an estimated 1 billion people 
world-wide today [2].  In the United States alone, more than 480,000 deaths are due to 
cigarette smoking.  This is approximately one in five total deaths annually, or 1300 deaths 
every day [4]. On average, smokers die approximately 10 years earlier than non-smokers, 
with up to half of tobacco users dying as a result of prolonged tobacco consumption [1, 2].  
Tobacco use results in an increased risk for developing lung diseases, cardiovascular 
disease, chronic obstructive pulmonary disease (COPD), diabetes and several types of 
cancer [1, 4, 5].  Many smokers are aware of these risks, with 68.9% of adult smokers in 
the United States claiming they would like to stop smoking.  However, the additive 
component in tobacco, nicotine, is one of the primary barriers in successful smoking 
cessation  [6-9].  Nicotine acts as an agonist of nicotinic acetylcholine receptors (nAChRs).  
These receptors are also activated by the endogenous neurotransmitter acetylcholine [10].  
It is well documented that chronic nicotine exposure induces a variety of physiological 
changes in nicotinic acetylcholine receptors (nAChRs), leading to an undefined link 
between nAChRs and nicotine addiction. 
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1.1.2   Nicotine 
 Nicotine has a long history of being cultivated and used by humans due to its vast 
pharmacological effects.  (S)-Nicotine is the most abundant alkaloid isolated from the 
tobacco plant, Niotiana tabacum, and has been manufactured into a variety of tobacco 
products.  The concentration of nicotine varies greatly between types of products and 
species of tobacco used, but typically accounts for 1-2% of the dry tobacco weight and 
around 3-8% of a tobacco product [11, 12].  The most typical form of use is smoking, in 
which nicotine is vaporized and inhaled along with other toxic substances such as carbon 
monoxide, carbon dioxide, hydrogen cyanide, other carcinogenic components, and 
numerous aldehydes and ketones.  Also,  since nearly 75% of the volatiles emitted from a 
cigarette enters the environment [13], nonsmokers exposed to second hand smoke in their 
environment are also at risk for developing lung cancer and other smoke exposure related 
diseases [14].   Nicotine is rapidly absorbed throughout the body, reaching the brain within 
8 seconds of inhalation [15].  This allows a smoker to titrate their dose, or vary the rate and 
intensity of puffs on a cigarette, to achieve a desired effect.  Nicotine is reported by users 
to enhance cognitive and psychomotor behaviors [16-19], but is also inherently toxic and 
increases blood pressure and heart rate.  Tobacco is also thought to be addictive, causing 
moderate changes in nicotine-rewarded learning processes within the brain [20].  Model 
systems have shown that low concentrations of nicotine have measurable physiological 
effects.  In smokers, these effects are primarily mediated by the nicotinic acetylcholine 
receptors (nAChRs), where nicotine binds as a full agonist. 
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1.1.3   Cotinine, the Primary Metabolite of Nicotine 
 Once consumed, approximately 80% of nicotine is metabolized to cotinine by the 
enzyme cytochrome P450 2A6 [21-24].  Nicotine and cotinine are very similar in structure, 
varying by only an acetyl group [25], as shown in Figure 1.1.  Tobacco exposure leads to 
the accumulation of cotinine in the body due to cotinine's long pharmacological half-life 
of approximately 20-24 hours, which is about ten times that of nicotine [3, 26].   This 
accumulation is highly dependent on the rate of cotinine formation in combination with the 
rate of cotinine removal, both of which are mediated by the cytochrome P450 2A6 enzyme.  
Variations in the gene coding for this enzyme, CYP2A6, have been linked to differences 
in rate of cotinine accumulation between individuals [3, 25].  Lower levels of cotinine are 
seen in individuals expressing a shorter form of CYP2A6, such as CYP2A6*4 [27], while 
cotinine accumulates in individuals with slower CYP2A6 activity [28].  Also, rates of 
cotinine clearance from the body vary between ethnic groups, with African Americans 
showing less cotinine clearance than Caucasians [29-31], possibly due to the frequency of 
reduced function variants of the CYP2A6 gene.   Individuals that prefer menthol cigarettes 
also have higher levels of cotinine in their bloodstream compared to other smokers, 
regardless of genetic background [32].  One possible reason for this is that menthol soothes 
airway irritation, which may allow smokers to inhale more nicotine.  Menthol may also 
slow the metabolism of nicotine, causing higher concentrations of nicotine and metabolites 
to accumulate [33, 34].  Recent studies suggest menthol increases expression of some 
nAChR subtypes [35, 36]. Taken together, these variations lead to differences in cotinine 
levels between individuals with the same tobacco exposure. 
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Figure 1.1 Structures of nicotine and cotinine.   Nicotine and its primary metabolite, 
cotinine, differ in structure by only an acetyl group.  Nicotine is metabolized to cotinine 
by the enzyme cytochrome P450 2A6.  
   
5 
 
 Traditionally, cotinine has been used as a biomarker for nicotine exposure [14].  
The effective concentration of nicotine and other compounds that are absorbed from a 
cigarette is not directly related to the number of cigarettes consumed.  Cotinine is used to 
assess the amount of nicotine ingested by smokers as well as secondhand exposure in 
nonsmokers. On average, manufactured cigarettes contain between 6 and 12 mg of 
nicotine, although the amount of nicotine entering the bloodstream of a smoker varies 
greatly [13].    Cotinine as a biomarker enables the assessment of a correlation between 
tobacco consumption and risk of disease compared to unexposed controls.  It meets criteria 
for a good biomarker, such its specificity for nicotine exposure and easy detectability.  
Cotinine is more ideal as a biomarker than nicotine due to its longer pharmacological half-
life, meaning detected concentrations are less reliant on the time of sampling than in 
measuring nicotine [14].  For these reasons, cotinine has long been thought of as nothing 
more than a convenient biomarker to link tobacco exposure to risk of disease. 
  Recently, cotinine has generated some interest as a pharmacologically active 
compound.  Cotinine has been shown to reduce effects of chronic stress such as synaptic 
loss, anxiety, and depression [37].  It has also been shown to facilitate increases in cognition 
and executive function [23], and improvements in memory, learning, and attention  [25, 
38].  Although nicotine is addictive, increases blood pressure and heart rate, and is 
inherently toxic  [39], exposure to cotinine does not lead to these effects and is not 
considered addictive [14].  Cotinine is also able to cross the blood-brain barrier [40] and 
acts as a partial agonist to nicotinic acetylcholine receptors [41-44], and therefore may be 
at least partially responsible for physiological effects previously attributed to nicotine 
exposure. 
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1.2   Nicotinic Acetylcholine Receptor Structure and Assembly 
1.2.1   Neuronal Nicotinic Acetylcholine Receptor Overview 
 Nicotinic acetylcholine receptors (nAChRs) are ligand-gated transmembrane ion 
channels, activated by the endogenous neurotransmitter acetylcholine.  nAChRs are cation-
selective, ionotropic members of the cys-loop superfamily of receptors, expressing 
throughout the central and peripheral nervous systems [45, 46].   nAChRs primarily 
mediate fast synaptic transmission in the periphery and modulate neurotransmitter function 
in the central nervous system [47, 48].  The cys-loop superfamily includes other receptors 
that function as cationic or anionic ion channels [49].  Cationic members are 5-HT3 (5-
hydroxytryptamine) receptors, in addition to nAChRs.  Anionic channels include GABAA 
(γ-aminobutryic acid), GABAc, and glycine receptors.  The cys-loop superfamily is 
characterized by a large N-terminal extracellular domain containing a stable cys-loop of 
two cysteine residues linked in a disulfide bridge around 13 hydrophobic amino acids [46, 
50-52]. As ligand-gated ion channels, nAChRs are functional upon activation by an 
agonist, such as acetylcholine or nicotine, which induces a conformational change in the 
extracellular region of the receptor to open the channel, allowing the flux of cations such 
as Na+, K+, or Ca2+ on the timescale of microseconds to milliseconds [45, 46].  Another 
functional characteristic of nAChRs is that they desensitize, or decrease in response to 
agonist, after repeated activation, much faster than any other ion channel.  Upon 
desensitization, nAChRs adopt a high affinity, non-conducting conformation, in spite of 
agonist binding [53, 54]   This desensitization is more prevalent for the cation channels, 
such as nAChR, than typical anion channels [55].  For α4β2 nAChRs, this desensitization 
happens within seconds to a few minutes of agonist exposure. [56].  It is also noteworthy 
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that many nAChRs are thought to be desensitized when exposed to typical levels of 
nicotine seen in smokers [57, 58].  Upon nAChR activation, these membrane receptors are 
involved in the rapid, phasic effects of acetylcholine in the brain, leading to the release of 
essential neurotransmitters, including dopamine, serotonin, glutamate, and γ-aminobutyric 
acid (GABA) [45].  For this reason, there has been significant interest in targeting nAChRs 
to treat numerous neurological disorders such as Alzheimer’s disease, Parkinson’s disease, 
epilepsy, ADHD, schizophrenia, and tobacco addiction [59-65].  
 
1.2.2   nAChR Subunits and Assembly 
 A substantial challenge in using nAChRs as drug targets rises from the complex 
diversity of nAChR subtypes.  Mature nAChRs are pentameric, formed by the assembly of 
five individual subunits around a central hydrophilic pore, as illustrated in Figure 1.2.  
Neuronal subunits are categorized as alpha (α2-α10) and beta (β2-β4) subunits [45, 46, 52, 
66], with each pentameric combination differing in expression, distribution, physiological 
and pharmacological properties throughout the nervous system.  Each subunit weighs 40-
70 kDa, contributing to an assembled pentamer with a mass of 270-300 kDa [67].  There 
are nine alpha (α2, α3, α4, α5, α6, α7, α9, α10) and three beta (β2, β3, β4) subunits 
expressed in the human brain, each encoded by a distinct gene.  After translation, free 
subunits are assembled into pentameric receptors in the endoplasmic reticulum, and 
trafficked to the plasma membrane to function as an ion channel. 
 Since functional nAChRs are a combination of five individual subunits, multiple 
subtypes can be assembled.  Subtypes are broadly classified as homopentamers or  
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Figure 1.2 Structure of nAChRs.  (A) Cartoon of a pentameric nAChR.  Functional 
nAChRs are cation channels with ligand binding between adjacent subunits.  (B) Each 
subunit has a large N-terminal, a cys-loop, four TMDs, a variable loop between TM3 
and TM4, and a short C-terminal.  Alpha subunits have a cys-cys pair involved in 
binding.  (C) Crystal structure of (α4)2(β2)3 with α4 subunits shown in green and β2 
subunits shown in blue.  Spheres represent nicotine (red), sodium (pink), and disulfide 
bonds (yellow).  (D) Perpendicular view of the (α4)2(β2)3 crystal structure from the 
extracellular region.  
 
 
 
 
 
C and D: Reprinted by permission from Macmillan Publishers Ltd: [Nature]  
(Morales-Perez CL, Noviello CM, & Hibbs RE (2016) X-ray structure of the human 
alpha4beta2 nicotinic receptor. Nature. 538(7625): 411-415), copyright (2016). 
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heteropentamers.  Homopentamers consist of five identical subunits, with a binding domain 
between each subunit, as seen in α7 or α9 subtypes.  Heteropentamers are a combination 
of five alternating alpha and beta subunits.  These subtypes require at least two essential 
alpha and two essential beta subunits, with two orthosteric agonist binding sites between 
adjacent alpha and beta subunits [68-71].  A recent crystal structure of (α4)2(β2)3 shows 
that this heteropentamer has a peudo-symmetrical cylindrical shape around the axis of the 
channel, as shown in Figure 1.2C.  These alternating subunits are in a specific α4-β2-α4-
β2-β2 order around the hydrophilic pore (Figure 1.2D) [54]. 
 Although slight differences between subunits give rise to distinct pharmacological 
properties, all subunits show substantial sequence homology.  Overall, the genes that 
encode neuronal nAChRs are 40-55% homologous [67].  As a result, all subunits have a 
similar linear amino acid sequence, with an approximately 200 amino acid extracellular N-
terminal, four alpha helical transmembrane (TM) domains packed around the hydrophilic 
pore, a variable loop between TM3 and TM4, and a short extracellular COOH-terminal 
domain, as shown in Figure 1.2B.  Homology is highest throughout the transmembrane 
domains, as well as certain portions of the extracellular region involved in binding.  TM2 
of each subunit lines the hydrophilic pore, along with a portion of TM1 [72].  This 
transmembrane region is involved in gating cations passing through the pore, by action of 
a series of electronegative glutamic acid residues [73]. The residues in TM2 allow ion flux, 
selectivity, and channel conductivity.  Opposite of this lies TM4, which interacts with the 
hydrophobic lipid bilayer.  TM1 and TM3 are perpendicular to these, completing the helix 
bundle [46].  The largest intracellular domain, a variable region between TM3 and TM4, 
is highly diverse between subunits [74].  The structure, suspected to be a mix of α-helices 
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and β-strands, is involved in regulation, desensitization, and specific cellular functions of 
each unique subunit.  Recently, a crystal structure of (α4)2(β2)3 confirmed an amphipathic 
MX helix in this intracellular region [54].  Within this TM3-TM4 region, trafficking motifs 
specific to a particular subunit are present. These trafficking motifs control trafficking of 
assembled pentameric receptors out of the endoplasmic reticulum [75, 76].  To date, it is 
known that export LXM motifs (where X is any amino acid), located in the TM3-TM4 loop 
of α4, α3, and β4 subunits, govern trafficking out of the endoplasmic reticulum (ER).  Also, 
a retention RXRR motif in the β2 subunit is associated with retention in the ER [76].  The 
large extracellular NH2 domain has an overall β-barrel configuration.  A recent crystal 
structure of (α4)2(β2)3 shows this extracellular N-terminal is composed of α-helices and 
ten β-strands [54].  This extracellular region contains the cys-loop, a cys-cys pair, and 
critical amino acid residues involved in binding [45, 46, 52]. Although the cys-loop is 
highly conserved, slight variations in residues within each subtype are partially responsible 
for differences in ligand binding response, signal transduction, and kinetics.  
Since nAChRs are ligand-gated ion channels, ions pass through the pore as a result 
of an agonist binding in a binding site.  This is traditionally within the orthosteric binding 
pockets located at the interface of essential alpha and beta subunits for a heteromeric 
receptor, or between alpha subunits in a homomeric receptor.  This binding within the β-
barrel of the large extracellular domain results in a conformation change, rotating TM2 of 
each subunit towards an open conformation to allow ion flux.  The alpha subunit is required 
at the front, or "positive" side of the binding site, where the cys-cys pair is located alongside 
hydrophobic residues to determine ligand affinity.  The back, or "negative" side of the 
binding site then is in the adjacent subunit, often a beta subunit, where key residues 
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determine ligand selectivity [46].  Loops A, B, and C from the alpha subunit, and loops D,  
E, and F from the beta subunit, come together to complete the orthosteric binding site at 
the interface of these subunits [54].   
All alpha subunits are traditionally distinguished by the presence of two vicinal 
cysteines at positions 191 and 192, known as the cys-cys pair, within the extracellular 
domain near TM1.  This cys-cys pair is necessary for agonist binding, in addition to key 
hydrophobic residues within the alpha subunit.  These are primarily aromatic amino acids, 
known as an “aromatic box”, and include Tyr 93, Trp 149, Tyr 190, and Tyr 198 [45, 46].   
These aromatic residues are thought to stabilize the positively charged endogenous agonist, 
acetylcholine, in a cation-π interaction.  This cation-π interaction is a noncovalent 
interaction between the electron rich π system of the aromatic residues and positively 
charged ligands that bind within this binding pocket, including acetylcholine and nicotine  
[77-79].   The positively charged ligand is also stabilized by electronegativity in the binding 
site from the disulfide bridge and cys-cys pair.   The (α4)2(β2)3 nAChR was recently co-
crystalized with nicotine binding in the orthosteric agonist site.  In this position, nicotine 
is oriented to form the cation-π, with addition stability from aromatic and hydrophobic 
interactions with side chains in the binding pocket [54]. 
In heteropentameric subtypes, the first four positions are alternating alpha and beta 
subunits, with ligand binding occurring at the interface of adjacent subunits.  If the 
heteropentamers consist of just two types of subunits, the fifth position can be occupied by 
either an alpha or beta subunit.  This gives rise to the possibility for different 
stoichiometries to exist for the same subtype of nAChR.  A heteropentamer can assemble 
as either a three alpha, two beta version, (α)3(β)2, or a three beta, two alpha version (α)2(β)3 
   
12 
 
depending on an α or β being incorporated into the fifth position. These two 
stoichiometries, although they belong to the same subtype, differ slightly in terms of 
sensitivity to agonists, expression, or rates of desensitization.  For example, the differences 
in EC50 of the α4β2 subtype as a result of stoichiometry indicate that (α4)2(β2)3 is of higher 
sensitivity to agonists than the alternative low sensitivity (α4)3(β2)2 stoichiometry [80], 
while (α4)3(β2)2 stoichiometry shows higher permeability to calcium [81].  Also, an 
additional agonist binding site was recently discovered at the α4(+)/α4(-) interface of 
(α4)3(β2)2 [82-84].  A recent crystal structure of (α4)2(β2)3 shows differences in the 
negative side of the subunit interface when an alpha versus beta subunit occupies the fifth 
position.  When β2 is present, three hydrophobic groups are located in the potentially 
negative side of this binding pocket.  However, when the fifth position is filled with an α4, 
the hydrophobic groups are replaced with polar side chains.  The presence of polar groups 
in the α4(-) could account for differences in agonist binding to the α4(+)/α4(-) interface in 
(α4)3(β2)2 [54].  It is suggested that occupation of this binding site by an agonist contributes 
to nAChR activation and agonist sensitivity [82, 84].  Different stoichiometries also vary 
in their specificity to pharmacological agents, which plays an important role in utilizing 
these subtypes as drug targets.  In addition, pharmacological agents can preferentially 
induce the expression of one stoichiometry over another.  This is the case after exposure to 
nicotine, for nicotine has been shown to alter the expression of α4β2 stoichiometry to favor 
(α4)2(β2)3 [85]. 
Although the first four positions are alternating alpha and beta subunits, the fifth 
position can be occupied with an additional alpha or beta subunit, or an accessory subunit 
such as α5 or β3 [86-88].  Accessory subunits can only be incorporated into the fifth 
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position of a pentamer, as they cannot bind ligands or form functional receptors on their 
own. The α5 subunit possesses the necessary cys-cys pair to be characterized as an alpha 
subunit, but lacks one of the key aromatic residues to enable agonist binding.  In this case, 
the tyrosine in position 198 is substituted for an aspartic acid residue, unable to participate 
in the cation-π interaction required to stabilize an agonist.  In the case of the β3 subunit, a 
tryptophan residue in loop D is absent, preventing ligand binding on the complementary 
face [89].  Incorporation of an accessory subunit can further alter receptor trafficking or 
function.  For example, it has been shown that the α4β2α5 and α4β2β3 subtypes have 
higher calcium permeability than (α4)2(β2)3, comparable to (α4)3(β2)2 [81].  The β3 subunit 
also mediates striatal dopamine release in α6* containing nAChRs [88]. 
 
1.3 Major nAChR Subtypes and Distribution 
 In the central nervous system, the most abundant subtypes of nAChRs are 
composed to α4, β2 and α7 subunits, as shown in Figure 1.3.  Other subunits are localized 
to more specific regions of the brain, such as α6, or can also be found throughout the 
peripheral nervous system, such as α3 and β4.  The majority of nAChR capable of binding 
nicotine with high affinity are thought to be α4β2* [90].   Due to a possibility of the 
inclusion of other types of subunits, IUPHAR nomenclature includes an asterisk (*) to 
signify other subunits may be present in the pentamer.  In general, neuronal nAChR are 
primarily located on the presynaptic terminus.  Here, nAChRs are the target of tonically 
released acetylcholine, and are believed to modulate neurotransmitter release [91]. 
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Figure 1.3 Major nAChR subtypes in the brain.  The most common subtypes in the 
brain contain β2* subunits.  Subtypes containing α6, α3 or β4 are localized to more 
specific regions. 
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1.3.1   α4β2* Subtype 
 The α4β2* subtype accounts for more than 90% of high affinity binding sites within 
the brain [92, 93].  In β2 knock-out models, all high affinity nicotine binding sites are 
eliminated [94].  Knocking out α4 decreases high affinity binding sites, but compensation 
from other α subtypes is possible in these models [95].  This suggests the majority of 
nAChRs are, at least partially, composed of α4 and β2 subunits.  The α4β2 subtype has a 
100-fold higher affinity to nicotine than any other subtype, with Ki equal to 1-3 nM [96].  
The α4β2* is also the subtype with the highest functional sensitivity to nicotine, inducing 
a response at a concentration of 116 nM in the high sensitivity (α4)2(β2)3 stoichiometry and 
2700 nM in the low sensitivity (α4)3(β2)2 stoichiometry in clonal cell lines [80, 97-99].  
The low sensitivity (α4)3(β2)2 stoichiometry also shows higher permeability to calcium 
[81].  Overall, the α4β2* subtype is recognized by high affinity for nicotine. 
The highest levels of this subtype are typically found within the midbrain regions 
and cortex, making them important mediators of memory, cognition, and sensory 
processing [45, 51].  Nicotine induced activation of subtypes containing α4* are required 
for nicotine reward, tolerance and sensitization [100].  The α4β2* subtype, particularly the 
β2 subunit, is required for systemic nicotine reinforcement [101-104].  Specifically, β2 
present in the ventral tegmental area (VTA) is crucial for nicotine self-administration and 
tolerance [18, 105, 106].  Beta 2 knock-out models also show a decrease in cognitive 
function, while α4 knock-out models lose neuroprotective effects and conditioned place 
preference for nicotine [100, 107].  These data suggest α4β2 plays a role in rewarding 
properties of nicotine.  
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1.3.2   α6β2* and β3 Subtypes 
 α6* subtypes are characterized by selective antagonism to α-conotoxin MII [108].  
As another subtype containing the β2 subunit, α6β2* is also required to establish systemic 
nicotine reinforcement and self-administration. The α6 subunit is often coexpressed with 
α4, as seen in the dopaminergic neurons of the VTA, although each cannot functionally 
compensate for the absence of the other in knock-out models [18].  Alpha 6 subunits are 
typically localized to dopaminergic neurons, such as within the VTA, substantia nigra, and 
locus coeruleus [109, 110].  The α6 subunit has also been shown to contribute to the 
locomotor stimulating effects of nicotine, potentially due to enhanced transmission in these 
regions [111, 112].  An accessory subunit, β3, often assembles with the α6β2 subtype.  The 
gene coding for this subunit is part of the CHRNB3/CHRNA6 gene cluster on chromosome 
8, along with α6 [113].  Addition of β3 is shown to impact striatal dopamine release and 
related behaviors [88].  Incorporation of the β3 subunit also increases expression of α6β2 
and alters the response to nicotine [114, 115]. Together, α6β2* subtypes may be involved 
in nicotine reward and withdrawal [116]. 
 
1.3.3   α7* Subtype 
 The α7 subtype typically exists as a homopentamer, but recent evidence suggests 
β2 can also be incorporated into the functional pentamer [117-119].  The α7 subtype is the 
second most common subtype in the brain.  Unlike α4β2, α7 has a very low affinity for 
nicotine, but is able to bind the muscle-type antagonist, α-bungarotoxin, with high 
specificity [10, 120].  This subtype is characterized by fast activation, fast rates of 
desensitization, and high calcium permeability [64, 121], giving it a role in slower calcium 
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dependent intracellular signaling [122].  It is involved in recent learning and neuronal 
plasticity [123], in addition to rapid signaling and neurotransmitter release.  The α7 subtype 
is distributed throughout the brain, and is most prominent in the hippocampus, 
hypothalamus, and cortex regions [45].  Data from α7 knock-out mice suggest this subtype 
may mediate long term effects of nicotine, but is not involved in the acute rewarding effects 
of nicotine [18].  
 
1.3.4   α3β4* and α5 Subtypes 
The ganglionic nAChR subtype, α3β4, are localized to very specific regions of the 
brain, such as the thalamus, medial habenula, and interpenduncular nucleus, but express 
abundantly throughout the peripheral nervous system [124, 125].  They have a lower 
affinity for nicotine than α4β2*, and are therefore less likely to be desensitized at the 
concentrations of nicotine often seen in smokers [126].  Although α3 knockout mice suffer 
from high perinatal mortality, β4 knockouts have provided insight into the role of α3β4 on 
nicotine-mediated behaviors.  The β4 subunit has been connected to the aversive properties 
of nicotine, including effects of withdrawal [127], seizures [128], and anxiety [126].  In 
addition, overexpression of β4 increased nicotine self-administration [126]. 
 The α3 and β4 subunits are often co-expressed with an accessory subunit, α5.  The 
α5 is therefore often incorporated into the fifth position of the α3β4 pentamer.  The genes 
coding for these three subunits are part of the CHRNA5/CHRNA3/CHRNB4 gene cluster 
on chromosome 15q25 [129-131].  Incorporation of the α5 subunit alters desensitization 
and calcium permeability in α3* nAChRs [132].  Knock out models of α5 self-administer 
greater amounts of nicotine, and have higher rates of desensitization on dopaminergic 
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neurons [133].  The accessory α5 can also be assembled with α4β2*, where it increases 
receptor function [134].  Single nucleotide polymorphisms within the 
CHRNA5/CHRNA3/CHRNB4 gene cluster have also been connected to an increased risk 
of nicotine dependence and small-cell lung cancer causally related to cigarette smoking 
[135-138].  One such variant is a single nucleotide polymorphism in the α5 sequence that 
translates to an amino acid change from aspartic acid to asparagine at position 398 (α5-
D398N) [139, 140].  This D398N variant increases the risk of tobacco dependence by about 
30% in individuals with just one allele with the polymorphism, and is also associated with 
the "pleasurable buzz" from tobacco use [141].  Although α5 does not appear to influence 
the development of nicotine dependence, this subunit might affect self-administration of 
nicotine.  Together, α3β4α5 may play a modulatory role in nicotine reward pathways.   
 
1.4   Nicotine Induced Upregulation of nAChRs 
1.4.1   Upregulation of α4β2* in the Brain 
 In vivo fMRI and PET measurements have shown that smokers have 25-330% more 
nAChRs compared to non-smoker [142-144].  Chronic nicotine exposure is known to alter 
reward systems within the brain.  It is suspected that nicotine alters dopamine reward 
circuits to increase their sensitivity to successive nicotine exposure.  Some studies suggest 
nicotine dependence is initiated by activation of the ventral tegmental area, ultimately 
resulting in dopamine release into the nucleus accumbens [145, 146].  Regardless, nicotine 
exposure increases dopamine release in midbrain regions [57, 147-149].  In an attempt to 
resolve a mechanism for these changes, upregulation of nAChRs as a result of nicotine 
exposure has been given significant interest.  Countless articles have implicated 
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upregulation in the addictive nature of nicotine [6, 45, 46, 55, 64, 66, 76, 150, 151].  Since 
its discovery in 1983, the definition of upregulation has evolved to fit current evidence, 
although a mechanism of this upregulation is yet to be resolved.  At this time, nAChR 
upregulation is considered an increase in receptor number, as well as changes in trafficking 
and stoichiometric assembly [55, 97, 152-155].   Due to complex cellular processes that 
affect upregulation, the mechanism and functional consequences are yet to be understood.  
However, it is now accepted that this upregulation is post-translational, evident by a lack 
of change in receptor subunit mRNA levels [150, 156].  It is therefore believed that post-
transcriptional mechanisms are responsible for increases in nAChR abundance. 
 The upregulation of nAChRs is brain region and cell type specific.  Upregulation 
is robustly measured in the brainstem, cerebellum, prefrontal cortex, and hippocampus 
[156-159].   Other regions, such as the thalamus and medial habenula, appear to be less 
affected, if at all [160, 161].  In some regions, such as the VTA and substantia nigra, a cell-
specific effect has been reported.  In the midbrain, α4* nAChRs upregulate in GABAergic 
neurons of the VTA, substantia nigra pars reticulata (SNr), and substantia nigra pars 
compacta (SNc) [158, 162].  In contrast, no upregulation has been detected on 
dopaminergic neurons of these regions.   Differences in α4* containing subtypes and 
stoichiometries between these regions has been proposed as a possible explanation.   It is 
suggested that GABAergic neurons in these regions contain α4β2α5 nAChRs, in addition 
to α4β2 [163].  Nicotine might alter the incorporation of α5, leading to an upregulation of 
receptors.  However, dopaminergic neurons in these regions express many variations of 
β2* containing nAChRs, including α4β2*, α4α6β2*, and α6β2* [164, 165].  The lack of 
upregulation seen in dopaminergic neurons may suggest that α4β2* are assembled with 
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other subunits, such as α6.   The upregulation of α4β2* is accompanied by an increase in 
sensitivity to nicotine [166].  This is thought to be the result of an increase in the number 
of high sensitivity (α4)2(β2)3 stoichiometry receptors in relation to (α4)3(β2)2 stoichiometry 
[81, 97, 154, 167].  As a result of chronic nicotine exposure, nAChRs respond to lower 
concentrations of acetylcholine and other agonists as the sensitivity to stimulation is 
increased.   
The pharmacological consequences of these changes in α4* expression are not well 
defined.  Some studies suggest the increase in α4* of the GABAergic neurons of the VTA 
increases the baseline firing rate and excitatory effect of nicotine in these neurons, while 
the baseline firing rate and excitatory effects are decreased in dopaminergic neurons.  This 
would mean it is possible that upregulation on GABAergic neurons increases inhibition of 
dopaminergic neurons in the VTA [162, 168, 169].  Other studies have shown nicotine 
increases firing frequency of dopaminergic neurons of the VTA [145, 146].  These 
measurements could be subtype dependent.  The α6 subunit is robustly expressed in 
dopaminergic neurons of the VTA, and therefore is likely to co-assemble with α4 and β2 
subunits in this region.  However, the functional role of α6* within this region is not fully 
resolved [18, 112].  Based on current studies, it is likely that α4* and α6* subunits affect 
the function of dopaminergic neurons in the VTA. 
   
1.4.2   Effects of Other nAChR Ligands 
 Most smoking cessation agents on the market today have targeted the α4β2* 
subtype.  One such drug, cytisine, is an alkaloid isolated from the seeds of Cytisus 
laborinum.  This drug has been available for more than 40 years.  It is currently available 
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in Europe [151, 170-172], and has a similar efficacy to FDA-approved drugs available in 
the United States [173, 174].  Cytisine acts as a partial agonist at α4β2, and a full agonist 
of α7 and α3β4 [151].  Cytisine has been shown to upregulate α4β2, as well as alter the 
stoichiometry.  While nicotine increases the assembly of the high sensitivity, (α4)2(β2)3 
isoform, previous studies suggest cytisine exposure results in a preference for the low 
sensitivity, (α4)3(β2)2, receptor at the plasma membrane [85, 151, 154].  A potential 
explanation for this difference lies in recent evidence that an additional binding site for 
cytisine exists at the α/α interface within (α4)3(β2)2 [82, 175].  Another α4β2 partial agonist, 
varenicline, is available as a smoking cessation agent in the United States [176].  This drug, 
a derivative of cytisine, also acts as a full agonist at α7 nAChRs, and exhibits weak actions 
at α3β2 and α6β2 [177].  Varenicline has also been shown to increase expression of α4β2 
[176, 178], and may decrease α6β2 nAChRs.  Mecamylamine, a nonselective nAChR 
antagonist, also facilitates smoking cessation [179].  However, it is not commonly used in 
smoking cessation today due to its widespread ganglionic side effects.   This drug is a 
noncompetitive open channel blocker that also upregulates α4β2 nAChRs [150].  
Bupropion, originally marketed as an antidepressant in 1989, has also been approved as a 
smoking cessation agent [180, 181].  Recently, bupropion was determined to act as a 
noncompetitive antagonist of nAChRs.  Photoaffinity labeling studies show bupropion has 
two distinct binding sites on the Torpedo nAChR.  One high affinity site is found in the 
middle of the ion channel, within TM2.  A second site is near the extracellular end of TM1 
within α subunits [181].  Another interesting nAChR ligand, sazetidine A, shows 
stoichiometry dependent binding properties.  This nicotine analog acts as a partial agonist 
at the (α4)2(β2)3 isoform but as an antagonist at the (α4)3(β2)2 isoform [182, 183].  Overall, 
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a variety of pharmacological agents with various binding properties interact with specific 
nAChR stoichiometries or induce upregulation of these receptors, summarized in Table 
1.1.  This is a key factor when targeting specific subtypes for development of more 
effective smoking cessation agents.   
 
1.4.3   Upregulation Theories 
 Upregulation of nAChRs has been measured in a variety of samples, including 
humans, mice, cultured neurons, and clonal cell lines [68, 184, 185].  In both humans and 
rodents, nicotine induced upregulation is detected throughout the midbrain, prefrontal 
cortex, brainstem, and cerebellum [115, 156, 159, 168].  The robustness of upregulation 
suggests a common mechanism is responsible between samples.  However, the exact 
mechanism of upregulation has not been resolved although many suggestions have been 
put forward.  Long standing theories include upregulation as a result of activation or 
desensitization [186].  The assumption was that nAChR activation initiates Na+ and Ca2+ 
flux to alter downstream events.  These theories are being phased out, at least for most 
subtypes, in response to findings that upregulation occurs at concentrations lower than 
required for activation.  Upregulation has been measured at 100 nM nicotine, when less 
than 4% high sensitivity (α4)2(β2)3 are activated, while no low sensitivity (α4)3(β2)2 are 
activated [55].  In addition, antagonists have been shown to upregulate, suggesting ion flow 
is not required for an increase in receptor number [150, 187, 188].  However, the binding 
of ligands to nAChRs is likely necessary for upregulation to occur [187], even if this is 
independent of receptor activation or desensitization.   Although nAChR activation or 
   
23 
 
Table 1.1: nAChR Ligand Properties 
Ligand Type 
Cessation 
Efficacy 
(12 Months) 
nAChR 
Upregulation?
Nicotine Agonist 18% Yes 
Cytisine 
Partial Agonist: α4β2 
Full Agonist: α7, α3β4 
14% Yes 
Varenicline 
Partial Agonist: α4β2 
Full Agonist: α7 
20.5% Yes 
Mecamylamine 
Noncompetitive Antagonist 
Nonselective Open Channel Blocker
40% Yes 
Bupropion 
Noncompetitive Antagonist 
αTM1 or TM2 
15.2% N/A 
Sazetidine A 
Partial Agonist: (α4)2(β2)3 
Antagonist: (α4)3(β2)2 
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desensitization might not be required  for upregulation, both are likely to contribute to 
behaviors related to nicotine addiction [189].  
Another mechanism suggests surface binding is able to increase without an increase 
in receptor number, as receptors change conformation to a high affinity binding state [190, 
191].  This conformational change interpretation suggests upregulation is independent of 
increases in trafficking through the secretory pathway or a net increase in receptors on the 
plasma membrane.  Instead, the mechanism suggests nAChRs transition into an 
“upregulated” high affinity state on the plasma membrane, allowing the same number of 
receptors to bind a higher concentration of ligand [190, 191].  Since other detection 
methods, independent of binding detection, show an increase in nAChR number, this event 
is unlikely to be responsible for robustly measured increases in nAChRs, but is perhaps 
complementary to the primary mechanism of upregulation.     
An increase in nAChR stability on the plasma membrane has also been suggested, 
although contradictory results have been reported for this mechanism.  This includes a 
decreased turnover on the plasma membrane, and slower internalization and degradation 
to result in a net increase in number of nAChRs on the plasma membrane [97, 188].  Early 
studies using high nicotine concentrations found a four-fold increase in the time receptors 
remain on the plasma membrane surface after inhibition of protein synthesis  [188].  
Surface biotinylation in conjunction with more physiologically relevant nicotine 
concentration also show a large increase in half-life of nAChRs on the plasma membrane 
[97].   Increased half-life of nAChRs as a result of decreased ER degradation, and 
consequently increased subunit assembly [191] has also been proposed.  Other studies, at 
varying concentrations of nicotine, fail to detect any differences in nAChR turnover upon 
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nicotine treatment [152, 153, 190], and contribute changes to trafficking.  At this point, it 
is unclear if nicotine increases stability of nAChRs, and perhaps works synergistically with 
other mechanisms to increase membrane expression of nAChRs. 
Recently, evidence has strongly supported the theory that nicotine acts 
intracellularly to induce upregulation, known as “inside-out” neuropharmacology [160].  
Indications for an intracellular mechanism include increased maturation enhancement of 
subunits and pharmacological chaperoning effects in the presence of nicotine [55, 97, 115, 
123, 153].   A pharmacological chaperone binds the target protein and stabilizes this protein 
in its most stable state [160].  These effects are measured at low concentrations of nicotine, 
100-200 nM, that remain in the brain of smokers at a steady state [192, 193].  This 
hypothesis began in the mid 90’s, following evidence that nicotine exposure increased an 
intracellular storage of nAChRs that was undetectable from surface binding mechanisms 
[194].  Further evidence suggests 85% of high affinity [3H]-epibatidine binding sites are 
located intracellularly [195].  Nicotine and other ligands are able to permeate cell 
membranes, interact with intracellular receptors, and alter the expression of nAChRs.  
Intracellular actions of nicotine influence pharmacological chaperoning, matchmaking, and 
intracellular trafficking [152, 160].   In early stages of subunit maturation, glycosylation 
sites are occupied to facilitate movement towards the plasma membrane.  This maturation 
is a slow, inefficient process that dramatically increases in the presence of nicotine [153].  
As a pharmacological matchmaker, nicotine stabilizes subunit-subunit interactions.  FRET, 
Förster resonance energy transfer, measurements have provided evidence that nicotine 
increases these inter-subunit interactions by showing α4 and β2 subunits are in close 
proximity within the whole-cell region measured, which includes the endoplasmic 
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reticulum [115, 196, 197].  As a pharmacological chaperone, nicotine would act as a 
stabilizing agent for the lowest energy conformation of nAChRs.  This requires binding at 
a pharmacologically relevant site on the substrate.   Nicotine then facilitates movement of 
nAChRs through the secretory pathway, ultimately resulting in an increase of nAChRs 
located on the plasma membrane.   It has been shown that intracellular cycling is a 
necessary component for upregulation.  Brefeldin A, an inhibitor of anterograde transport, 
blocks nicotine-induced upregulation [152]. The number of ER exit sites and density of 
nAChRs at these sites is increased, indicating anterograde transport, mediated by COPII, 
is increased [198].  Retrograde transport, mediated by COPI, is also required to achieve 
upregulation.  Mutations of COPI binding motifs prevent upregulation in the presence of 
nicotine without altering the increase in ER exit sites and density [115].  
 Regardless of the mechanism, upregulation involves changes in receptor 
trafficking, subunit assembly including changes in stoichiometry, changes in ER export 
and vesicle transport, and increases in number of receptors on the plasma membrane.  New 
evidence continues to suggest an intracellular mechanism for these processes, but definitive 
evidence of changes within the endoplasmic reticulum are yet to be resolved.  Future efforts 
in the development of therapeutics may target similar substrates as nicotine, and modulate 
pharmacological chaperoning and intracellular trafficking as well.  Therefore, 
understanding the mechanism of nicotine induced upregulation is vital to understanding 
the process of nicotine addiction.   
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1.5   Novel Methods to Study nAChRs 
1.5.1   Fluorescence Microscopy 
 Advances in the understanding of nAChR expression and upregulation are, in part, 
due to improvements in measurement techniques.  In the last two decades, the use of 
fluorescence microscopy has expanded rapidly in biological imaging.  Fluorescence 
microscopy has allowed investigators to monitor protein dynamics, study protein 
interactions and expression, resolve structures, and determine cellular pathways.  
Fluorescence measurements are enabled by labeling proteins and subcellular components 
with fluorescent probes.  Such labels are often fluorophore conjugated antibodies, stains, 
organic dyes [199, 200], quantum dots [201], or fluorescent proteins.  The ability to 
selectively label biomolecules of interest, coupled with high sensitivity detection, makes 
fluorescence microscopy an exceptionally powerful technique. 
 Fluorescent probes, or fluorophores, are able to specifically identify target cells, 
proteins, or subcellular components amongst nonfluorescent background.  This is possible 
because fluorophores are excited by specific wavelengths of excitation and subsequently 
emit light of longer wavelength.  The most basic principle of fluorescence microscopy is 
to excite the fluorescent component of the sample with the desired wavelength, and collect 
exclusively the emitted fluorescence from the sample, demonstrated in Figure 1.4.   
Separation of excitation and emission wavelengths is accomplished using appropriate 
filters.   The wavelength of excitation, typically from a laser or lamp, passes through an 
excitation filter to allow passage of only the specific, desired wavelength.  The filtered 
wavelength then reflects off a dichroic mirror before passing through the objective towards 
the sample.  Once the excitation wavelength reaches the sample, fluorophores emit a longer 
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Figure 1.4 Basic setup of a fluorescence microscope.  The excitation beam passes 
through a bandpass (BP) filter, reflects off a dichroic mirror, and passes through the 
objective lens before reaching the sample.  Upon excitation, fluorophores in the sample 
emit a longer wavelength of radiation that is able to pass through the dichroic mirror 
and a bandpass filter to be collected by a detector. 
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wavelength of light.  This emission is collected by the objective before subsequently 
passing through a barrier filter blocking the stronger, shorter excitation wavelength.  Also, 
since the emission wavelength is longer than that of excitation, it is able to pass through 
the dichroic mirror towards the detector.  The intensity of emission is quantifiable, as it is 
a relative measure of concentration of fluorophore present.    
 
1.5.2   Green Fluorescent Protein and Derivatives 
A key milestone in the advancement of fluorescence microscopy was the discovery 
of green fluorescent protein (GFP) [202, 203].  GFP, like all fluorescent proteins, are 
genetically encoded reporter molecules.  The primary amino acid sequence for GFP is 
directly incorporated into the amino acid sequence of the protein of interest.  Since 
expression of the fluorophore is genetically linked to expression of the protein of interest, 
sensitivity is increased and nonspecific binding issues are eliminated [203].   Since its 
isolation from the Aequorea victoria jellyfish in 1991, GFP has been crystallized [204] and 
cloned [205].   Since these early studies, GFP has been engineered to produce a wide class 
of fluorescent proteins, varying in wavelengths of excitation or emission across the visible 
spectrum [203]. 
The 27 kDa structure of GFP consists of 11 beta-sheets folded into a beta-barrel, 
with an alpha-helix located along the central axis, as shown in Figure 1.5 [206].  This 
structure is essential to stabilize the tripeptide that acts as the fluorophore component of 
the structure.  This tripeptide contains residues of Ser65, Tyr66, and Gly67.   The wild-
type GFP from the Aequorea victoria jellyfish has a major excitation peak at 395 nm, with 
emission at 508 nm, and a minor excitation peak at 475 nm with corresponding emission 
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Figure 1.5 Structure of GFP. A three-dimensional ribbon diagram of wild type GFP 
isolated from Aequorea victoria jellyfish.  The structure contains 11 beta sheets, shown 
in green, alpha helices shown in red, and the three amino acid chromophore.  
   
 
 
 
 
 
Image is reprinted with permission from: (Brejc K, et al. (1997) Structural basis for dual 
excitation and photoisomerization of the Aequorea victoria green fluorescent protein. Proc. 
Natl. Acad. Sci. U.S.A. 94:2306-2311.) "Copyright (1997) National Academy of Sciences, 
U.S.A." 
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at 503 nm [207].    In order to fold more efficiently at 37oC, the most commonly used 
variant is enhanced green fluorescent protein, or eGFP.  This contains key mutations of 
F64L and S65T to increase stability at physiological temperature and shift the maximum 
excitation wavelength to 488 nm, and emission to around 508 nm [202, 208].   Other 
variants, derived from the mutagenesis of GFP, range in photostability, photoactivability, 
or pH sensitivity, allowing the choice of fluorophore to be tailored to a particular 
application [202].  GFP based techniques have been used to study countless biological 
systems, including the nAChRs.  Fluorescent proteins have been successfully expressed in 
a diverse set of systems, including cultured cells, neurons, and even mice [35, 168, 209] 
GFP and variants have been used to measure nAChR trafficking, subcellular distribution, 
and expression levels throughout the cell and on the plasma membrane [85, 115, 168, 198, 
210].   
 
1.5.3   Total Internal Reflection Fluorescence Microscopy 
 Superior spatial and temporal resolution can be achieved with specialized 
fluorescence microscopy techniques.   One such technique is total internal reflection 
fluorescence, or TIRF.  This technique utilizes totally internally reflected excitation light 
to selectively excite fluorophores near a sample-glass interface, such as adherent cells on 
a glass coverslip.  By focusing on just one optical plane at this interface, TIRF minimizes 
out-of-focus fluorescence and increase the signal-to-noise ratio, particularly at the plasma 
membrane.   Specifically focusing on the plasma membrane is particularly useful when 
evaluating nAChRs, since the majority of nAChR are thought to be internal [195].  Total 
internal reflection of the excitation beam occurs at the interface of two materials with 
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different refractive indices [211, 212].  In objective-style TIRF, illustrated in Figure 1.6, 
the laser beam is transitioned laterally across the back aperture of the objective lens using 
a stepper motor.  The beam penetrates through the coverslip, and reflects off the lower 
refractive index sample.  If the angle of incidence is greater than the critical angle, the beam 
is totally internally reflected, forming an evanescent wave.   The critical angle, in relation 
to the normal, is given by Snell’s law: 
Θc = sin-1(η1 / η2)  (Eq. 1.1) 
where η1 is the lower refractive index of the sample while η2 is the higher refractive index 
of the coverslip.  For cell based studies, the numerical aperture of the objective must be 
higher than the 1.38 refractive index of the cell sample to reach TIR. 
If the angle of incidence is less than the critical angle, excitation light is able to 
propagate through the entire sample.  This is seen in traditional wide field imaging, or 
epifluorescence mode.  If the beam of excitation is parallel to the normal, or at some angle 
less than the critical angle, fluorophores throughout the entire cell are excited (Figure 
1.6A).  Once the beam passes the critical angle, only fluorophores located within the 
evanescent field are excited (Figure 1.6B).  The evanescent wave decays exponentially 
with distance from this sample-coverslip interface, and is responsible for excitation of 
fluorophores when TIRF is achieved.  Typically, this evanescent wave penetrates 
approximately 150 nm into the sample, meaning only fluorophores within this region are 
excited.  In a cellular sample, this corresponds to fluorophores, or fluorescent proteins 
integrated with a nAChR near the plasma membrane to be detected.  This increases the 
signal to noise ratio since background fluorescence from the intracellular region is reduced  
or eliminated [211, 212].   
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Figure 1.6: Schematic of epifluorescence and total internal reflection 
fluorescence. (A) In epifluorescence, a wide field of excitation passes through the 
entire depth of a sample, exciting fluorophores throughout the sample. (B) In total 
internal reflection fluorescence (TIRF), the beam of excitation approaches the sample 
at an angle higher than a critical angle (Θc), causing total internal reflection of the 
incoming beam.  The resulting evanescent wave is responsible for exciting 
fluorophores within approximately 150 nm from the sample-coverslip interface.  
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Photodamage to a living specimen is also reduced since the majority of the cell is not 
exposed to radiation, allowing live cell imaging over the course of time. 
Due to increased resolution at the plasma membrane, TIRF is ideally suited to 
measure cellular events in this region.  TIRF has been successfully used to monitor 
endocytosis [213, 214], exocytosis [215], and intracellular signaling events [216].  TIRF 
has also been used to image nAChRs coupled to a pH sensitive derivative of GFP, 
superecliptic pHluorin (SEP) [198] to determine subcellular localization and trafficking.  
Due to the high resolution and sensitivity achievable with TIRF, subcellular localization 
and trafficking dynamics of membrane receptors can be resolved with SEP [217, 218]. 
 
1.5.4 Single Molecule Fluorescence Microscopy  
 Ensemble techniques, simultaneously detecting multiple fluorophores, have been 
quintessential in most recent advancements in the understanding of subcellular components 
[219].  These bulk studies have been used to elucidate structure and cellular dynamics for 
many biological systems.  Recent advances in fluorescence microscopy have led to the 
development of complementary single molecule techniques.  These single molecule 
techniques measure fluorescence from a single fluorophore to provide a more detailed 
understanding of biological processes measured with ensemble techniques.  Ensemble 
techniques, due to detection of multiple fluorophores, measure an average intensity across 
an entire sample.  Due to the averaging of multiple signals, individual dynamics are lost.  
Single molecule techniques, on the other hand, are able to detect specific structural and 
kinetic events by resolving measurements from a individual fluorophore.  Such techniques 
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have been used to help resolve dynamics of many complex biological systems to date, 
including ion channels [220-224].   
 One commonly used single molecule technique is single molecule photobleaching.  
In biological samples, there is rising interest in detecting photobleaching of a GFP 
genetically encoded into a protein of interest.  An inherent property of fluorophores is that, 
eventually, they transition into a dark state upon continuous excitation, known as 
bleaching.  The photobleaching of a single GFP molecule is a discrete process, meaning 
fluorescence intensity will decrease as a stepwise decay.  This is ideal to measure structural 
properties of complex biological proteins, such as the nAChRs.  Since a single GFP 
molecule corresponds to a single stepwise decrease in intensity, the number to steps reveal 
the number of GFP molecules, or GFP-labeled subunits, that are present in the complex.  
Limitations of single molecule techniques are mostly based on signal sensitivity.  Labeled 
membrane proteins, including nAChRs, diffuse along the plasma membrane and 
accumulate in high densities [225].  Autofluorescence from the bulk of the cell makes it 
difficult to isolate a single GFP or nAChR.  Also, higher excitation intensities are required 
to produce emission that is intense enough for detection.  In order to reduce these 
complications, new techniques are being developed to isolate single receptors. 
 
 
 
 
 
 
Copyright © Ashley Mae Loe 2016 
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CHAPTER 2: OVERVIEW AND STATEMENT OF PROJECTS  
 
2.1   Project Motivation and General Overview 
 One of the most well-documented effects of chronic nicotine exposure is the 
upregulation of its target, nAChRs.  This upregulation of nAChRs is believed to contribute 
to the addictive nature of nicotine, although functional consequences are not completely 
understood [6, 45, 55, 64, 66, 76].  Upregulation of nAChRs is defined as an increase in 
receptor number, changes in receptor trafficking, or altered assembly of stoichiometry.  The 
upregulation of α4β2* is accompanied by an increase in sensitivity to nicotine.  This is the 
result of an increase in the number of high sensitivity (α4)2(β2)3 stoichiometry receptors 
compared to (α4)3(β2)2 stoichiometry [81, 97, 154].  As a result of chronic nicotine 
exposure, nAChRs respond to lower concentrations of acetylcholine and other agonists as 
the sensitivity to stimulation is increased.  Despite significant research interest, a full 
mechanism for upregulation has not been resolved.  New evidence continues to converge 
on the idea an intracellular mechanism is responsible for these processes, but definitive 
evidence of changes within the endoplasmic reticulum need to be detected.  Nicotine and 
other ligands are thought to permeate cell membranes, interact with intracellular receptors, 
and alter the expression of nAChRs.  Evidence for an intracellular mechanism for nicotine 
induced effects include pharmacological chaperoning, matchmaking, and intracellular 
trafficking [160].  Upregulation has been robustly measured in a variety of systems, yet 
seems to be cell type and brain region dependent in vivo.  Also, upregulation has been 
documented as a result of exposure to both agonists and antagonists. Understanding these 
changes on a mechanistic level is important to the development of nAChRs as drug targets.  
For this reason, cutting edge methodologies are being developed and employed to pinpoint 
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distinct changes in localization, assembly, export, vesicle trafficking and stoichiometry in 
order to further understand the physiology of these receptors.  In an effort to develop more 
effective therapeutics, nicotine’s role in modulating upregulation needs to be better 
defined.    This dissertation utilizes novel techniques to elucidate the mechanism of nicotine 
induced upregulation to identify target nAChR structures for the development of smoking 
cessation therapeutics.   
 
2.2   Cotinine Alters Expression, Trafficking, and Assembly of a Subset of nAChRs 
 Traditionally, the importance of nicotine’s primary metabolite, cotinine, has been 
limited to a biomarker of nicotine exposure [14].  More recently, cotinine has been shown 
to also be a pharmacologically active compound, reducing effects of chronic stress and 
increasing cognitive and executive function [23, 37].   Cotinine has been shown to cross 
the blood-brain barrier [40] and acts as a partial agonist to nicotinic acetylcholine receptors 
[41-44].  Also, tobacco exposure leads to the accumulation of cotinine throughout the body 
due to cotinine's long pharmacological half-life [3, 26].  However, nAChR expression 
studies have focused almost exclusively on nicotine’s effects, with few studies considering 
the effect of cotinine or other nicotine metabolites on nAChR assembly or trafficking [38].  
Since nicotine and cotinine are structurally similar, differing by only an acetyl group 
(Figure 1.1), we hypothesized that cotinine could induce similar changes as nicotine in 
trafficking and expression of nAChRs, and therefore may be at least partially responsible 
for physiological effects previously attributed to nicotine exposure.  To test this hypothesis, 
transiently transfected Neuroblastoma (N2a) cells were exposed to cotinine treatment for 
48 hours.  The alpha subunits of an assembled nAChR pentamer were genetically labeled 
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with a pH sensitive version of GFP, known as superecliptic pHluorin (SEP).  Total internal 
reflection fluorescence was used to measure expression and distribution of SEP-labeled 
nAChRs.  We further hypothesized that cotinine may alter the assembly of α4β2, as seen 
with nicotine exposure.  To test this hypothesis, transiently transfected human embryonic 
kidney (HEK-293T) cells underwent nitrogen cavitation after exposure to cotinine to 
encapsulate single nAChRs in nanoscale containers derived from the endogenous cell 
membrane.  The alpha subunits of the assembled nAChR pentamer were genetically labeled 
with a GFP.  Isolated nanovesicles underwent single molecule photobleaching upon 
continuous 488 nm excitation.  The number of bleaching steps corresponds to the number 
of alpha subunits present, and thus the stoichiometry.   
 
2.2.1   Total Internal Reflection Fluorescence (TIRF) 
 Due to their endogenous role as acetylcholine receptors in the central nervous 
system, functional nAChRs are located on the plasma membrane.  Although the functional 
consequences of nicotine induced upregulation of nAChRs is not fully understood, 
receptors in this region are likely to contribute to upregulation induced effects.  In order to 
increase resolution of fluorophore-labeled nAChRs at the plasma membrane, TIRF 
microscopy is used.  Specifically focusing on the plasma membrane is particularly useful 
when evaluating nAChRs, since the majority of nAChR are thought to be internal [195].  
TIRF limits detection to the plasma membrane and nearby peripheral endoplasmic 
reticulum to selectively quantify nAChRs within the trafficking pathway.  TIRF excitation 
focuses on a single optical plane, limiting excitation to a narrow region extending 
approximately 150 nm from the interface between an adherent cell and glass.   In live cells 
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expressing nAChRs, this excitation volume corresponds to the cell plasma membrane or 
nearby peripheral endoplasmic reticulum, limiting detection to nAChRs within this region.    
 A basic TIRF microscopy setup is illustrated in Figure 2.1.  Since the nAChRs are 
genetically linked to an SEP fluorophore, a 488 nm diode-pumped solid state (DPSS) laser 
is used for excitation.  The excitation beam is fiber coupled to a stepper motor, allowing 
the beam to be translated laterally across the back aperture of a high numerical aperature 
objective.  In order to surpass the critical angle required to achieve TIRF, an objective with 
a numerical aperture higher than the refractive index of the sample (> 1.38 for cells) is 
required.  Total internal reflection of the incident radiation forms an evanescent wave 
responsible for SEP excitation.   Emission is collected on an electron multiplying charge 
coupled device (EMCCD).  Since the bulk of the sample is not excited, background 
fluorescence is decreased and an increased signal to noise ratio at the plasma membrane is 
observed [211, 212].   
 
2.2.2   Super-Ecliptic pHluorin (SEP) to Measure Expression  
 Super-ecliptic pHluorin (SEP), a pH sensitive variant of GFP, takes advantage of 
pH differences between subcellular regions within a cell.  This fluorophore has been 
successfully incorporated into numerous receptor subunits, including AMPA, GABA, and 
nAChRs [198, 217, 226].  The pH sensitivity corresponds to a change in fluorescence 
emission based on the pH of the local environment of the fluorophore.  Below a pH of 6, 
SEP remains in an off state, but fluoresces at higher pHs when excited with 488 nm 
excitation.  This pH sensitive property makes SEP particularly useful to study subcellular 
localization and vesicle dynamics [198, 217, 226].   The alpha subunits of an assembled 
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Figure 2.1 Schematic of a TIRF microscope. To excite SEP, a 488 nm DPSS laser is 
fiber coupled to a stepper motor.  The critical angle is reached by moving the position 
of the incident beam laterally across the back aperture of the objective.  SEP emission 
is detected by an electron-multiplying charge coupled device (EMCCD). 
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nAChR pentamer were genetically labeled with an SEP on the C-terminus of the nAChR 
subunit.  The C-terminus of the nAChR, including the SEP, is exposed to the luminal pH 
in the endoplasmic reticulum and trafficking vesicles, but the extracellular pH upon 
insertion into the plasma membrane.  Therefore, existing pH gradients within a cell, or 
manipulation of extracellular pH, modulates the fluorescence of SEP, enabling direct 
monitoring of nAChR-SEP location.  Using this pH sensitive fluorophore in conjunction 
with TIRF microscopy allows subcellular localization and single vesicle insertion events 
to be resolved within the evanescent wave excitation volume.  Differences in expression, 
distribution and trafficking of nAChRs within this field of view upon exposure to cotinine 
are measured.   
 
2.2.2.1   Relative Expression and Distribution of nAChRs within Evanescent Field 
    The pH sensitivity of SEP enables intracellular nAChRs in the endoplasmic 
reticulum to be distinguished from nAChRs residing on the plasma membrane.  By 
measuring the fluorescence intensity of the same cells at varying pHs, the relative location 
of SEP-labeled nAChRs within the TIRF field of view can be determined.  Since SEP is 
pH dependent, the fluorescence of SEP-labeled nAChRs on the plasma membrane is 
determined by the pH of the extracellular solution.  When the pH of the extracellular 
solution is 7.4, receptors within the peripheral endoplasmic reticulum and plasma 
membrane fluoresce.  The extracellular solution can then be exchanged to an otherwise 
identical solution of pH 5.4, causing nAChRs on the plasma membrane to transition into 
an off state, meaning all detected fluorescence is from nAChRs within the endoplasmic 
reticulum [115, 198, 227].  This process is illustrated in Figure 2.2.  The relative number 
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Figure 2.2 Cartoon illustrating changes in SEP detection with pH.  When the 
extracellular solution (ECS) is at pH 7.4, SEP-labeled nAChRs in the endoplasmic 
reticulum and on the plasma membrane fluoresce. When the ECS is exchanged to an 
identical solution at pH 5.4, SEP-labeled nAChRs on the plasma membrane transition 
into an off state and are no longer detected. 
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of nAChRs on the plasma membrane, known as plasma membrane integrated density   
(PMID), is mathematically calculated by subtracting the integrated density of fluorescence 
intensity at pH 5.4, corresponding to ER resident nAChRs, from the integrated density at 
pH 7.4, corresponding to the total number of detected nAChRs.  The difference between 
these values corresponds to the PMID, or relative measure of nAChRs localized to the 
plasma membrane, as shown in Equation 2.1. 
	 	 	7.4 	 	 	5.4  (Eq. 2.1) 
Images of a representative cell exposed to pH 7.4 and pH 5.4 is shown in Figure 2.3.  In 
Figure 2.3A, cells at pH 7.4 appear the most intense, with a combination of the reticulated 
pattern of the ER and a smoother pattern of nAChRs dispersed across the PM both visible.  
In Figure 2.3B, only the reticulated pattern is detected, as nAChRs located on the PM in an 
off state at pH 5.4.  The difference, shown in Figure 2.3C, corresponds to the smoother 
fluorescence pattern of those nAChRs localized to the PM.  The PMID of cells exposed to 
cotinine is measured in comparison to control cells.  Upregulation of nAChRs corresponds 
to an increase in PMID, or relative number of receptors on the plasma membrane.  Once 
the relative number of nAChRs on the plasma membrane is calculated, this value can be 
compared to the total number of nAChRs within the field of view to quantify changes in 
distribution as a result of cotinine exposure.  PMID is divided by the total integrated density 
at pH 7.4, and converted to a percentage, as shown in Equation 2.2. 
%	 	
	 	 	 .
	 	100 (Eq. 2.2) 
The percentage of detected nAChRs located on the plasma membrane is a measure of 
nAChR trafficking.  Changes in % PM as a result of cotinine exposure are measured.  
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Figure 2.3 Example of an N2a cell expressing SEP-nAChRs. (A) All SEP-labeled 
nAChRs within the TIRF field of view fluoresce when ECS is pH 7.4.  (B) SEP-labeled 
nAChRs on the plasma membrane fail to fluoresce when ECS is pH 5.4, meaning all 
detected fluorescence is from ER resident nAChRs. (C) Visual representation of the 
differences between cell at pH 7.4 and pH 5.4, corresponding to SEP-labeled nAChRs 
located on the plasma membrane. 
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Increases in % PM corresponds to increased trafficking of nAChRs towards the plasma 
membrane.   
 
2.2.2.2   Detection of Single Vesicle nAChR Insertion Events 
 Since trafficking vesicles inherently have a pH less than 6, SEP-labeled nAChRs 
within these vesicles do not fluoresce [217].   Upon insertion into the plasma membrane, 
these fluorophores of the low pH trafficking vesicle are then exposed to a higher 
physiological extracellular pH of 7.4 at the plasma membrane, causing them to transition 
into an on state.  This appears as a burst of fluorescence at the plasma membrane as SEP-
nAChRs transition to a fluorescent state.  Figure 2.4 illustrates an increase in fluorescence 
intensity and spreading across the membrane as nAChRs are inserted and diffuse across 
the plasma membrane amongst previously inserted nAChRs.  The number of insertion 
events per cell are counted, allowing the number of trafficking vesicle arrival events to be 
quantified.  Changes in frequency of insertion events upon exposure to cotinine are 
compared to control cells.   An increase in the number of insertion events corresponds to 
an increase in the number of transport vesicles carrying nAChRs to the plasma membrane.   
 
2.2.3   Green Fluorescent Protein (GFP) to Measure Stoichiometry 
 Labeling individual subunits with GFP provides a means to measure stoichiometry 
of assembled nAChRs.  Our lab has developed a novel method that isolates individual 
nAChRs in nanoscale containers derived from the native cell membrane [228].  Once single 
nAChRs are isolated, single molecule photobleaching of GFP molecules is used to deduce 
stoichiometry.   In these studies, the alpha subunits of the nAChR are genetically encoded 
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Figure 2.4 Cartoon of a single vesicle insertion event.  SEP-labeled nAChRs are 
trafficked to the plasma membrane in low pH trafficking vesicles.  Upon arrival of a 
trafficking vesicle at the plasma membrane, SEP is exposed to a pH of 7.4, causing 
these fluorophores to turn on.  As the vesicle fuses with the plasma membrane, a burst 
of fluorescence is seen on the plasma membrane, followed by a spreading of this burst.  
After insertion, the newly inserted nAChRs blend in with the bulk fluorescence of 
previously inserted nAChRs on the plasma membrane. 
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with a GFP fluorophore.  HEK-293T cells transiently expressing α4-GFP / β2 nAChRs 
underwent nitrogen cavitation to trap a single α4β2 nAChR in a nanovesicle derived from 
the native cell membrane.   Once vesicles containing α4β2 nAChRs are formed, they are 
spatially isolated on a glass substrate by a conventional pull-down mechanism using an 
anti-GFP antibody to capture GFP-labeled nAChRs within nanovesicles.  This process is 
illustrated in comparison to live cell SEP based experiments in Figure 2.5.  Isolated 
nAChRs are imaged with TIRF to detect single GFP molecules.  In Figure 2.6, α4-GFP/β2 
nAChRs isolated on a glass coverslip (Figure 2.6B) are shown in contrast to a live cell 
expressing α4-GFP/β2 in TIRF (Figure 2.6A).  Each field of view of isolated nAChRs 
undergo continuous 488 nm excitation.   Changes in fluorescence intensity over time is 
measured for vesicles in each region.  Since GFP inherently stochastically undergoes 
photobleaching when excited, the number of bleaching steps, or transitions into off states, 
can be measured.  A bleaching step is measured as a stepwise decrease in fluorescence 
intensity, corresponding to a single fluorophore losing fluorescence.  Since only one 
nAChR is present at each isolated location, detection of two bleaching steps corresponds 
to the presence of two alpha subunits, or (α4)2(β2)3 stoichiometry (Figure. 2.7A).  In 
contrast, detection of three bleaching steps signifies three alpha subunits are present, and 
thus (α4)3(β2)2 stoichiometry.  The number of bleaching steps detected in vesicles derived 
from cells exposed to cotinine are compared to control vesicles.  Counted bleaching steps 
are fit to a binomial distribution, accounting for a 90% probability that GFP will be folded 
correctly and fluorescent during experimentation.  The fitted distribution provides a ratio 
of α4β2 isoforms present at each condition.  An increase in the number of vesicle showing 
   
48 
 
 
 
 
 
 
 
Figure 2.5 Cartoon illustrating isolation of nAChRs for single molecule imaging.  
In the SEP studies, live cells are imaged at pH 7.4 and pH 5.4 to determine localization 
to the plasma membrane.  In the single molecule studies, live cells undergo nitrogen 
cavitation, encapsulating single nAChRs in their native membranes at that time.  
Nanovesicles are then isolated on a glass surface and imaged to detect single GFP 
bleaching steps. 
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Figure 2.6 Formation of nanovesicles from cells expressing α4-GFP/β2.  (A) TIRF 
image showing a cell expressing nAChRs. (B) Isolated nanovesicles each contain a 
single α4β2 nAChR. 
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Figure 2.7 Representative time traces showing stepwise decreases in fluorescence 
intensity.  Time traces of α4-GFP/β2 showing two (A) or three (B) bleaching steps are 
used to determine the stoichiometry of that nAChR. 
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two bleaching steps, or two GFP-labeled alpha subunits, corresponds to a shift in assembly 
to preferentially form the (α4)2(β2)3 isoform. 
  
2.3   nAChR Ligands Alter Expression, Trafficking, and Assembly of α4β2 
 Changes in nAChRs as a response to nicotine exposure have been the most widely 
characterized.  Nicotine upregulates α4β2 and increases expression of the high sensitivity, 
(α4)2(β2)3 isoform  [85, 154].  Many smoking cessation agents target the α4β2* subtype of 
nAChRs.  Some of these drugs, including mecamylamine and varenicline, have been shown 
to upregulate the α4β2* nAChRs [150, 176, 178].  Another cessation agent, cytisine, has 
been shown to increase expression of the low sensitivity, (α4)3(β2)2, isoform at the plasma 
membrane [85].   These therapeutics have varying pharmacological properties and binding 
sites, but all seem to interact with specific nAChR stoichiometries or induce upregulation 
of these nAChRs.   Understanding the effects of existing drugs on expression and assembly 
of α4β2 would provide insight into the mechanism of successful smoking cessation with 
these agents.  We hypothesized that current smoking cessation agents may also alter the 
distribution between intracellular and plasma membrane resident nAChRs.  In order to test 
this hypothesis, N2a cells were transiently transfected with α4β2 and exposed to cytisine, 
varenicline, or bupropion for 48 hours.  Alpha 4 subunits were genetically labeled with the 
pH sensitive fluorophore, SEP.  TIRF microscopy was used to measure expression and 
distribution of SEP-labeled nAChRs within the field of view, as shown above in Figure 
2.2.  Increases in PMID and % PM correspond to upregulation in number of α4β2 nAChRs 
and distribution towards the plasma membrane, respectively.  We further hypothesized that 
cytisine, varenicline, and bupropion may alter stoichiometry of α4β2 throughout the whole 
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cell.  To test this hypothesis, alpha subunits were encoded with a GFP molecule to undergo 
single molecule photobleaching.  Transiently transfected HEK-293T cells expressing α4-
GFP/β2 underwent nitrogen cavitation to form cell-derived nanoscale vesicles, as shown 
in Figure 2.5.   Bleaching steps were detected for vesicles formed from cells exposed to 
cytisine, varenicline, or bupropion.  The number of bleaching steps corresponds to the 
number of alpha subunits present, and thus the stoichiometry.  Bleaching steps are counted 
and fit to a binomial distribution to obtain a distribution of each α4β2 isoform present.  
Changes in the number of bleaching steps detected indicates a shift in predominate 
stoichiometry when exposed to that drug.   
 
2.4   Nicotine Intracellularly Alters α4β2 Stoichiometry 
Despite correlations between nAChR upregulation and nicotine addiction, the 
mechanism of nicotine induced upregulation has not been fully resolved.  Recent evidence 
supports the theory that nicotine acts intracellularly to induce upregulation, known as 
“inside-out” neuropharmacology [160].  In such a way, nicotine would act intracellularly 
to increase maturation enhancement of subunits and pharmacologically chaperone nascent 
nAChRs [55, 97, 115, 153].  This requires nicotine to permeate cell membranes, interact 
with intracellular receptors, and alter the expression of nAChRs internally to favor a high 
sensitivity (α4)2(β2)3 stoichiometry.  FRET, Förster resonance energy transfer, based 
studies show an increase in the number of α4 and β2 subunits in close proximity within the 
whole-cell region measured, which includes the endoplasmic reticulum [115, 196, 197].  
However, no structural changes solely within the endoplasmic reticulum have been 
measured.  This is primarily due to a lack of existing techniques that can directly measure 
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complex structural assembly of membrane proteins intracellularly.  We hypothesized that 
nicotine alters the assembly of α4β2 nAChRs within the endoplasmic reticulum, and this 
could be detected using a single molecule analysis of nAChRs embedded in cell-derived 
nanovesicles.  To test this hypothesis, we developed a technique to separate nAChRs 
localized to the endoplasmic reticulum or plasma membrane.  HEK-293T cells transiently 
expressing α4-GFP/β2 nAChRs underwent nitrogen cavitation to trap a single α4β2 
nAChR in a nanovesicle derived from the native cell membrane, as discussed above in 
Figure 2.5.  During nitrogen cavitation, the pressure is increased to promote fragmentation 
of the plasma membrane.  Once vesicles containing α4β2 nAChRs are formed, density 
gradient centrifugation is used to separate nanovesicles derived from the membranes of the 
endoplasmic reticulum and plasma membrane, as illustrated in Figure 2.8.  After separation 
of ER and PM derived nanovesicles containing a single nAChR, they are spatially isolated 
on a glass substrate using the same pull-down mechanism mentioned earlier (Figure 2.6).  
The stoichiometry of α4β2 is determined by counting single molecule bleaching steps of 
the GFP-labeled alpha subunits.  Two bleaching steps corresponds to (α4)2(β2)3, whereas 
three bleaching steps corresponds to (α4)3(β2)2 stoichiometry of the nAChR in that 
location.  By separating nAChRs based on the membrane of origin, structural differences 
and preferential trafficking between receptors located within the ER can be differentiated 
from those on the PM.  Changes in stoichiometry of α4β2 within the ER and PM upon 
exposure to nicotine are compared to control cell by fitting the counted number of 
bleaching steps in each condition to a binomial distribution.  In addition, preferential 
trafficking of an assembly with or without nicotine is measured.   
 
Copyright © Ashley Mae Loe 2016 
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Figure 2.8 Cartoon illustrating separation of ER and PM derived nanovesicles.  
Cells undergo nitrogen cavitation, encapsulating single nAChRs in their native 
membranes at that time.  nAChRs originating from the ER and PM are separated on a 
density gradient.  Nanovesicles are then isolated on a glass surface and imaged to detect 
single GFP bleaching steps. 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1   Materials 
3.1.1   Pharmacological Agents 
(-)-Nicotine hydrogen tartrate salt (≥ 98%), (-)-cotinine (≥ 98%), cytisine (≥ 99%), 
varenicline (≥ 98%), and bupropion hydrochloride (≥ 98%), were purchased from Sigma-
Aldrich. 
 
3.1.2   Reagents 
Poly-D-lysine was purchased from VWR.  Lipofectamine 2000 transfection reagent 
was purchased from Fisher Scientific.  35 mm glass bottom petri dishes were obtained from 
Cell E&G.  Biotin-PEG-silane was purchased from Laysan Bio., Inc.  NeutrAvidin was 
obtained from Thermo Scientific. 
 
3.1.3   Antibodies 
Biotinylated polyclonal (GOAT) anti-GFP antibody was purchased from Rockland 
Immunochemicals, Inc.  Polyclonal rabbit anti-calnexin and polyclonal mouse anti-plasma 
membrane calcium ATPase were obtained from Santa Cruz Biotechnology.  Secondary 
rabbit and mouse antibodies were obtained from Jackson ImmunoResearch. 
 
3.1.4   Nicotinic Receptor Plasmid Constructs  
All nAChR subunit plasmids are of mouse origin. Super ecliptic pHluorin (SEP) 
fluorophores were incorporated on the C-terminus of α4, α6, and α3 subunits in a pCI-neo 
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vector.  The α4-SEP was previously constructed using PCR amplification with a forward 
primer sequence of 5’-CATGGTTGGCTGGTATGATCAGTAAAGGAGAAGAACTT-
3’ and a reverse primer sequence of 5’-ATGGATGAACTATACAAATAGGGAATAGC 
GGCACCT-3’ using Pfu-Turbo polymerase [198].  Plasmids containing nAChRs labeled 
on the C-terminus with SEP have previously been shown to be functional based on whole 
cell patch clamp studies [85, 115, 198].  A green fluorescent protein (GFP) fluorophore 
was previously incorporated into the TM3-TM4 loop of the α4 subunit.  All plasmids 
assemble normally and have been used in previous reports [196, 198].  The QuikChange II 
XK site-directed mutagenesis kit was used to create the α5-D398N mutation commonly 
associated with an increase in risk of smoking and lung cancer. The D398N corresponds to 
an aspartic acid to asparagine change in position 397 in the mouse plasmid [126].  
 
3.2   Methods to Determine nAChR Expression and Trafficking 
3.2.1   Cell Culture 
Undifferentiated mouse neuroblastoma 2a (N2a) cells were cultured using standard 
tissue culture techniques at 37 oC and 5% CO2.  N2a cells were maintained in growth media 
consisting of Dulbecco’s Modified Eagle Medium (DMEM) and Opti-MEM Reduced 
Serum Media, supplemented with 10% fetal bovine serum, penicillin, and streptomycin 
[151, 198]. 
 
3.2.2   Transfection  
N2a cells were plated by adding 90,000 cells to poly-D-lysine coated 35-mm glass 
bottom dishes.  The following day, growth medium was replaced with Opti-MEM for cell 
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transfection.  Cells were transfected with 500 ng of each nAChR subunit plasmid mixed in 
250 μL Opti-MEM.  The plasmids for alpha subunits contained a sequence for super-
ecliptic pHluorin (SEP).  A separate aliquot of 2 μL Lipofectamine-2000 and 250 μL Opti-
MEM were incubated at room temperature for 5 minutes then combined with the plasmid 
solution for an additional 25 minutes before being added to pre-plated N2a cells.  After 24 
hours at 37°C, transfection mixture was replaced with growth media and incubated for an 
additional 24 hours at 37°C before imaging.   
 
3.2.3   Exposure to Pharmacological Agents 
For drug exposed cells, the indicated concentration of the appropriate drug was 
added at the time of the transfection and replenished in the growth medium replacement 
for a total of 48 hours of exposure before imaging.   Nicotine and its metabolite, cotinine, 
were added at varying concentrations.  Cytisine, varenicline, and buproprion were added 
at a concentration of 500 nM.  Transfection efficiency was approximately 80% and was 
not influenced by the presence of a drug. 
 
3.2.4   TIRF Imaging of Super-Ecliptic pHluorin 
Samples were imaged with objective style total internal reflection fluorescence 
microscopy with an inverted fluorescence microscope (Olympus ix83). TIRF imaging 
reduces background fluorescence by focusing on a single optical plane.  Excitation of 
fluorophores is limited to within approximately 100-200 nm from the cell-glass bottom 
dish interface, visualizing receptors localized to the plasma membrane or peripheral 
endoplasmic reticulum [211].   Within this region, resolution is greatly increased, 
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particularly at the plasma membrane.  SEP were excited with a 488 nm DPSS laser (~1.00 
W/cm2) fiber coupled stepper motor to adjust the critical angle of the excitation beam.  The 
excitation beam travels through the objective (Olympus, 1.49NA, 60x oil immersion) and 
is detected by an electron multiplying charge coupled device (EMCCD) (Andor iXon Ultra 
897).  To obtain total internal reflection (TIR), the laser was focused on the back aperture 
of the objective lens and the angle was adjusted using a stepper motor to translate the beam 
laterally across the objective lens.  Due to low excitation intensity, photobleaching is not 
an issue on the timescale of these measurements. 
 
3.2.5   Measuring Receptor Expression and Distribution 
 The pH sensitivity of SEP was utilized to determine subcellular location within the 
TIRF field. SEP undergoes 488 nm excitation at neutral pH but is dark under acidic 
conditions of pH < 6 [217], enabling differentiation between intracellular and inserted 
nAChRs. The SEP tag is fused with the C terminus of the nAChR subunit so that it is 
exposed to the pH on the luminal side of the organelles within the secretory pathway. 
Before imaging, growth medium was exchanged for extracellular solution (150 mM NaCl, 
4 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 10 mM HEPES and 10 mM glucose) adjusted to 
pH 7.4 using NaOH. Receptors in the ER (pH > 7), and on the PM (pH of ECS, 7.4) are 
visible, while those in the lower pH environments of the Golgi and secretory vesicles are 
not fluorescent [198, 229]. After images were collected at pH 7.4, the solution was 
exchanged with an otherwise identical solution adjusted to pH 5.4 using HCl. When the 
pH of the ECS is < 6, nAChRs located on the PM transition into the off state, so the 
observed fluorescence is solely from nAChRs in the peripheral ER [115, 211, 230]. The 
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integrated density of cells imaged in TIRF, showing relative number of fluorescent 
receptors, are collected at both pH 7.4 and pH 5.4.  The integrated density at pH 5.4 is 
subtracted from the total integrated density of fluorophores in the ER and on the PM shown 
at pH 7.4 to determine the integrated density of receptors on the plasma membrane (PMID).  
The ratio of receptors on the plasma membrane (% PM) is the PMID divided by the total 
integrated density at pH 7.4, multiplied by 100, to provide a percentage of receptors within 
the TIRF view that reside on the membrane. Increased PMID reflects an upregulation in 
the number of receptors found on the PM. An increase in the percentage of receptors found 
on the plasma membrane (% PM) corresponds to a change in the distribution of receptors 
between the ER and PM.   
 
3.2.6   Receptor Expression Data Analysis  
Quantification of fluorescence intensity was determined using ImageJ by manually 
selecting an intensity-based threshold and region of interest.  Background was subtracted 
using the sliding paraboloid method.  Plasma membrane integrated density (PMID) was 
calculated by subtracting the integrated density of a cell at pH 5.4 from the integrated 
density of the same cell at pH 7.4.  The percentage on the plasma membrane within the 
TIRF field of view (% PM) was calculated by dividing the PMID by the total integrated 
density at pH 7.4, multiplied by 100.  All figures show results from a single imaging session 
that are representative of data collected on at least three separate occasions.  All graphs 
show the mean with error bars representing S.E.M.  P-values were determined using a two-
tailed t-test with equal variance not assumed. 
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3.2.7   Measuring Receptor Trafficking 
Real time images were acquired at a frame rate of 200 ms for 1500 frames to capture 
fusion of nAChR containing transport vesicles with the plasma membrane. These studies 
allow us to identify changes in the number of vesicles that contain SEP-labeled nAChRs 
but not in total number of vesicles. Insertion events were manually counted per cell during 
a randomly chosen 50 frames (10 seconds) using ImageJ.  Insertion events were defined as 
a burst of fluorescence at the PM lasting at least 2 frames (400 ms) and including lateral 
spreading of fluorophores to ensure transient full fusion of the vesicle and delivery of 
nAChRs to the membrane.  Persistent, continuously repeating bursts of fluorescence were 
not counted since a discrete exocytic event could not be guaranteed.  Statistical differences 
in the number of insertion events in the presence of cotinine were determined using a two-
tailed t-test with equal variance not assumed. 
 
3.3   Methods to Determine nAChR Assembly 
3.3.1   Cell Culture 
Undifferentiated human embryonic kidney 293T (HEK-293T) cells were cultured 
using standard tissue culture techniques at 37 oC and 5% CO2.  HEK-293T cells were 
maintained in growth media consisting of DMEM, supplemented with 10% fetal bovine 
serum, penicillin, and streptomycin.  Flasks were coated with matrigel matrix (VWR), a 
solubilized basement membrane preparation, to encourage cell adherence and 
differentiation in culture. 
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3.3.2   Transfection  
HEK-293T cells were plated by adding 3 million cells to matrigel coated T75 cell 
culture flasks.  The following day, growth medium was replaced with Opti-MEM for cell 
transfection.  Cells were transfected with 3500 ng of each nAChR subunit plasmid mixed 
in 250 μL Opti-MEM.  The alpha subunits contained the genetic sequence for green 
fluorescent protein (GFP).  A separate aliquot of 14 μL Lipofectamine-2000 and 250 μL 
Opti-MEM were incubated at room temperature for 5 minutes then combined with the 
plasmid solution for an additional 25 minutes before being added to pre-plated HEK-293T 
cells.  After 24 hours at 37°C, transfection mixture was removed prior to vesicle formation. 
Biased transfections were performed by adding unequal amounts of α4-GFP and 
β2-wt plasmid during the transfection of HEK-293T cells.  These control studies were 
completed using 10:1, 4:1, and 1:4 ratios of α4-GFP to β2-wt plasmid.  Equal amounts of 
plasmid were used for all other studies.  
 
3.3.3   Exposure to Pharmacological Agents 
nAChR ligands were added at the time of transfection. Nicotine, cytisine, 
varenicline, and bupropion were all added at a concentration of 500 nM.  Cotinine was 
added at a concentration of 1 μM.  Transfection efficiency was approximately 80% and 
was not influenced by the presence of a drug. 
 
3.3.4   Preparation of Nanovesicles for Whole Cell Stoichiometry 
Vesicles were prepared from HEK-293T cells expressing α4-GFP/ β2-wt using 
nitrogen cavitation [228].  Briefly, transfection mix is removed from previously transfected 
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cells.  Cells were then washed with 1X PBS, and detached from the flask by incubation 
with 5 mL 1X versene (Invitrogen) at 37 oC for 5 minutes.  The cells were pelleted from 
the collected cell slurry by centrifugation at 200 x g for 5 minutes.   The cell pellet was 
resuspended in 5 mL sucrose-HEPES buffer supplemented with a protease inhibitor (250 
mM sucrose, 10 mM HEPES, 1 Pierce protease inhibitor mini tablet per 10 mL buffer 
(ThermoScientific), pH 7.5).  Once resuspended, cells were added to a commercially 
available nitrogen decompressor (Parr Instrument Company, Illinois, USA), attached to a 
nitrogen tank.  Nitrogen cavitation at a pressure of 250 psi for 20 minutes was used to lyse 
cells.  In this method, cells are saturated with pressurized gas, causing the cells to expand.  
Rapid decompression of the gas causes the cell membranes to rupture.  Cell lysate 
containing nanovesicles is collected once the pressure valve on the nitrogen decompressor 
is released.  Cell lysate was then centrifuged at 4000 x g for 10 minutes.  Supernatant was 
collected and centrifuged at 10,000 x g for 20 minutes.  Supernatant was again collected 
and centrifuged at 100,000 x g for 1 hour.  The pellet was resuspended in 800 μL sucrose 
HEPEs buffer (250 mM sucrose, 10 mM HEPES, pH 7.5).  Nanovesicles were stored at 
-80 oC until use. 
 
3.3.5   Cleaning Glass Bottom Dishes for Single Molecule Imaging 
 Fluorescence impurity on the glass imaging substrates were removed before the 
functionalization and addition of vesicles.  Glass coverslips (22 mm x 22 mm, #1.5, 
ThermoScientific) were cleaned by sonication in 5 M NaOH for 60 minutes at 50 oC, 
followed by thorough rinsing with deionized H2O (18 MΩ) and denatured ethanol three 
times.   Glass coverslips were then sonicated in 0.1 M HCl for an additional 60 minutes at 
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50 oC, and rinsed with deionized H2O (18 MΩ) and denatured ethanol three times.  After 
the final rinsing, glass coverslips were dried with nitrogen gas and glued to a 35 mm petri 
dish with a 13 mm opening in the center (Cell E&G).  Assembled dishes were then treated 
in an oxygen plasma cleaner (21% O2) (Harrick PDC-32G) on high for at least 5 minutes 
to ensure fluorescent organic impurities were completely removed.   
 
3.3.6    Immobilization on Glass 
Vesicles were immobilized on clean glass bottom dishes functionalized with 1 
mg/mL Biotin-PEG-Silane (Laysan Bio, Inc.), 0.1 mg/mL NeutrAvidin (Thermo 
Scientific), and 1 µg/mL biotinylated anti-GFP antibody.  On a cleaned, assembled, glass 
bottom dish, 200 μl of 1 mg/mL Biotin-PEG Silane dissolved in 95% ethanol was added.  
The dish was incubated for 35 minutes and rinsed three times with 95% ethanol and once 
with 1X PBS.  After rinsing, 200 μL of 0.1 mg/mL NeutrAvidin in 1X PBS was incubated 
on the dish for 30 minutes, then rinsed three times with 1X PBS.  A biotinylated anti-GFP 
antibody was then added at 1 μg/mL in 1X PBS and incubated for 30 minutes.  Excess 
antibody was removed by rinsing three times with 1X PBS.  Prepared vesicles were 
unthawed and diluted approximately 1:100 to ensure single vesicle level binding to the 
antibody.  Vesicles were incubated on the dish for 45 minutes, then rinsed three times with 
1X PBS.  Vesicles were maintained in 1 mL 1X PBS.  All incubations were done at room 
temperature.     
Single vesicles were spatially isolated and immobilized using the GFP in the 
receptor binding to a substrate immobilized anti-GFP antibody. Generating small enough 
vesicles, based on the pressure used during nitrogen cavitation, limits the probability of 
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capturing more than one receptor in a single vesicle.  Control experiments using 
monomeric receptors showed that there was a low probability of having more than one 
receptor per isolated vesicle. Of the vesicles generated via nitrogen cavitation 
approximately 15% contain a receptor [228].   
 
3.3.7   TIRF Imaging of GFP Photobleaching 
Single molecule isolation and immobilization of these vesicles within the TIRF 
illumination enables single receptor measurements.  Samples were imaged with objective 
style total internal reflection fluorescence microscopy with an inverted fluorescence 
microscope (Olympus ix83).  Green fluorescent protein (GFP) were excited with a 488 nm 
DPSS laser (~60 W/cm2), fiber coupled to a stepper motor to adjust the critical angle of the 
excitation beam.  The excitation beam travels through the objective (Olympus, 1.49NA, 
100x oil immersion) and is detected by an electron multiplying charge coupled device 
(EMCCD) (Andor iXon Ultra 897).  Each field of view was imaged continuously for 1000 
frames with an exposure time of 100 ms while undergoing continuous 488 nm excitation 
with an intensity of 60 W/cm2. Auto focus (Olympus ZDC2) was used to minimize focal 
drift.   
 
3.3.8   Time Trace Analysis  
 A customized Matlab program was written in our lab to accumulate time traces for 
each immobilized vesicle in the field of view.  Briefly, a 3-pixel x 3-pixel region of interest 
(ROI) was selected around each vesicle based on the mean intensity of this region, 
determined by a manually defined threshold.   Background was subtracted from each ROI 
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by calculating the mean value of pixels located along a 5-pixel x 5-pixel concentric ring 
around the selected ROI.  The calculated background intensity was subtracted from the 
ROI mean value. Time traces that showed a decrease in fluorescence intensity over time 
were identified by measuring the difference in mean intensities between the first 20 and 
last 20 frames in the time trace.   If this difference was greater than twice the standard 
deviation of the last 20 frames, the time trace was collected and analyzed.  A second 
customized Matlab program was written in our lab to display time traces for manual 
determination of bleaching steps. 
 
3.3.9   Photobleaching Step Analysis 
Photobleaching steps are identified as stepwise decreases in fluorescence decay, 
corresponding to a single molecule transitioning into a dark state.  Photobleaching steps 
were determined manually as previously described [224, 228, 231].  Previously, a discrete 
bleaching step was confirmed to correspond to one subunit [228, 231].   A single molecule 
was considered present in a time trace if at least one clear bleaching step was 
distinguishable.  Time traces showing a continuous decrease in fluorescence intensity or 
indistinct number of bleaching steps were rejected.  To qualify as a bleaching step, the GFP 
molecule fluorescence had to last at least 1 second (10 frames).  The mean intensity also 
needed to be three times higher than the standard deviation of the mean of the background 
intensity.  Each data set was independently analyzed three times.  Upon comparison of 
results from each round of independent analysis, time traces that were assigned the same 
number of bleaching steps were accepted.  Data reported is an accumulation of counted 
bleaching steps over the course of all imaging sessions and sample preparations.    
   
66 
 
3.3.10   Fitting Data to a Binomial Distribution 
GFP fails to mature a small percentage of the time leading to some subunits not 
exhibiting typical fluorescence, which would result in the occasional undercounting of 
bleaching events [224, 228]. To account for this, the probability of observing one, two, or 
three photobleaching steps in the time traces for each stoichiometry were calculated using 
a custom Matlab script by fitting data to a binomial distribution, using the probability of 
GFP fluorescing equal to 0.90 [224].  The agreement of theoretical and experimental data 
was determined using a chi squared goodness of fit analysis.  The probability of observing 
a specific number of photobleaching steps, for a receptor with fixed number of subunits is 
calculated using: 
F k, n, p !
! !
	p 1 p  (Eq. 3.1) 
Where, n is the total number of labeled subunits, k is the number of observed units, p is the 
probability of GFP being in an observable state, and F is the probability of observing k 
number of photobleaching steps from n number of labeled subunits.  Modeling the 
probability of observing a specific number of photobleaching steps for α4β2 requires two 
binomial distributions (Equation 3.2) for k = 1, 2, and 3 for both F1 and F2.  
Ftot = a1 · F1 (k, n1, p) + a2 · F2 (k, n2, p) (Eq. 3.2) 
Where F1 corresponds to the case when n1 GFP labeled subunits are in a receptor and F2 
when there are n2.   Observed results are plotted beside the expected fit based on the 
binomial probability.  Error bars on the observed data are calculated as the square root of 
the number of counted events, corresponding to a Poisson distribution of counting events. 
Once the data was fit to a binomial distribution, percentage distributions are summarized 
in a single graph to highlight differences in the fraction of each isoform present.  Error bars 
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on these percentage based graphs correspond to confidence intervals based on the number 
of vesicles analyzed.  Confidence intervals are calculated based on the equation: 
	 	 /    (Eq. 3.3) 
Where z is 1.96 for a 95% confidence internal, and n is the number of vesicles analyzed. 
 
3.4   Methods to Separate ER and PM Derived Vesicles 
3.4.1   Cell Culture and Transfection 
 As described in detail above, HEK-293T cells were maintained in matrigel matrix 
coated T75 flasks in a growth media of DMEM supplemented with 10% fetal bovine serum, 
penicillin, and streptomycin.   The day before transfection, 3 million cells were plated.  
Cells were transfected with 3500 ng of each nAChR subunit plasmid mixed in 250 μL Opti-
MEM.  The alpha subunits contained the sequence for green fluorescent protein (GFP).  A 
separate aliquot of 14 μL Lipofectamine-2000 and 250 μL optiMEM were incubated at 
room temperature for 5 minutes then combined with the plasmid solution for an additional 
25 minutes before being added to pre-plated HEK-293T cells.  After 24 hours at 37°C, 
transfection mixture removed was prior to vesicle formation. 
 
3.4.2   Preparation of Organelle Specific Vesicles 
 Plasma membrane and endoplasmic reticulum derived vesicles were prepared from 
transfected HEK-293T cells using nitrogen cavitation [228].  The day after transfection, 
half of the HEK-293T cell flasks were rinsed one time with 1X PBS and incubated for 20 
minutes in hypotonic solution (10 mM NaCl, 10 mM Tris-HCl, 1.5 mM MgCl2, 0.2 mM 
CaCl2, pH 7.4) at 0 oC.  This hypotonic solution swells cells, to increase fragmentation of 
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the plasma membrane for the formation of PM derived nanovesicles containing a single 
nAChR.  After the 20 minute incubation for plasma membrane vesicle destined flasks, all 
cells were treated with 5 mL of 1X versene and incubated 37 oC for 5 minutes to detach 
cells from the flask.  Cells were then pelleted by centrifugation at 200 x g for 5 minutes 
and resuspended in 3 mL sucrose buffer plus protease inhibitors (250 mM sucrose, 10 mM 
HEPES, 1 Pierce protease inhibitor mini tablet per 10 mL buffer (ThermoScientific), pH 
7.5) before undergoing nitrogen cavitation in a nitrogen decompressor (Parr Instrument 
Company, IL, USA).   The flasks that were previously swollen in hypotonic solution, to 
prepare plasma membrane nanovesicles, were pressurized to approximately 600 psi for 20 
minutes.  This higher pressure increases the fragmentation of the plasma membrane.  The 
other flasks, to prepare endoplasmic reticulum nanovesicles, were pressurized to 
approximately 250 psi for 20 minutes. At this pressure, plasma membrane rupturing is 
minimal and therefore nanoscale vesicle formation from this organelle is negligible.  In 
each case, cell lysate was collected and dispensed onto an OptiPrep gradient. 
 
3.4.3   Separation of Organelle Specific Vesicles 
 After vesicle formation by nitrogen cavitation, a three step OptiPrep (60% (w/v) 
iodixanol in H2O, Accurate Chemical & Scientific Corp., NY, USA) gradient was used to 
isolate plasma membrane and endoplasmic reticulum nanovesicles.  The 60% (w/v) 
iodixanol stock solution was diluted to 30%, 20%, and 10% in sucrose buffer (250 mM 
sucrose, 10 mM HEPES, pH 7.5) to prepare OptiPrep gradient solutions.  OptiPrep 
solutions were stored at 4 oC until use.  The gradient was prepared in an Ultra-Clear 
centrifuge tube (Beckman Coulter), with the densest, 30%, fraction added first.  Each 
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concentration used was dispensed in a 3 mL volume.  Cell lysate was added to the top of 
the 10% fraction.   Endoplasmic reticulum and plasma membrane nanovesicle containing 
cell lysates were added to individual columns.  The lysate gradient was then centrifuged at 
112,000 x g for 1.5 hours.  After centrifugation, fractions were collected using a peristalic 
pump. Tubing connected to the pump was vertically inserted into the centrifuge tube so 
that the highest density fraction is collected first.  The volume of each collected fraction 
was 1.5 mL, with nanovesicles localizing to fraction interfaces.  After fractions were 
collected, nanovesicles were centrifuged at 10,000 x g for 1 hour to remove OptiPrep and 
resuspended in 500 μL sucrose HEPES buffer (250 mM sucrose, 10 mM HEPES, pH 7.5).  
Purified vesicles were stored at -80 oC until used.  
 
3.4.4   Western Blot Analysis  
 Western blots were used to determine which fractions from the OptiPrep gradient 
contain plasma membrane or endoplasmic reticulum vesicles.  Gradient fractions, from 
lysate formed at 250 psi or 600 psi, were loaded on prepackaged NuPAGE 4-12% Bis-Tris 
gels (Life Technologies).  Fractions from lysate at each pressure were loaded onto separate 
gels, for detection of both endoplasmic reticulum and plasma membrane markers 
individually in each condition.  Following electrophoresis, bands were transfered to a 
nitrocellulose membrane.  Prior to antibody binding, the membrane was blocked with a 
PBST solution (5% non-fat milk, 0.1% Tween in 1X Phosphate Buffered Saline) for one 
hour at room temperature.  Primary antibodies specific for endogenous membrane proteins 
were used to detect fractions with ER and PM vesicles.  Endoplasmic reticulum vesicles 
were detected with calnexin (Santa Cruz, calnexin antibody (H-70): sc-11397), while 
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plasma membrane vesicles were identified with plasma membrane calcium ATPase 
(PMCA) (Santa Cruz, PMCA antibody (D-1): sc-271193).  Endogenous calnexin is solely 
found in the membrane of the endoplasmic reticulum, while PMCA is expressed on the 
plasma membrane, therefore enabling the identification fractions that consist of exclusively 
endoplasmic reticulum or plasma membranes.  Primary antibodies were added to the 
membrane in a 1:1000 dilution, and incubated overnight at 4 oC.   The following morning, 
excess primary antibodies were rinsed off with four repeated five minute washes with 
PBST.  Secondary rabbit or mouse antibody were added in a 1:5000 dilution, to bind 
calnexin or PMCA antibodies, respectively.  Secondary antibodies were incubated for one 
hour at room temperature, followed by a series of four five minute rinses with PBST.   
Western blotting substrate for chemiliminescence (Clarity, Bio-Rad) was reacted with the 
bands to enable visualization.  Blots were imaged on a Chemi-Doc system (Bio-Rad). 
 
3.4.5   Vesicle Immobilization and TIRF Imaging 
 Vesicles were spatially isolated on clean glass coverslips, as discussed above.  
Briefly, background fluorescence was removed from glass by 1 hour incubations in 5 M 
NaOH and 0.1 M HCl, followed by plasma cleaning.  Vesicles were immobilized on 
coverslips functionalized with 1 mg/mL Biotin-PEG-Silane (Laysan Bio, Inc.), 0.1 mg/mL 
NeutrAvidin (Thermo Scientific), and 1 µg/mL biotinylated anti-GFP antibody.  Samples 
were imaged in TIRF with excitation from a 488 nm DPSS laser traveling through the 
objective (Olympus, 1.49NA, 100x oil immersion).  Each field of view was imaged 
continuously at an intensity of about 60 W/cm2 for 1000 frames at a frame rate of 100 ms.  
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Auto focus (Olympus ZDC2) was used to minimize focal drift.  Emission was detected by 
an electron multiplying charge coupled device (EMCCD) (Andor iXon Ultra 897).  
 
3.4.6   GFP Photobleaching Analysis 
 Stepwise decreases in fluorescence intensity were identified manually as described 
above [224, 228, 231].  Time traces showing at least one distinct bleaching steps were 
counted, while time traces showing an indistinct number or a continuous decrease in 
fluorescence intensity were discarded.  Each data set was independently analyzed three 
times, and consistent results from each round were assigned bleaching steps.   Since GFP 
occasionally fails to fluorescence, counted bleaching steps were fit to a binomial 
distribution based on the probability of observing one, two, or three photobleaching steps 
for each isoform, as discussed in detail above.  The agreement of theoretical and 
experimental data was determined using a chi squared goodness of fit analysis.  Data 
reported is an accumulation of counted bleaching steps over the course of all imaging 
sessions and sample preparations.    
 
 
 
 
 
 
 
 
Copyright © Ashley Mae Loe 2016 
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CHAPTER 4: RESULTS 
 
[Some of these results were originally published in Journal of Biological Chemistry. 
AM Fox, FH Moonschi, and CI Richards. J. Biol. Chem. (2015) 290:24403-24412.  
© the American Society for Biochemistry and Molecular Biology] 
 
4.1   Cotinine Alters Expression and Trafficking of α4β2 
4.1.1   Nicotine Upregulates α4β2 
Super-ecliptic pHluorin (SEP), a pH sensitive variant of green fluorescent protein 
(GFP) [198, 217, 232], was used to quantify the upregulation of α4β2 nAChRs in the 
presence of nicotine and cotinine. SEP undergoes 488 nm excitation and exhibits green 
fluorescence at neutral pH but is not fluorescent under acidic conditions of pH < 6 [217].  
N2a cells expressing α4-SEP and β2-wt subunits were exposed to nicotine or cotinine for 
48 hours.   Nicotine induced upregulation has been measured in a variety of systems over 
the last few decades.  In this study, we successfully detected nicotine induced upregulation 
using our TIRF microscopy setup.  SEP-labeled nAChRs within the TIRF field of view 
were analyzed.  The extent of upregulation was quantified by calculating the PM integrated 
density (PMID) of α4β2 nAChRs with and without nicotine or cotinine.  PMID was 
calculated by subtracting the integrated density of cells at pH 5.4 from the total integrated 
density of the same cell at pH 7.4 (Equation 2.1).  Distribution of α4β2 receptors within 
the cell are compared using percent plasma membrane (% PM), calculated by dividing the 
PMID by the total integrated density of receptors fluorescing on the PM and ER at pH 7.4, 
multiplied by 100 (Equation 2.2). 
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N2a cells were exposed to 200 nM or 500 nM nicotine for 48 hours, and compared 
to control cells with no drug exposure.  The PMID of control cells was 4.8 x 105 ± 3.3 x 
104.  Upon nicotine exposure, the PMID of cells expressing α4β2 was increased nearly 
two-fold for cells exposed to 200 nM nicotine (8.5 x 105 ± 8.9 x 104) or three-fold for those 
exposed to 500 nM nicotine (1.4 x 106 ± 2.0 x 105) (Figure 4.1A).  An increase in 
distribution of α4β2 towards the plasma membrane was also observed, shown by a shift in 
% PM from 20.4 ± 0.8% for control cells compared to 26.1 ± 1.2% for 200 nM and 28.8 ± 
1.5% for 500 nM nicotine exposure (Figure 4.1B).  The α4β2 PMID and % PM values upon 
exposure to 200 nM or 500 nM nicotine were significantly higher than control values, based 
on a two-tailed t-test.  This shows nicotine increases the expression of α4β2 on the plasma 
membrane, as well as alters the distribution of this subtype to favor trafficking towards the 
plasma membrane (Figure 4.1; P < 0.001). 
 
4.1.2   Cotinine Upregulates α4β2 
To measure cotinine induced changes in α4β2 expression levels, N2a cells were 
exposed to physiologically relevant concentrations of cotinine ranging from 50 nm to 10 
μM.  Increased expression of α4β2 on the plasma membrane was observed when cells were 
treated with as little as 100 nM cotinine, showing a 25% increase in number of receptors 
on the membrane, (Figure 4.2A; P < 0.05), with a PMID of 1.4 x 106 ± 1.8 x 105 compared 
to a control PMID of 9.0 x 105 ± 1.3 x 105.  The highest levels of upregulation were reached 
in the presence of 1 μM cotinine, resulting in more than a two-fold increase in PMID at 2.3 
x 106 ± 3.2 x 105, compared to control (Figure 4.2A; P < 0.001).  Exposure to 500 nM and 
5 µM cotinine also showed an increase in α4β2 over no drug, with PMIDs of 1.9 x 106 ± 
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Figure 4.1 Nicotine induced upregulation of α4β2. (A) Quantification of α4β2 PMID 
shows an upregulation of α4β2 nAChRs with exposure to nicotine.  (B) Nicotine also 
alters the distribution of α4β2 nAChRs within the field of view, as shown by an 
increase in % PM. (n = 40, 29, 22) Data are mean values ± SEM (***, P < 0.001), a.u., 
arbitrary units. 
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Figure 4.2 Cotinine induced upregulation of α4β2. (A) Quantification of α4β2 
PMID shows an upregulation of α4β2 nAChRs with exposure to as little as 100 nM 
cotinine. (B) Cotinine also alters the distribution of α4β2 nAChRs within the field of 
view, as shown by an increase in % PM. (n = 40, 21, 21, 23, 13) Data are mean values 
± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001), a.u., arbitrary units. 
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2.4 x 105 and 1.3 x 106 ± 1.2 x 105, respectively, but the effect was much less than observed 
with 1 μM cotinine (Figure 4.2A; P < 0.05).  Similar results were observed at low and high 
concentrations where exposure to 50 nM or 10 μM cotinine did not result in a significant 
increase in number of receptors on the PM (Figure 4.2A), with PMIDs of 1.1 x 106 ± 1.4 x 
105 and 9.2 x 105 ± 1.2 x 105, respectively.   
These SEP based studies also show cotinine alters the distribution of α4β2 to favor 
the plasma membrane.  Upon exposure to 1 µM cotinine, there is almost a 50% shift in 
distribution toward the plasma membrane (Figure 4.2B; P < 0.001), with an increase in % 
PM to 33.8 ± 2.0% from a control of 20.4 ± 1.5%.  Increases in % PM were also seen at 
lower concentrations of 100 nM (27.3 ± 1.6%) and 500 nM (33.5 ± 1.8%), but not at 50 
nM cotinine (23.2 ± 1.5%).  A concentration of 5 µM cotinine increased % PM to 28.6 ± 
1.4%.  Although 10 µM cotinine did not increase the relative number of α4β2 on the PM, 
since PMID was unaltered, the distribution of receptors at 10 μM slightly favors the PM 
with a % PM of 24.8 ± 1.1% (Figure 4.2B; P < 0.05).  These values suggest that some 
pharmacologically relevant concentrations of cotinine increase the trafficking of α4β2 
towards the plasma membrane. 
Figure 4.3 shows representative TIRF images of N2a cells expressing α4-SEP/β2-
wt treated with no drug (Figure 4.3A), 500 nM nicotine (Figure 4.3B) or 1 μM cotinine 
(Figure 4.3C). For all rows, the first column shows a cell imaged in TIRF with an 
extracellular pH of 7.4 (ER and PM fluorescing), the second column shows an image of 
the same cell at pH 5.4 (fluorescence from ER only), and the third column shows a 
subtracted image representing just the PM component.  Brighter images in the third column 
in the presence of nicotine or cotinine corresponds to a higher number of α4-SEP/β2 
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Figure 4.3 TIRFM images illustrating increased α4β2 PMID with nicotine or 
cotinine exposure.  Representative TIRFM images of α4-SEP/β2 exposed to no drug 
(A), 500 nM nicotine (B), or 1 μM cotinine (C).  The first column shows respective 
cells at pH 7.4, with nAChRs on the plasma membrane and endoplasmic reticulum 
fluorescing, whereas the second column shows the same cells at pH 5.4 with all 
fluorescence from nAChRs in the endoplasmic reticulum.  The third column shows 
images constructed by subtracting the pH 5.4 image from the pH 7.4 image, resulting 
in receptors located on the plasma membrane (PMID). 
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nAChRs residing on the plasma membrane.  While the subtracted TIRF footprint shown in 
the third column qualitatively shows PM expression for the given cells, the extent of 
upregulation was quantified by calculating the PM integrated density (PMID) of α4β2 
receptors with and without addition of cotinine.  
 
 
4.1.3   Co-administration of Nicotine and Cotinine 
  
 No additive effects were detected when cells were simultaneously exposed to both 
nicotine and cotinine at physiological concentrations for 48 hours.  An array of 
concentrations of nicotine and cotinine were used.  Cells were exposed to nicotine at 50 
nM or 500 nM, and compared to cells also exposed to cotinine at 300 nM, 1 µM, or 5 µM, 
as shown in Figure 4.4.   Control cells exposed to no drug had a PMID of 2.1 x 106 ± 2.1 x 
105 (Figure 4.4A).  When nicotine was added, the PMIDs of cells were measured to be 2.7 
x 106 ± 2.8 x 105 for 50 nM, and 3.1 x 106 ± 3.0 x 105 for 500 nM.  Cells exposed to cotinine 
had PMIDs of 2.8 x 106 ± 3.1 x 105 for 300 nM, 3.3 x 106 ± 2.4 x 105 for 1 µM, and 2.7 x 
106 ± 3.6 x 105 for 5 µM.  Co-administration of nicotine and cotinine at these concentrations 
still showed an increase in PMID over the control cells, but were not significantly different 
than exposure to these concentrations of nicotine or cotinine alone.  Cells co-exposed to 
300 nM cotinine and 50 nM nicotine had a PMID of 2.6 x 106 ± 1.9, x 105, compared to 
those co-exposed to 300 nM cotinine and 500 nM nicotine with a PMID of 3.2 x 106 ± 3.7 
x 105.  The PMID of cells co-exposed to 1 µM cotinine and 50 nM nicotine was 3.2 x 106 
± 3.6 x 105, while those exposed to 1 µM cotinine and 500 nM nicotine showed a PMID of 
2.9 x 106 ± 3.2 x 105.  PMIDs of cell co-exposed to 5 µM cotinine and 50 nM or 500 nM 
nicotine were 2.7 x 106 ± 3.0 x 105 and 3.0 x 106 ± 3.6 x 105, respectively.  Although all 
   
79 
 
 
 
Figure 4.4 Co-administration of nicotine and cotinine.  Quantification of α4β2 
PMID (A) and % PM (B) upon simultaneous exposure to both nicotine and cotinine 
did not show any additive effects.  Nicotine and cotinine both increased PMID and % 
PM compared to control cells exposed to no drug.  (n = 28, 17, 19, 20, 26, 14, 25, 20, 
18, 17, 24, 17) Data are mean values ± SEM (***, P < 0.001 compared to no drug 
controls), a.u., arbitrary units. 
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values were significantly different than control cells (Figure 4.4A; P < 0.001), there were 
no significant differences in expression on the plasma membrane between samples of 
different concentrations.   
 Likewise, differences in distribution towards the plasma membrane were detected 
in comparison to control cells, but not between samples of varying concentrations of 
cotinine and nicotine, as shown in Figure 4.4B.  Control cells showed 24.1 ± 0.8% of α4β2 
nAChRs within the TIRF field of view were located on the plasma membrane.  Cells 
exposed to 50 nM or 500 nM nicotine showed a significant increase in this number to 31.4 
± 1.5% and 35.1 ± 1.2%, respectively.  Exposure to cotinine also increased the % PM to 
31.2 ± 1.7% for 300 nM cotinine, 33.8 ± 1.3% for 1 µM cotinine, and 29.6 ± 1.3% for 5 
µM cotinine.  Co-exposure of 300 nM cotinine with 50 nM or 500 nM nicotine lead to 
increases in % PM to 31.3 ± 1.2% and 30.3 ± 1.3%, respectively.  Cells exposed to 1 µM 
cotinine in addition to 50 nM nicotine had a % PM of 31.1 ± 1.3%, while cells co-exposed 
to 500 nM nicotine had a % PM of 32.3 ± 1.2%.  Exposure to 5 µM cotinine and 50 nM or 
500 nM nicotine had % PM values of 29.7± 1% and 30.8 ± 1.5%, respectively.  Although 
all values were significantly different than control cells (Figure 4.4B; P < 0.001), there 
were no significant differences in distribution towards the plasma membrane between 
samples of different concentrations.   
 
4.1.4   Cotinine Increases Number of α4β2 Insertion Events  
SEP-labeled nAChRs were used to quantify α4β2 nAChR containing vesicle 
trafficking by measuring the number of single vesicle insertion events at the plasma 
membrane. The SEP tag is oriented on the luminal side of secretory vesicles so they are 
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maintained at a low pH prior to delivery to the PM.  As a result, receptors are not 
fluorescent as they are trafficked to the PM but turn on as the vesicle fuses with the PM, 
when the SEP tag is exposed to the extracellular solution of pH 7.4 [217, 232].  In this 
study, an insertion event is defined as a burst of fluorescence appearing at the plasma 
membrane and lasting for more than two frames, or 400 ms, which corresponds to the 
insertion of an SEP-tagged nAChR into the plasma membrane.  After the initial insertion 
of a trafficking vesicle, a lateral spread of fluorescence was observed corresponding to full 
fusion of the vesicle and subsequent diffusion of the SEP-labeled nAChRs.  Figure 4.5 
shows a representative series of TIRF images of an insertion event in an N2a cell, 
illustrating a whole cell (Figure 4.5A) and a close up of frames prior to insertion (Figure. 
4.5 B1), during arrival of the vesicle shown as a burst of fluorescence (Figure 4.5 B2), 
followed by a lateral spread (Figure 4.5 B3-B6) and diffusion across the membrane (Figure 
4.5 B7-B9).  
Insertion events were manually counted in cells expressing α4β2, α4β2α5, or 
α4β2α5-D398N, comparing those exposed to no drug or 1 μM cotinine, as shown in Figure 
4.6. Cells treated with 1 μM cotinine exhibited approximately a 30% increase in the number 
of trafficking vesicles that contained α4β2 compared to untreated cells (Figure 4.6; P < 
0.001), with the detected number of insertion events increasing from 15.4 ± 0.4 to 19.4 ± 
0.7 within the measured ten seconds per cell.  When the α5D or α5N auxiliary subunit was 
co-expressed with α4 and β2 subunits, there were no differences in the trafficking rate of 
nAChRs in the presence of cotinine.  Cells expressing α4β2α5 showed 15.8 ± 0.4 insertion 
events in the absence of a drug, but 15.4 ± 0.5 when 1 µM cotinine is present.  Similarly, 
cells expressing α4β2α5-D398N showed 16.0 ± 0.5 insertion events in the ten second span 
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Figure 4.5 Representative TIRFM images during an insertion event.  (A) A 
representative N2a cell expressing α4-SEP and a close up of frames (B) during series 
of images illustrating an insertion event prior to insertion (B1), during arrival of the 
vesicle shown as a burst of fluorescence (B2), followed by a lateral spread (B3-B6) 
and diffusion across the membrane (B7-B9).  
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Figure 4.6 Cotinine increases the number of α4β2 insertion events.  Insertion events 
were counted for α4-SEP/β2, α4-SEP/β2/α5, and α4-SEP/β2/α5-D398N after exposure 
to 1 μM cotinine for 48 hours.  Data are mean values ± SEM (**, P < 0.01) (n = 5). 
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when no drug was present, and 16.0 ± 0.4 when 1 µM cotinine is present (Figure 4.6).  
Overall, an increase in α4β2 trafficking events was seen in the presence of cotinine.  
Cotinine did not alter the number of insertion events in α4β2α5 or α4β2α5-D398N under 
these conditions. 
 
4.2   Upregulation of α4β2 is Lost Upon Incorporation of α5 
4.2.1   Nicotine does not Upregulate α4β2α5D or α4β2α5N 
 When α4β2 is exposed to 500 nM nicotine, an increase in PMID is detected as 
previously described.  However, when the α5 subunit is incorporated into this pentamer, 
this nicotine induced upregulation effect is not detected in these SEP based studies.  In the 
absence of nicotine, the PMID of α4β2 is 7.6 x 105 ± 9.3 x 104 (Figure 4.7A).  When α5 in 
incorporated, the PMID is 7.2 x 105 ± 1.1 x 105 and 6.9 x 105 ± 9.3 x 104 upon addition of 
500 nM nicotine.  When the α5-D398N subunit is present in the α4β2 pentamer, a 
statistically significant increase in PMID was not detected upon addition of nicotine.  
Measured PMID values for the α4β2α5-D398N pentamer are 6.8 x 105 ± 1.1 x 105 in the 
absence of nicotine and 1.1 x 106 ± 2.1 x 105 after nicotine is added (Figure 4.7A).  Nicotine 
increased the expression of α4β2, but not α4β2α5 or α4β2α5-D398N (Figure 4.7; P < 
0.001). 
 No statistical differences in the distribution towards the plasma membrane as a 
result of nicotine exposure are detected in these studies for either α5 containing subtypes 
(Figure 4.7B).  Upon addition of nicotine, the % PM of α4β2 is increased to 32.3 ± 2.9% 
from a control of 19.1 ± 1.4% (Figure 4.7B; P < 0.001).  In α4β2α5, % PM is measured as 
21.8 ± 1.9% and 23.6 ± 2.7% for cells in the absence or presence of nicotine, respectively.  
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Figure 4.7 Nicotine upregulates α4β2 but not α4β2α5D or α4β2α5N. Nicotine 
causes an increase in PMID (A) and % PM (B) of α4β2, but not α4β2α5D or α4β2α5N.  
α4β2α5N has a higher % PM than α4β2α5D, independent of nicotine exposure. (n = 
14, 15, 13, 11, 16, 10) Data are mean values ± SEM (#, P < 0.05 compared to α4β2α5D; 
***, P < 0.001 compared to α4β2 without nicotine), a.u., arbitrary units. 
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For cells expressing α4β2α5-D398N, the % PM is 26.0 ± 2.2% with no drug exposure and 
25.2 ± 1.4% after the addition of nicotine.  Both of these values are higher than the % PM 
of α4β2 or α4β2α5D, although this increase in distribution appears to be independent of 
the presence of nicotine (Figure 4.7B; P < 0.001).  Nicotine increases the distribution of 
α4β2 towards the plasma membrane, but does not alter trafficking of α4β2α5 or α4β2α5-
D398N. 
 
4.2.2   Cotinine does not Upregulate α4β2α5D 
 No significant changes in the expression levels or distribution towards the plasma 
membrane were measured in these SEP based studies in α4β2α5D upon exposure to 
cotinine, as shown in Figure 4.8.  PMID was detected for α4β2α5D exposed to varying 
concentrations of cotinine from 100 nM to 5 µM.  Control α4β2α5D cells with no exposure 
to cotinine had a PMID of 4.2 x 105 ± 5.2 x 104 (Figure 4.8A).  Cells exposed to 100 nM, 
500 nM, 1 µM or 5 µM cotinine had PMIDs of 4.4 x 105 ± 6.1 x 104, 4.5 x 105 ± 4.1 x 104, 
4. 5 x 105 ± 7.7 x 104, and 4.3 x 105 ± 4.4 x 104, respectively. No significant differences in 
α4β2α5D PMID were detected between control cells and those exposed to cotinine at any 
concentration evaluated.  
 There were also no significant differences detected in the distribution of α4β2α5D 
upon exposure to cotinine.  The % PM of α4β2α5D in the absence of cotinine is 24.8 ± 
1.9% (Figure 4.8B).  Upon addition of cotinine, the % PM is measured as 25.1 ± 1.4%, 
23.8 ± 1.7%, 26.2 ± 1.7%, and 24.1 ± 1.3% for cells exposed to 100 nM, 500 nM, 1 µM or 
5 µM cotinine, accordingly.  Cotinine did not alter the % PM of α4β2α5D at any 
concentration used in this study.  Representative images of cells transiently transfected 
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Figure 4.8 Cotinine does not alter expression of α4β2α5D.  Quantification of (A) 
PMID or (B) % PM show no significant differences when α4β2α5D is exposed to 100 
nM to 5 µM cotinine. (n = 19, 21, 20, 10, 37) Data are mean values ± SEM, a.u., 
arbitrary units. 
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with α4β2α5D are shown in Figure 4.9.  Cells expressing α4β2α5D in the absence of drug 
(Figure 4.9A), or in the presence of nicotine (Figure 4.9B), or cotinine (Figure 4.9C), 
appear similar in distribution of α4-SEP/β2/α5D towards the plasma membrane and relative 
expression of these nAChRs on the plasma membrane. 
 
4.2.3   Incorporation of α5-D398N into α4β2 Increases Distribution to the PM 
 Similar to α4β2 pentamers containing α5D, incorporation of α5-D398N resulted in 
a loss of upregulation in expression or trafficking of α4β2 when exposed to cotinine.  The 
PMID of cells transfected with α4β2α5-D398N in the absence of any drug was 7.4 x 105 ± 
1.1 x 105 (Figure 4.10A).  Upon the addition of 100 nM, 500 nM, 1 µM, or 5 µM cotinine, 
the PMIDs were 7.6 x 105 ± 1.1 x 105, 8.0 x 105 ± 9.8 x 104, 7.3 x 105 ± 7.0 x 104, and 7.7 
x 105 ± 6.7 x 104, respectively.  Addition of cotinine did not significantly change PMID of 
α4β2α5-D398N at the concentrations measured in this study.   There were also no statistical 
differences between the PMID of cells expressing α4β2α5-D398N compared to those 
expressing α4β2α5D, with a PMID of 5.8 x 105 ± 1.0 x 105 (Figure 4.10A). 
 Likewise, no cotinine dependent differences in distribution towards the plasma 
membrane were detected in cells expressing α4β2α5-D398N (Figure. 4.10B).  In the 
absence of cotinine, the % PM for α4β2α5-D398N cells was 30.8 ± 2.2%.  This value was 
measured to be 32.2 ± 3.3%, 30.1 ± 2.3%, 35.3 ± 2.8%, and 37.5 ± 2.8% for cells exposed 
to 100 nM, 500 nM, 1 µM, and 5 µM cotinine, respectively (Figure 4.10B).  Interestingly, 
the % PM for all cells expressing the α5-D398N version of the accessory subunit was 
significantly higher than the % PM of cells expressing the α5D version.  The % PM for 
α4β2α5D was lower than α4β2α5-D398N, with a % PM of 19.4 ± 2.6% (Figure 4.10B; P 
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Figure 4.9 Representative TIRF images of cells expressing α4β2α5D. N2a cells 
expressing α4-SEP/β2/α5D exposed to (A) no drug, (B) 500 nM nicotine, or (C) 1 µM 
cotinine at pH 7.4, and pH 5.4.  Similar PMID footprints are detected in each condition. 
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Figure 4.10 Incorporation of α5-D398N increases distribution towards the PM.  
No significant changes in PMID (A) are seen between α4β2α5D and α4β2α5-D398N, 
or α4β2α5-D398N exposed to cotinine, but α4β2α5-D398N has a higher % PM than 
α4β2α5D (B) independent of cotinine concentration. (n = 14, 23, 26, 33, 24, 30) Data 
are mean values ± SEM (**, P < 0.01 compared to 398D), a.u., arbitrary units. 
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< 0.01).  This increase in distribution towards the plasma membrane appears to be 
independent of the presence of cotinine, since all % PM values of α4β2α5-D398N 
expressing cells are not significantly different from each other.  Representative images of 
cells transiently transfected with α4β2α5-D398N compared to α4β2α5D, with or without 
nicotine or cotinine are shown in Figure 4.11.  Cells in the absence of drug expressing 
α4β2α5D (Figure 4.11A), or α4β2α5-D398N (Figure 4.11B) show higher distribution 
towards the plasma membrane when α5-D398N is present.  There are no apparent 
differences in relative expression or distribution towards the plasma membrane in cell 
expressing α4β2α5-D398N upon exposure to nicotine (Figure 4.11C), or cotinine (Figure 
4.11D).  
 
4.3   Low Concentrations of Cotinine Decreases α6β2β3 nAChR Density on the PM 
4.3.1   Cotinine does not Upregulate α6β2 
 Labeling the α6 subunit with SEP for pH sensitive studies showed that the density 
of α6β2 nAChRs on the plasma membrane does not depend on the presence of cotinine.  
There were no detected changes in the PMID of α6β2 nAChRs when cells were exposed 
physiologically relevant concentrations of cotinine.  The PMID of cells expressing α6β2 in 
the absence of drug was 8.9 x 105 ± 1.2 x 105 (Figure 4.12A).  The relative levels of 
expression of these cells upon addition of cotinine are 8.7 x 105 ± 7.5 x 104, 8.5 x 105 ± 1.0 
x 105, 8.9 x 105 ± 9.1 x 104, and 9.5 x 105± 1.7 x 105 at concentrations of 100 nM, 500 nM, 
1 µM or 5 µM cotinine, respectively.  No significant differences in α6β2 PMID were 
detected between control cells and those exposed to any concentrations of cotinine 
evaluated in this study (Figure 4.12A). 
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Figure 4.11 Representative TIRF images of cells expressing α4β2α5-D398N. N2a 
cells expressing α4-SEP/β2/α5-D398N exposed to (B) no drug, (C) 500 nM nicotine, 
or (D) 1 µM cotinine show a higher % PM than α4β2α5D (A) but no difference in 
PMID. 
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Figure 4.12 Cotinine does not alter expression of α6β2.  Quantification of (A) PMID 
or (B) % PM show no significant differences when α6β2 is exposed to 100 nM to 5 
µM cotinine. (n = 18, 11, 9, 18, 8) Data are mean values ± SEM, a.u., arbitrary units. 
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 The distribution of α6β2 towards the plasma membrane was also not affected by 
the addition of cotinine.  Control cells expressing α6β2 showed a % PM of 22.2 ± 1.0% 
(Figure 4.12B).  The % PM upon exposure to 100 nM, 500 nM, 1 µM or 5 µM cotinine 
were 23.4 ± 1.2%, 24.7 ± 2.2%, 18.6 ± 1.3%, and 19.4 ± 1.1%, respectively.  This SEP 
based method did not show any significant differences in the distribution of α6β2 between 
the plasma membrane and peripheral endoplasmic reticulum at any concentrations of 
cotinine measured (Figure 4.12). 
 
4.3.2   Low Concentrations of Cotinine Decreases α6β2β3 nAChR Density on the PM 
The effect of cotinine on the expression of α6β2β3 nAChRs was also evaluated.  
Matching previous reports, these SEP based studies with the α6 subunit labeled show that 
incorporation of the β3 subunit into an α6β2 pentamer increases expression levels on the 
plasma membrane [115] (Figure 4.13A; P < 0.05), with the PMID of α6β2β3 being 1.2 x 
106 ± 1.5 x 105 compared to that of α6β2 at 8.3 x 105 ± 6.5 x 104.  Once β3 is included in 
the pentamer, there appears to be a cotinine concentration dependent response resulting in 
lower levels of α6β2β3 nAChR on the plasma membrane.  At low levels of cotinine (100 
nM), there is a trend towards a decreased number of α6β2β3 nAChRs, with a PMID of 7.8 
x 105 ± 1.7 x 105.  This decrease reaches a level of significance with 500 nM cotinine 
(Figure 4.13A; P < 0.05), with a PMID corresponding to 8.1 x 105 ± 5.9 x 104.  The 
downregulated level of expression of α6β2β3 with 500 nM cotinine is comparable to that 
of α6β2 when the β3 subunit is absent.  Downregulation is less pronounced, although not 
significant, when cotinine treatment was increased to 1 μM cotinine, with a PMID of 9.2 x 
105 ± 1.1 x 105.  At 5 μM cotinine, downregulation is completely lost, as the PMID of 1.2 
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Figure 4.13 Cotinine induced downregulation of α6β2β3.  (A) Quantification of 
PMID for α6β2β3 compared to α6β2 shows a significant increase in number of 
receptors on the PM when β3 is incorporated.  When β3 is present, 500 nM cotinine 
significantly decreases the PMID.  (B) No changes in % PM in the presence of cotinine 
or compared to α6β2 were detected. (n = 18, 19, 27, 16, 11, 11) Data are mean values 
± SEM (*, P < 0.05 compared to α6β2; #, P < 0.05 compared to α6β2β3 with no drug), 
a.u., arbitrary units. 
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x 106 ± 2.2 x 105 is comparable to α6β2β3 with no drug (Figure 4.13A).  This shows α6β2β3 
nAChRs are downregulated at low concentrations of cotinine (500 nM) in this study. 
The percentage of α6β2β3 within the TIRF field of view was not altered by the 
addition of cotinine (Figure 4.13B).  Also, the % PM value for α6β2β3 nAChRs were not 
significantly different than the % PM of α6β2.  The % PM of α6β2β3 was 27.1 ± 2.7%, 
compared to 23.9 ± 1.0% for α6β2.  Exposing α6β2β3 nAChRs to 100 nM, 500 nM, 1 µM 
or 5 µM cotinine lead to % PM values of 25.0 ± 1.5%, 27.9 ± 2.5%, 26.4 ± 3.1% and 25.3 
± 3.5%, respectively.  No significant differences were measured when comparing the % 
PM of α6β2 to α6β2β3, or between α6β2β3 nAChRs upon addition of any concentration of 
cotinine (Figure 4.13B).  Representative cell images expressing α6β2 and α6β2β3 in the 
presence or absence of cotinine are shown in Figure 4.14.  Exposing α6β2 expressing cells 
to cotinine does not alter the relative number of nAChRs located on the plasma membrane.  
Incorporating the accessory β3 subunit increases the PMID, evident by a higher intensity 
on the plasma membrane.  Upon addition of 500 nM cotinine, the α6β2β3 are 
downregulated to a level comparable to α6β2 alone, as seen in cells with a similar PMID 
footprint. 
 
4.4   Nicotine and Cotinine do not Alter Expression or Distribution of α3β4 nAChRs 
4.4.1   Nicotine does not Increase Expression of α3β4 nAChRs 
 Cells were transiently transfected with α3-SEP/β4, with or without the accessory 
α5 or α5-D398N subunit.  These cells were exposed to a physiologically relevant 
concentration of 500 nM nicotine for 48 hours.  Detection of SEP-labeled nAChRs showed 
no differences in relative expression of α3β4 on the plasma membrane upon addition of 
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Figure 4.14 Representative TIRF images of cells expressing α6β2 or α6β2β3. N2a 
cells expressing α6-SEP/β2 exposed to no drug (A), or 500 nM cotinine (B), show no 
significant changes.  However, α6β2β3 is significantly downregulated upon exposure 
to 500 nM cotinine (D), compared to no drug (C). 
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nicotine, as measured by PMID (Figure 4.15A).  The PMID of α3β4 with no drug exposure 
was 3.3 x 106 ± 7.5 x 105, compared to 2.9 x 106 ± 3.7 x 105 after exposure to 500 nM 
nicotine.  After α5 is incorporated into the pentamer, the PMID of α3β4α5 is 3.2 x 106 ± 
6.8 x 105 versus 3.6 x 106 ± 5.1 x 105 after addition of nicotine.  Including α5-D398N in 
α3β4 also does not change the PMID, with values of 3.8 x 106 ± 6.9 x 105 and 2.8 x 106 ± 
7.1 x 105 before and after the addition of nicotine, respectively.  There were no statistical 
differences in the PMID of cells expressing α3β4, α3β4α5, or α3β4α5-D398N regardless 
of exposure to 500 nM nicotine (Figure 4.15A). 
 
4.4.2   Nicotine does not Alter Distribution of α3β4 nAChRs 
 Cells expressing α3β4, with or without an accessory α5 or α5-D398N subunit, were 
also evaluated for changes in distribution of nAChRs within the plasma membrane and 
peripheral endoplasmic reticulum when exposed to nicotine (Figure 4.15B).  The % PM of 
α3β4 was 48.1 ± 3.5%, compared to 49.9 ± 2.6% after exposure to nicotine.  Cells 
expressing α3β4α5 had a % PM of 50.9 ± 2.5% without exposure to a drug and 45.7 ± 4.1% 
after addition of nicotine.  Cells with incorporation of the α5-D398N subunit into the α3β4 
pentamer had a % PM of 40.1 ± 3.9%, and 46.5 ± 2.7% with nicotine exposure.  In each 
case, there were no significant changes in the distribution of these nAChR subtypes 
towards the plasma membrane when 500 nM nicotine is present (Figure 4.15B). 
 
4.4.3   Cotinine does not Increase Expression of α3β4 nAChRs 
 Cells transfected with α3β4, α3β4α5, or α3β4α5-D398N were exposed to 1 µM 
cotinine to evaluate changes in expression levels.  No signficant differences in relative 
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Figure 4.15 Nicotine does not alter expression of α3β4.  Quantification of (A) PMID 
or (B) % PM show no significant differences in nAChR number or distribution when 
α3β4, α3β4α5, or α3β4α5-D398N is exposed to 500 nM nicotine. (n = 13, 14, 11, 11, 
4, 8) Data are mean values ± SEM, a.u., arbitrary units. 
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expression on the plasma membrane were detected upon addition of nicotine, as measured 
by the PMID of SEP-labeled nAChRs (Figure 4.16A).  The PMID of control α3β4 was 3.3 
x 106 ± 7.5 x 105, and 2.7 x 106 ± 4.5 x 105 after exposure to cotinine.  When α5 is combined 
with the α3β4 pentamer, the PMID is 3.2 x 106 ± 6.8 x 105 with no drug exposure, compared 
to 3.0 x 106 ± 6.2 x 105 in the presence of cotinine.  Cells expressing α3β4α5-D398N 
showed a PMID of 3.8 x 106 ± 6.9 x 105 without drug, and 3.0 x 106 ± 4.3 x 105 upon 
addition of cotinine.  No statistical differences in the PMID of cells expressing α3β4, 
α3β4α5, or α3β4α5-D398N were measured in the absence or presence of 1 µM cotinine 
(Figure 4.15A). 
 
4.4.4   Cotinine does not Alter Distribution of α3β4 nAChRs 
 Changes in distribution of nAChRs within the TIRF field of view was also assessed 
for cells expressing α3β4, with or without an accessory α5 or α5-D398N subunit after 
exposure to cotinine.  No differences in % PM were measured using the SEP based 
technique (Figure 4.16B).  The % PM of cells expressing α3β4 was 48.1 ± 3.5% and 46.4 
± 2.9% with and without the addition of cotinine, respectively.  The % PM of control 
α3β4α5 cells was 50.9 ± 2.5% compared to 44.1 ± 3.3% upon the addition of cotinine.  
Cells expressing α3β4α5-D398N showed a % PM of 40.1 ± 3.9% without exposure to drug 
or 45.7 ± 3.5% after cotinine is added.  No statistically different changes in trafficking were 
detected with α3β4, α3β4α5, or α3β4α5-D398N expressing cells were exposed to 1 µM 
cotinine for 48 hours (Figure 4.16B). 
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Figure 4.16 Cotinine does not alter expression of α3β4.  Quantification of (A) PMID 
or (B) % PM show no significant differences in nAChR number or distribution when 
α3β4, α3β4α5, or α3β4α5-D398N are exposed to 1 µM cotinine (n = 13, 14, 11, 7, 4, 
18) Data are mean values ± SEM, a.u., arbitrary units. 
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 Representative TIRF images of N2a cells expressing α3β4, α3β4α5, or α3β4α5-
D398N with and without exposure to 500 nM nicotine or 1 µM cotinine are shown in Figure 
4.17, Figure 4.18, and Figure 4.19, respectively.  In each case, the PMID footprint of 
control cells compared to those exposed to nicotine or cotinine appear similar in intensity, 
corresponding to no changes in the expression levels of these nAChRs on the plasma 
membrane.  Also, no changes in trafficking were measured, meaning the relative intensity 
differences between cells at pH 7.4 and pH 5.4 are similar.  However, the distribution of 
α3β4, α3β4α5, and α3β4α5-D398N favors expression on the plasma membrane to a higher 
degree than β2-containing nAChRs, such as α4β2* or α6β2*.  This is evident by a more 
pronounced PMID footprint in the third column of these figures. 
 
4.5   Cotinine Exposure Results in Preferential Assembly of (α4)2(β2)3 
Since nAChRs are pentameric, α4β2 can assemble with either (α4)3(β2)2 or 
(α4)2(β2)3 stoichiometry.  To determine assembly, a technique that our lab recently 
developed was used to perform single molecule analysis of subunit stoichiometry by 
spatially isolating nAChRs embedded in cell-membrane derived vesicles [228].  Vesicles 
were generated from cells expressing α4-GFP and β2-wt subunits. These vesicles were 
isolated on glass substrates, and TIRF microscopy was used to visualize the GFP 
fluorescence signal.  Single step photobleaching of GFP was used to identify the number 
of α4-GFP subunits in each receptor. The number of bleaching steps corresponds to the 
number of GFP-tagged subunits present and, therefore, indicates the stoichiometry of the 
receptor [85, 224].  The number of individual vesicles showing one, two, or three bleaching 
steps was fit to a binomial distribution to account for the 90% probability that GFP will be 
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Figure 4.17 Representative TIRF images of cells expressing α3β4. N2a cells 
expressing α3-GFP/β4 exposed to (A) no drug, (B) 500 nM nicotine, or (C) 1 µM 
cotinine show no significant differences in the PMID footprint. 
   
104 
 
 
 
 
 
 
Figure 4.18 Representative TIRF images of cells expressing α3β4α5D. N2a cells 
expressing α3-GFP/β4/α5 exposed to (A) no drug, (B) 500 nM nicotine, or (C) 1 µM 
cotinine show no significant differences in the PMID footprint. 
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Figure 4.19 Representative TIRF images of cells expressing α3β4α5-D398N. N2a 
cells expressing α3-GFP/β4/α5-D398N exposed to (A) no drug, (B) 500 nM nicotine, 
or (C) 1 µM cotinine show no significant differences in the PMID footprint. 
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in a fluorescent state. The total number of observed one, two, or three bleaching steps in 
the presence of no drug, nicotine, or cotinine, is included in Table 4.1.   
For cells not exposed to any compound, binomial distributions weighted for 40% 
(α4)2(β2)3 and 60% (α4)3(β2)2 fit the observed distribution.  This distribution is verified 
using a chi-squared goodness of fit analysis.  In the control sample, 8 ± 1% of vesicles 
showed one bleaching step, 48 ± 4% showed two bleaching steps, and 45 ± 4% showed 
three bleaching steps.  These percentages correspond to observed fractions of 0.08 ± 0.01, 
0.48 ± 0.04, and 0.45 ± 0.04, respectively, as shown in blue in Figure 4.20A.  Error bars 
represent the square root of the number of counted events, given a Poisson distribution.  
These ratios are compared to expected fractions based on a 40:60 binomial distribution.  
Since α4β2 can assemble with either a (α4)3(β2)2 or (α4)2(β2)3, only two or three GFP 
molecules will be present.  For two GFP molecules seen in (α4)2(β2)3, with a 90% 
probability of GFP being in a fluorescent state, the contributions of 0.07 from one steps 
and 0.33 from two steps should be expected, shown in black in Figure 4.20A.  For three 
GFP-labeled subunits, as in (α4)3(β2)2, again fluorescing 90% of the time, the contributions 
of 0.02 from one steps, 0.15 from two steps, and 0.44 from three steps is expected, shown 
in red in Figure 4.20A.  Taken together, the total number of one steps detected is expected 
to be 0.07 (from two GFPs) plus 0.02 (from three GFPs), or 0.09 as an expected value.  
This expected fraction of one steps, 0.09, is compared to the observed fraction of 0.08 ± 
0.01 to get a chi-squared goodness of fit for detecting one bleaching step.  For two steps, 
0.33 (from two GFPs) and 0.15 (from three GFPs) are added for an expected value of 0.48, 
compared to the observed 0.48 ± 0.04 fraction of two counted bleaching steps.  For three 
steps, the 0.44 (from three GFPs) is compared to the observed 0.45 ± 0.04.  These expected  
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Table 4.1: Total Distribution of Observed α4-GFP/β2 Bleaching Steps with 
Nicotine or Cotinine Exposure 
 
# Vesicles 
Counted 
1 Step 2 Steps 3 Steps 4 Steps 
No Drug 359 28 171 160 12 
Nicotine 325 40 202 83 11 
Cotinine 305 47 194 64 10 
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Figure 4.20 Binomial distributions showing a shift in stoichiometry when nicotine 
or cotinine are present.  Observed (blue bars) and fitted (black/red bars) distributions 
of one, two, or three bleaching steps when α4-GFP/β2 is exposed to no drug (A), 500 
nM nicotine (B) or 1 µM cotinine (C).  Error bars are the square root of the number of 
vesicles counted. 
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versus observed distributions fit a binomial of 40% (α4)2(β2)3 and 60% (α4)3(β2)2 for 
control cells, verified by a chi-squared goodness of fit. 
Treatment with 500 nM nicotine altered the stoichiometric distribution with a shift 
toward a higher percentage of receptors with the high sensitivity (α4)2(β2)3 stoichiometry. 
The distribution of nicotine exposed cells was best fit for binomial distributions weighted 
with 65% (α4)2(β2)3 and 35% (α4)3(β2)2 (Figure 4.20B).  This was derived from observed 
fractions of 0.12 ± 0.02 for one step, 0.62 ± 0.04 for two bleaching steps, and 0.26 ± 0.03 
for three bleaching steps.  The observed fractions were compared to expected values for a 
35:65 distribution.  The expected fraction of one steps is 0.13, or 0.12 from two α4-GFPs 
and 0.01 from three α4-GFPs. The expected fraction of two steps is 0.62, or 0.53 from two 
GFP molecules and 0.09 from three GFP molecules. The expected fraction of three steps 
is 0.26 with all three α4-GFPs in a pentamer fluorescing, with no contribution from two 
GFPs.  A chi-squared test verified that the observed fractions fit a binomial distribution of 
65% (α4)2(β2)3 and 35% (α4)3(β2)2. 
The presence of 1 μM cotinine also resulted in a shift in the stoichiometric 
distribution toward the high sensitivity (α4)2(β2)3 version.  The observed distribution fit to 
binomials weighted 70% (α4)2(β2)3 and 30% (α4)3(β2)2 (Fiure. 4.20C).  This corresponds 
to observed fractions of 0.15 ± 0.02 one steps, 0.64 ± 0.05 two steps, and 0.21 ± 0.03 three 
steps.  This fits expected values for the 30:70 (α4)2(β2)3 to (α4)3(β2)2 distribution.  The 
expected fraction of one steps for this distribution is 0.14, with 0.13 from two GFP-labeled 
subunits, and 0.01 from three GFP-labeled subunits.  The expected fraction of two steps is 
0.65, or 0.57 from two GFPs and 0.07 from three α4-GFPs.  The expected fraction of three 
steps is 0.22 when three GFPs are present, with no contribution from two α4-GFPs.  The 
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fit to a 70% (α4)2(β2)3 and 30% (α4)3(β2)2 binomial was verified with a chi-squared 
goodness of fit test. 
Figure 4.21 compares the stoichiometries derived from the weighted fits of α4β2 
with no drug, nicotine, and cotinine.  Error bars are 95% confidence intervals.  In the 
absence of a pharmacological agent, the inherent distribution fits a binomial of 40 ± 5% 
(α4)2(β2)3 and 60 ± 4% (α4)3(β2)2.  Once nicotine is added, this distribution is shifted to fit 
a binomial of 65 ± 4% (α4)2(β2)3 and 35 ± 6% (α4)3(β2)2.  Cotinine also alters the 
distribution towards the high sensitivity version, fitting a binomial of 70 ± 4% (α4)2(β2)3 
and 30 ± 6% (α4)3(β2)2.  Based on the 95% confidence intervals, both nicotine and cotinine 
distributions are different from the control distribution, although they are not different from 
each other (P < 0.05).  This shows exposure to either nicotine or cotinine results in the 
preferential assembly of the high sensitivity (α4)2(β2)3 receptor. 
 
4.6   Biased Transfection of α4:β2 to Verify Changes in Stoichiometry 
Previous studies have altered the primary stoichiometry of α4β2 expressed using 
biased transfections.  During transfection, unequal amounts of plasmid encoding a nAChR 
subunit are added, leading to one subunit expressed at higher levels than the other within 
the cell [151, 154, 191, 233, 234]. These types of studies have primarily used Xenopus 
oocyte expression systems with changes in stoichiometry determined from changes in the 
biphasic dose response based on whole cell current measurements. To verify our 
observations of nicotine and cotinine induced changes in α4β2 stoichiometry, a control 
experiment was performed with biased transfection ratios of 10:1, 4:1, 1:1, and 1:4 (α4:β2).  
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Figure 4.21 Nicotine and cotinine increase (α4)2(β2)3 expression.  When no drug is 
present, the counted bleaching steps fit a distribution of 40 ± 5% (α4)2(β2)3 and 60 ± 
4% (α4)3(β2)2.  The nicotine distribution fits a binomial of 65 ± 4% (α4)2(β2)3 and 35 
± 6% (α4)3(β2)2.  The cotinine distribution fits a binomial of 70 ± 4% (α4)2(β2)3 and 
30 ± 6% (α4)3(β2)2. Error bars are 95% confidence intervals.  
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The total number of counted vesicles for each ratio of plasmid, including those showing 
one, two, or three bleaching steps, is shown in Table 4.2.  Binomial distributions for each 
biased transfection are shown in Figure 4.22, with error bars corresponding to the square 
root of the number of counted events.  
The 10:1 (α4:β2) biased transfection fit a 30:70 (α4)2(β2)3 to (α4)3(β2)2 binomial 
distribution (Figure 4.22A).  Fractions of observed one, two, and three bleaching steps were 
0.08 ± 0.02, 0.40 ± 0.05, and 0.52 ± 0.06, respectively.  The observed fractions of each 
number of bleaching steps were compared to expected fractions based on GFP fluorescing 
90% of the time.  The expected fraction of one steps for this fit is 0.07, with 0.05 from two 
GFP labeled subunits and 0.02 from three GFP labeled subunits.  The expected fraction for 
two bleaching steps is 0.42, or 0.25 from two α4-GFPs and 0.17 from three α4-GFPs.  The 
expected fraction for three bleaching steps is 0.51, corresponding to all three present GFP 
molecules fluorescing.  Overall, the 10:1 biased transfection fit a 30% (α4)2(β2)3 to 70% 
(α4)3(β2)2 distribution. 
Both 4:1 (Figure 4.22B) and 1:1 (Figure 4.22C) α4:β2 transfections fit a 40:60 
(α4)2(β2)3 to (α4)3(β2)2 binomial distribution.  The expected fraction of one steps for this 
distribution are 0.09, or 0.07 from two GFP molecules and 0.02 from three GFP molecules.  
The expected fraction of two steps is 0.47, with 0.33 from two GFP-labeled subunits and 
0.15 from three GFP-labeled subunits.  The expected fraction of three steps is 0.44 if all 
three GFP-labeled subunits fluoresce, with no contribution from two GFP-labeled subunits.  
The observed fractions in the 4:1 transfection were 0.08 ± 0.02, 0.49 ± 0.06, and 0.43 ± 
0.05 for one, two, and three bleaching steps, respectively.  The 1:1 transfection had 
observed fractions of 0.08 ± 0.02 for one step, 0.48 ± 0.04 for two steps, and 0.47 ± 
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Table 4.2: Total Distribution of Observed α4-GFP/β2 Bleaching Steps for Biased 
Transfections 
 
# Vesicles 
Counted 1 Step 2 Steps 3 Steps 4 Steps 
10:1 α4GFP: β2wt 159 13 64 82 2 
4:1   α4GFP: β2wt 146 12 71 63 5 
1:1   α4GFP: β2wt 359 28 171 160 12 
1:4   α4GFP: β2wt 187 24 116 47 0 
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Figure 4.22 Binomial distributions for biased transfections.  Observed and 
expected distributions of one, two, or three bleaching steps when α4-GFP/β2 is 
transfected in varying ratios of 10:1 (A), 4:1 (B), 1:1 (C), or 1:4 (D).  Error bars are 
the square root of the number of vesicles counted. 
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0.04 for three steps.  Both 4:1 and 1:1 α4:β2 transfections fit a binomial distribution of 40% 
(α4)2(β2)3 to 60% (α4)3(β2)2, verified to match expected values with a chi squared test, as 
defined earlier.  
The 1:4 (α4:β2) biased transfection fit a 65:35 (α4)2(β2)3 to (α4)3(β2)2 binomial 
distribution (Figure 4.22D).  The expected fraction of one step is 0.13, with 0.12 from two 
GFP-labeled subunits and 0.01 from three GFP-labeled subunits.  The expected fraction of 
two steps is 0.62, with 0.53 from two GFP molecules and 0.09 from three GFP molecules.  
The expected fraction of three steps is 0.26, all from three GFP-labeled subunits.  This 
distribution fit the observed data with fractions of 0.13 ± 0.03, 0.62 ± 0.06, and 0.25 ± 0.04 
corresponding to one, two, and three bleaching steps, accordingly.  A chi-squared goodness 
of fit test verified the observed number of bleaching steps fit a binomial weighted to 65% 
(α4)2(β2)3 and 35% (α4)3(β2)2. 
Figure 4.23 compares the changes in α4β2 stoichiometry for all biased transfection 
ratios (α4:β2).  Error bars are 95% confidence intervals.  The 10:1 biased transfection fits 
a distribution of 30 ± 7 % (α4)2(β2)3 and 70 ± 7% (α4)3(β2)2.  The 4:1 biased transfection 
fits a distribution of 40 ± 7% (α4)2(β2)3 and 60 ± 4% (α4)3(β2)2.  The 1:1 transfection, as 
shown above, fits a 40 ± 4% (α4)2(β2)3 and 60 ± 5% (α4)3(β2)2.  Finally, the 1:4 biased 
transfection fits a distribution of 65 ± 6% (α4)2(β2)3 and 35 ± 9% (α4)3(β2)2.  Based on the 
95% confidence intervals, the fraction of (α4)3(β2)2 was reduced and the fraction of 
(α4)2(β2)3 increased when higher levels of β2 were transfected (1:4 (α4:β2)) (Figure 4.23).  
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Figure 4.23 Biased transfections shift the distribution of (α4)2(β2)3.  The 10:1 bias 
transfection fits a distribution of 30 ± 7% (α4)2(β2)3 and 70 ± 7% (α4)3(β2)2.  The 4:1 
bias transfection fits a distribution of 40 ± 7% (α4)2(β2)3 and 60 ± 4% (α4)3(β2)2.  The 
1:1 transfection fits a 40 ± 4% (α4)2(β2)3 and 60 ± 5% (α4)3(β2)2.  Finally, the 4:1 bias 
transfection fits a distribution of 65 ± 5% (α4)2(β2)3 and 35 ± 9% (α4)3(β2)2. Error bars 
are 95% confidence intervals. 
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4.7   Other nAChR Ligands Alter Expression, Trafficking, and Assembly of α4β2 
4.7.1   Cytisine Upregulates α4β2 
 Cells transiently expressing α4-SEP/β2 were exposed to 500 nM of the partial 
agonist cytisine to evaluate changes in α4β2 expression and trafficking due to the presence 
of this ligand.  The SEP based studies showed an upregulation of α4β2 upon exposure to 
cytisine (Figure 4.24).  An increase in expression of α4β2 was measured as an increase in 
PMID, corresponding to 2.8 x 106 ± 2.1 x 105 for control cells and 7.3 x 106 ± 6.4 x 105 
after exposure to 500 nM cytisine (Figure 4.24C; P < 0.001).  Trafficking of α4β2 is also 
altered by the presence of cytisine.  The distribution of α4β2 between the plasma membrane 
and peripheral endoplasmic reticulum is increased when cells are exposed to cytisine.  This 
is shown by an increase in the % PM, being 21.5 ± 0.8% without drug and 36.9 ± 1.5% 
upon addition of cytisine (Figure 4.24D; P < 0.001).  Representative TIRF images of cells 
expressing α4β2 with and without exposure to cytisine are shown in Figure 4.24.  A PMID 
footprint with a relatively higher intensity corresponds to an increase in the number of α4-
SEP/β2 nAChRs localized to the plasma membrane.  
 
4.7.2   Varenicline Upregulates α4β2 
 Differences in expression and trafficking were also measured in cells expressing 
α4β2 after exposure to 500 nM varenicline, a partial agonist.  A higher number of α4β2 
nAChRs are found on the plasma membrane when varenicline is present, evinced by an 
increase in PMID from 2.8 x 106 ± 2.1 x 105 in the absence of drug to 5.6 x 106 ± 5.5 x 105 
upon addition of varenicline (Figure 4.25C; P < 0.001).  Trafficking of nAChRs towards 
the plasma membrane is also increased upon addition of varenicline, evident by an increase 
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Figure 4.24 Cytisine upregulates α4β2.  Representative cell images expressing α4-
GFP/β2 exposed to no drug (A) or 500 nM cytisine (B).  Cytisine increases the 
expression of α4β2 on the plasma membrane (C) and the distribution towards the 
plasma membrane (D).  (n = 61, 42) Data are mean values ± SEM (***, P < 0.001), 
a.u., arbitrary units. 
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Figure 4.25 Varenicline upregulates α4β2.  Representative cell images expressing 
α4-GFP/β2 exposed to no drug (A) or 500 nM varenicline (B).   An increased PMID 
(C) and % PM (D) is measured when varenicline is present.  (n = 61, 38) Data are mean 
values ± SEM (***, P < 0.001), a.u., arbitrary units. 
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in % PM from 21.5 ± 0.8% to 32.3 ± 1.3% (Figure 4.25D; P < 0.001).  This is qualitatively 
shown in representative cell images exposed to varenicline, as seen in Figure 4.25.  
Addition of varenicline to cells increases the PMID and % PM, evident by a brighter PMID 
footprint. 
 
4.7.3   Bupropion Upregulates α4β2 
Bupropion, a noncompetitive antagonist, was also administered to cells expressing 
α4β2 at a concentration of 500 nM.  At this concentration, bupropion upregulates 
expression and trafficking of α4β2, as shown in Figure 4.26.  Cells exposed to bupropion 
show an increase in PMID, from 2.8 x 106 ± 2.1 x 105 with no drug to 4.6 x 106 ± 3.6 x 105 
upon bupropion exposure (Figure 4.26C; P < 0.001).  The distribution of α4β2 nAChRs 
towards the plasma membrane from the endoplasmic reticulum is also increased.  The % 
PM of control cells, 21.5 ± 0.8%, is increased to 31.4 ± 1.3% after exposure to bupropion 
(Figure 4.26D; P < 0.001).  This upregulation is seen in representative cell images exposed 
to no drug (Figure 4.26A) or bupropion (Figure 4.26B).  The increase in the PMID footprint 
reflects the increase in number of SEP-labeled α4β2 nAChRs located on the plasma 
membrane. 
 
4.7.4   Ligands Alter Assembly of α4β2 
In collaboration with another member of the Richards’ group, Faruk H. Moonschi, 
single molecule photobleaching was also used to detect changes in the stoichiometry of 
α4β2 when cytisine, varenicline, or bupropion are present.  Vesicles, generated from cells 
expressing α4-GFP/β2, were immobilized and imaged with TIRF microscopy.  Table 4.3 
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Figure 4.26 Bupropion upregulates α4β2.  Representative cell images expressing α4-
GFP/β2 exposed to no drug (A) or 500 nM bupropion (B).  Bupropion increases the 
expression levels of α4β2 on the plasma membrane (C) and trafficking of α4β2 towards 
the plasma membrane (D).  (n = 61, 51) Data are mean values ± SEM (***, P < 0.001), 
a.u., arbitrary units. 
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Table 4.3: Total Distribution of Observed Bleaching Steps for α4-GFP/β2 Upon 
Exposure to Cytisine, Varenicline, or Bupropion  
 
# Vesicles Counted 1 Step 2 Steps 3 Steps 4 Steps 
Cytisine 357 41 187 130 17 
Varenicline 833 94 459 280 30 
Bupropion 1089 102 598 389 43 
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shows the total number of counted vesicles showing one, two, or three bleaching steps for 
each condition.  These values were fit to a binomial distribution to account for the 90% 
probability that GFP will be in a fluorescent state. When α4β2 is not exposed to a 
pharmacological agent, a distribution of 40% (α4)2(β2)3 and 60% (α4)3(β2)2 was verified 
using a chi squared goodness of fit analysis, as discussed in detail above.   
Upon addition of 500 nM cytisine, this distribution is shifted to 50% (α4)2(β2)3 and 
50% (α4)3(β2)2, as shown in Figure 4.27B.  The observed fraction of one steps was 0.12 ± 
0.02, compared to an expected fraction of 0.10, with 0.09 from two-GFP labeled subunits 
and 0.01 from three-GFP labeled subunits.  The observed fraction of two steps was 0.52 ± 
0.04, compared to an expected fraction of 0.53, with 0.41 from two GFP molecules and 
0.12 from three GFP molecules in the pentamer.  The observed fraction of three steps was 
0.36 ± 0.03, corresponding to an expected ratio of 0.37 when three GFP-labeled subunits 
fluoresce.   
 The presence of 500 nM varenicline also shifts the α4β2 distribution to 54% 
(α4)2(β2)3 and 46% (α4)3(β2)2, seen in Figure 4.27C. The observed fraction of one steps 
was 0.11 ± 0.01, compared to an expected fraction of 0.11, with 0.10 from two GFP labeled 
subunits and 0.01 from three-GFP labeled subunits.  The observed fraction of two steps 
was 0.55 ± 0.03, compared to an expected fraction of 0.55, with 0.44 from two GFP 
molecules and 0.11 from three GFP molecules in the pentamer.  The observed fraction of 
three steps was 0.34 ± 0.02, corresponding to an expected ratio of 0.34 when three GFP-
labeled subunits fluoresce.   
 Treatment with 500 nM bupropion alters the α4β2 distribution to 55% (α4)2(β2)3 
and 45% (α4)3(β2)2, as shown in Figure 4.27D.  The observed fraction of one steps was 
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Figure 4.27 Binomial distributions showing a shift in α4β2 stoichiometry when 
cytisine, varenicline, or bupropion are present.  Observed and expected 
distributions for one, two, and three bleaching steps when α4-GFP/β2 is exposed to no 
drug (A), cytisine (B), varenicline (C), or bupropion (D).  Error bars are the square root 
of the number of vesicles counted. 
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0.12 ± 0.02, compared to an expected fraction of 0.11, with 0.10 from two GFP-labeled 
subunits and 0.01 from three GFP-labeled subunits.  The observed fraction of two steps 
was 0.55 ± 0.03, compared to an expected fraction of 0.56, with 0.45 from two GFP 
molecules and 0.11 from three GFP molecules in the pentamer.  The observed fraction of 
three steps was 0.33 ± 0.02, corresponding to an expected ratio of 0.33 when three GFP-
labeled subunits are present.   
Changes in the stoichiometric distribution of α4β2 upon addition of each ligand is 
shown in Figure 4.28.  Error bars are 95% confidence intervals.  As mentioned above, the 
control fits a distribution of 40 ± 4% (α4)2(β2)3 and 60 ± 5% (α4)3(β2)2.  Cytisine slightly 
alters the assembly towards the high sensitivity version, shifting the distribution to 50 ± 
4% (α4)2(β2)3 and 50 ± 5% (α4)3(β2)2.  Varenicline exposure also alters the preferential 
assembly of the high sensitivity stoichiometry, evinced by a distribution of 54 ± 3% 
(α4)2(β2)3 and 46 ± 4% (α4)3(β2)2.  Similarly, addition of bupropion alters the distribution 
to fit 55 ± 2% (α4)2(β2)3 and 45 ± 3% (α4)3(β2)2.  In each case, the nAChR ligand shifts 
the overall stoichiometric distribution of α4β2 towards the high sensitivity (α4)2(β2)3 
isoform. 
 
4.8   PM and ER Derived Nanovesicles can be Separated Based on Density 
 A single nAChR can be spatially isolated in a nanovescicle derived from native cell 
membranes [228].  Since nAChRs are pentameric, α4β2 can assemble with either a 
(α4)3(β2)2 or (α4)2(β2)3 stoichiometry.  These pentamers are assembled in the endoplasmic 
reticulum, then trafficked to the plasma membrane to function as ion channels.  Changes 
in assembly upon exposure to nicotine, cotinine, cytisine, varenicline, and bupropion, 
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Figure 4.28 Cytisine, varenicline, and bupropion increase (α4)2(β2)3 expression.  
Control cells expressing α4-GFP/β2 fits a distribution of 40 ± 4% (α4)2(β2)3 and 60 ± 
5% (α4)3(β2)2.  Cytisine slightly alters the assembly, shifting the distribution to 50 ± 
4% (α4)2(β2)3 and 50 ± 5% (α4)3(β2)2.  Varenicline exposure results in distribution of 
54 ± 3% (α4)2(β2)3 and 46 ± 4% (α4)3(β2)2.  Similarly, addition of bupropion alters the 
distribution to fit 55 ± 2% (α4)2(β2)3 and 45 ± 3% (α4)3(β2)2.  Error bars are 95% 
confidence intervals. 
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discussed in sections 4.5 and 4.7.4 above, were measured for nAChRs isolated from 
membranes throughout the whole cell.  Recent evidence suggests nicotine acts 
intracellularly to induce upregulation [55, 97, 115, 153].  This suggests nicotine permeates 
cell membranes and internally alters the assembly of nAChRs to favor a high sensitivity 
(α4)2(β2)3 stoichiometry.  The single molecule analysis studies discussed above were 
expanded to detect organelle specific changes in nAChR stoichiometry.  Nanovesicles were 
generated from cells expressing α4-GFP and β2-wt subunits using nitrogen cavitation 
pressures of 250 psi or 600 psi for 20 minutes.  Membranes were fragmented upon rapid 
decompression of nitrogen gas.  Cell lysate containing nanovesicles was added to a three 
step OptiPrep gradient at concentrations of 30%, 20%, and 10% in sucrose-HEPES buffer.  
After centrifugation, 1.0 mL fractions were collected, purified, ran on prepackaged 
NuPAGE 4-12% Bis-Tris gel, and transferred to a nitrocellulose membrane.  Primary 
antibodies specific for endogenous localized membrane proteins were used to detect 
fractions with ER and PM vesicles.  Endoplasmic reticulum derived vesicles were detected 
with calnexin.  Plasma membrane derived vesicles were identified with plasma membrane 
calcium ATPase (PMCA).  Imaged blots are shown in Figure 4.29.  Calnexin and PMCA 
were detected in whole cell lysate at 250 psi or 600 psi.  Calnexin is primarily detected 
upon formation at 250 psi, while PMCA is more prominent at 600 psi.  Figure 4.29A shows 
calnexin containing nanovesicles localize to fractions 1, 2, and 3 upon cavitation of 250 
psi.  Fraction 2 is collected for endoplasmic reticulum specific studies.  Although fraction 
1 has a higher relative number of nanovesicles, fraction 2 is chosen to avoid contamination 
from dense species at the bottom of the column.  Figure 4.29D shows PMCA containing 
nanovesicles localize most densely to fractions 5, 7, and 9.  Fraction 7 is collected for 
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Figure 4.29 Western blots showing separation of ER and PM derived vesicles.  
Calnexin is detected in higher density fractions when vesicles are formed at 250 psi 
(A) and at 600 psi (B).  A higher amount of PMCA is detected after swelling with a 
hypotonic solution and higher cavitation pressure of 600 psi (D), than at 250 psi (C).  
Fraction 2 at 250 psi is collected for ER vesicles.  Fraction 7 at 600 psi is collected for 
PM vesicles.  
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plasma membrane specific studies, to avoid contamination from endoplasmic reticulum 
derived vesicles in denser fractions (Figure 4.29B). 
 
4.9   Nicotine Increases Preferential Assembly of (α4)2(β2)3 in the ER 
 Endoplasmic reticulum specific vesicles were collected from fraction 2 of the 
OptiPrep gradient.  Purified fractions contained single nAChRs that were resident in the 
endoplasmic reticulum at the time of nitrogen cavitation, now encapsulated in 
nanovesicles.  These vesicles were isolated on glass substrates, and TIRF microscopy was 
used to visualize the GFP fluorescence signal.  Single step photobleaching of GFP was 
used to identify the number of α4-GFP subunits in each receptor, since the number of 
bleaching steps corresponds to the number of GFP-tagged subunits present [85, 224].  
Representative time traces showing two (Figure 4.30A) or three (Figure 4.30B) bleaching 
steps from α4-GFP/β2 nAChRs encapsulated in endoplasmic reticulum derived 
nanovesicles are shown. Table 4.4 shows the total number of counted endoplasmic 
reticulum vesicles expressing α4-GFP/β2 showing one, two, or three bleaching steps.  
These values were fit to a binomial distribution to account for the 90% probability that 
GFP will be in a fluorescent state.  
  For cells not exposed to any compound, the α4β2 nAChRs expressed in the 
endoplasmic reticulum primarily assemble in the low sensitivity version, fitting a binomial 
distribution weighted for 30% (α4)2(β2)3 and 70% (α4)3(β2)2.  This distribution is shown 
in Figure 4.31A, with error bars being the square root of the number of counted vesicles.  
The fit to a 30:70 distribution is verified using a chi-squared goodness of fit test.  The 
observed fraction of one steps was 0.06 ± 0.01, compared to an expected fraction of 
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Figure 4.30 Representative bleaching steps from ER derived vesicles.  Isolation 
(α4)2(β2)3 or (α4)3(β2)2 is determined by the detection of two (A) or three (B) GFP 
bleaching steps.  
  
   
131 
 
 
Table 4.4: Total Distribution of Observed Bleaching Steps for ER-Derived 
Vesicles Expressing α4-GFP/β2 
 
# Vesicles 
Counted 1 Step 2 Steps 3 Steps 4 Steps 
ER No Drug 458 26 199 233 14 
ER +500 nM Nic 465 40 273 152 27 
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Figure 4.31 Binomial distributions showing nicotine increases (α4)2(β2)3 within 
the ER.  Observed and expected fractions of one, two, and three steps within the 
endoplasmic reticulum with (A) or without nicotine (B). Error bars are the square root 
of the number of vesicles counted. 
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0.07 with 0.05 from two-GFP labeled subunits and 0.02 from three-GFP labeled subunits.  
The observed fraction of two steps was 0.43 ± 0.03, compared to an expected fraction of 
0.42, with 0.25 from two GFP molecules and 0.17 from three GFP molecules in the 
pentamer.  The observed fraction of three steps was 0.51 ± 0.03, corresponding to an 
expected ratio of 0.51.  In the absence of a pharmacological agent, α4β2 is predominately 
present as (α4)3(β2)2 in the endoplasmic reticulum. 
 Upon exposure to 500 nM nicotine, there is a shift in the distribution of α4β2 
present in the endoplasmic reticulum.  When nicotine is present, single molecule bleaching 
step analysis shows the majority of endoplasmic α4β2 is the high sensitivity isoform, fitting 
a 55% (α4)2(β2)3 and 45% (α4)3(β2)2 distribution, as shown in Figure 4.31B.  The observed 
fraction of one steps was 0.09 ± 0.01, compared to an expected value of 0.11, with 0.1 from 
two GFP labeled subunits and 0.01 from three GFP labeled subunits.  The observed fraction 
of two steps was 0.59 ± 0.04, compared to an expected fraction of 0.56, with 0.45 from two 
GFP molecules and 0.12 from three GFP molecules.  The observed fraction of three steps 
was 0.33 ± 0.03, compared to the expected 0.33 value when three subunits are labeled with 
GFP.  When nicotine is present in the endoplasmic reticulum, there is a shift in the 
distribution of α4β2 to favor the high sensitivity (α4)2(β2)3 isoform. 
 Figure 4.32 shows the change in α4β2 stoichiometry within the endoplasmic 
reticulum when nicotine is present.  Error bars are 95% confidence intervals.  When no 
nicotine is present, the α4β2 stoichiometry within the endoplasmic reticulum inherently 
favors the low sensitivity version, evinced by a distribution of 30 ± 4% (α4)2(β2)3 and 70 ± 
4% (α4)3(β2)2.  Once cells are exposed to nicotine, this distribution is shifted to 55 ± 4% 
(α4)2(β2)3 and 45 ± 5 % (α4)3(β2)2 favoring assembly of the high sensitivity stoichiometry 
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Figure 4.32 Nicotine increases the assembly of (α4)2(β2)3 within the ER. When no 
nicotine is present, the α4β2 stoichiometry fits a distribution of 30 ± 4% (α4)2(β2)3 and 
70 ± 4% (α4)3(β2)2.  Once cells are exposed to nicotine, this distribution is shifted to 
55 ± 4% (α4)2(β2)3 and 45 ± 5 % (α4)3(β2)2.  Error bars are 95% confidence intervals. 
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within the endoplasmic reticulum.  Based on the 95% confidence intervals, the fraction of 
α4β2 present in the high sensitivity (α4)2(β2)3 stoichiometry is increased within the ER 
when nicotine is present. 
 
4.10   Higher Expression of (α4)2(β2)3 on the PM 
When nanovesicles were formed at a pressure of 250 psi during nitrogen cavitation, 
fragmentation of the plasma membrane was minimal.  To encourage nanovesicle formation 
from the plasma membrane, cells were first swollen in a hypotonic solution, then 
pressurized to 600 psi during nitrogen cavitation for increased fragmentation before 
separation on an OptiPrep gradient.  Plasma membrane specific nanovesicles formed from 
cells expressing α4-GFP/β2 were collected from fraction 7 of the OptiPrep gradient.  The 
purified fraction contains single nAChRs encapsulated in nanovesicles formed from the 
plasma membrane at the time of nitrogen cavitation.  The plasma membrane specific α4β2 
vesicles were isolated on glass substrates. TIRF microscopy was used to visualize single 
step photobleaching of GFP.  The number of detected bleaching steps corresponds to the 
number of α4-GFP subunits in each receptor [85, 224].  Representative time traces of α4-
GFP/β2 isolated in plasma membrane derived nanovesicles showing two (Figure 4.33A) 
or three (Figure 4.33B) bleaching steps are shown. Table 4.5 shows the total number of 
counted plasma membrane vesicles showing one, two, or three bleaching steps.  These 
values were fit to a binomial distribution to account for the 90% probability that GFP will 
be in a fluorescent state. 
In control cells not exposed drug, the inherent distribution of α4β2 stoichiometries 
localized to the plasma membrane slightly favored the high sensitivity stoichiometry.  PM 
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Figure 4.33 Representative bleaching steps from PM derived vesicles.  Detecting 
two (A) or three (B) GFP bleaching steps corresponds to (α4)2(β2)3 or (α4)3(β2)2 
stoichiometry. 
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Table 4.5: Total Distribution of Observed Bleaching Steps for PM-Derived 
Vesicles Expressing α4-GFP/β2 
 
# Vesicles 
Counted 1 Step 2 Steps 3 Steps 4 Steps 
PM No Drug 545 26 199 233 1 
PM + 500 nM Nic 883 100 592 191 18 
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α4β2 fit binomial distributions weighted for 56% (α4)2(β2)3 and 44% (α4)3(β2)2, shown in 
Figure 4.34A.  The observed fraction of one steps was 0.12 ± 0.02, compared to an expected 
ratio of 0.11, with 0.10 from two GFP-labeled subunits and 0.01 from three GFP-labeled 
subunits.  The observed fraction of two steps was 0.56 ± 0.03, compared to an expected 
ratio of 0.57, with 0.46 from two GFP molecules and 0.11 from three GFP molecules.  The 
observed fraction of three steps was 0.32 ± 0.02, corresponding with the 0.32 expected 
value when three subunits are labeled with GFP.  In the absence of a pharmacological 
agent, α4β2 on the plasma membrane slightly favors (α4)2(β2)3 stoichiometry.  
Upon exposure to nicotine, the distribution of α4β2 on the plasma membrane is 
shifted more towards the high sensitivity version.  When nicotine is present, plasma 
membrane resident α4β2 fits a 70% (α4)2(β2)3 and 30% (α4)3(β2)2 distribution, shown in 
Figure 4.34B.  The observed fraction of one steps was 0.11 ± 0.01, compared to an expected 
ratio of 0.14 with 0.13 from two GFP-labeled subunits and 0.01 from three GFP-labeled 
subunits.  The observed fraction of two steps was 0.67 ± 0.03, compared to an expected 
ratio of 0.65, with 0.57 from two GFP molecules and 0.07 from three GFP molecules in 
the nAChR pentamer.  The observed fraction of three steps was 0.22 ± 0.02, corresponding 
with the 0.22 expected value when three α4-GFP subunits are present.  When nicotine is 
present, a higher percentage of α4β2 on the plasma membrane has (α4)2(β2)3 stoichiometry. 
Figure 4.35 shows the increase in (α4)2(β2)3 stoichiometry on the plasma membrane 
when nicotine is present.  Error bars are 95% confidence intervals.  When no nicotine is 
present, the α4β2 stoichiometry on the plasma membrane fits a distribution of 56 ± 3% 
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Figure 4.34 Binomial distributions showing (α4)2(β2)3 is the predominate 
stoichiometry on the PM. Observed and expected fractions of one, two, and three 
steps from vesicles expressing α4-GFP/β2 on the plasma membrane with (A) or 
without nicotine (B). Error bars are the square root of the number of vesicles counted. 
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Figure 4.35 Nicotine increases the fraction of (α4)2(β2)3 on the PM.  When no 
nicotine is present, the α4β2 stoichiometry on the plasma membrane fits a distribution 
of 56 ± 3% (α4)2(β2)3 and 44 ± 4% (α4)3(β2)2.  Upon the addition of nicotine, this 
distribution is increased to 70 ± 2% (α4)2(β2)3 and 30 ± 4% (α4)3(β2)2.  Error bars are 
95% confidence intervals. 
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(α4)2(β2)3 and 44 ± 4% (α4)3(β2)2.  Upon the addition of nicotine, this distribution is 
increased further towards the high sensitivity version, fitting a binomial of 70 ± 2% 
(α4)2(β2)3 and 30 ± 4% (α4)3(β2)2.  Based on the 95% confidence intervals, nicotine 
increases the percentage of the (α4)2(β2)3 isoform found on the plasma membrane. 
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CHAPTER 5: DISCUSSION 
 
 Tobacco consumption is the world’s leading preventable cause of death, affecting 
approximately one billion people world-wide today [1, 2].  The majority of users admit 
they would like to quit, but the addictive nature of tobacco prevents them from doing so 
[8].  Current smoking cessation therapeutics have not been tremendously successful is 
helping users overcome the barriers of nicotine addiction.  In order to develop more 
efficient therapeutics, the mechanism of nicotine addiction needs to be further resolved and 
specific nAChR subtypes and assemblies need to be identified as therapeutic targets.  
Nicotine is known to interact with nAChRs, resulting in changes to reward systems in the 
brain upon chronic exposure.  On a molecular scale, upregulation of nAChRs as a result of 
chronic nicotine exposure, potentially altering nAChR-dependent signaling, has been given 
significant interest [6, 45, 55, 64, 66, 76, 160].  Upregulation is considered an increase in 
nAChR number, changes in trafficking, and altered stoichiometric assembly [55, 97, 152-
155].  Upregulation seems to be brain region, cell type, and subtype specific.  As a result 
of this complexity, the underlying mechanism of upregulation, and its connection to 
nicotine addiction, is not fully understood.  Resolving the mechanisms of upregulation on 
a molecular scale advances the understanding of nicotine addiction, and therefore paves 
the way towards the development of new therapeutic targets aimed at facilitating smoking 
cessation.  This dissertation utilizes novel techniques to elucidate the mechanism of 
nicotine induced changes in expression, trafficking, and stoichiometry to identify target 
nAChR structures for the development of smoking cessation therapeutics.   
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5.1   Cotinine Induces Upregulation of a Subset of nAChRs 
It is well established that chronic nicotine exposure upregulates and alters the 
assembly of α4β2 nAChRs [51, 97, 161, 235], but the effects of nicotine metabolites on 
nAChR assembly and trafficking are not well studied.  In this work, drug induced changes 
in trafficking and expression of SEP-labeled nAChRs were measured using TIRF 
microscopy.  This technique is complementary to traditional methods of nAChR detection, 
offering particular advantages for analysis of receptors located near the plasma membrane.  
Autoradiographic studies have been monumental in providing detailed maps of distribution 
of nAChRs throughout mouse and rat brains [10, 159, 236, 237].  These studies typically 
measure the amount of radio-labeled ligand binding, such as [3H]-nicotine, [3H]-
acetylcholine, [125I]-epibatidine or [125I]-bungarotoxin, either on the plasma membrane or 
throughout the whole cell.  Detection is limited to the radioactivity of the bound ligand, 
instead of detecting the nAChR itself.  Distribution can be roughly measured by 
quantifying the proportion of radioligand binding sites on the cell surface, but this requires 
a comparison between multiple fixed samples.   Immunoblotting is also used to measure 
expression levels [238].  Antibodies are designed to be specific for one nAChR subunit, 
meaning assembled pentamers and unassembled subunits are indistinguishable in whole 
cell samples.  However, specificity to one single type of nAChR subunit is hard to achieve 
due to homology between subunit sequences.  These measurements are also complicated 
by the possibility that the specificity of an antibody can be conformation specific for one 
type of subunit [190, 191, 239].  Cell surface biotinylation assays are often used to quantify 
the ratio of nAChRs on the plasma membrane compared to the whole cell as well.  This 
process involves incubating cell lysates overnight with streptavidin agarose beads to 
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recover plasma membrane resident nAChRs [136, 191].  Again, this technique involves a 
comparison between samples once cells are lysed.  In contrast, the SEP-based technique 
used in this dissertation measures a genetically encoded reporter molecule, super-ecliptic 
pHluorin, which eliminates nonspecific binding or subunit conformation dependent 
detection.  Fluorescence intensity is directly related to the number of SEP-labeled nAChRs 
present.  Coupled with TIRF microscopy, superior resolution at the plasma membrane is 
achieved within the 150 nm field of TIRF excitation.  This allows surface nAChRs and 
those in the peripheral endoplasmic reticulum to be measured simultaneously in the same 
sample for an accurate depiction of nAChR distribution within this region.  Changes in 
distribution within this narrow region upon addition of a pharmacological agent correspond 
to differences in nAChR trafficking, since only plasma membrane resident or nearby 
nAChRs are detected.  These studies also measure nAChR expression in living cells.  Due 
to the pH sensitivity of SEP, single vesicle insertion events can be captured and resolved 
in real time.  Increases in α4β2 expression on the plasma membrane upon exposure to 
nicotine have been measured in this system and parallel the degree of upregulation seen in 
other systems. 
Due to structural similarities between nicotine and cotinine, we hypothesized that 
cotinine could also induce changes in expression levels or trafficking of nAChRs.  Cotinine 
has been shown bind to nAChRs and evoke dopamine release [41, 42, 240], meaning it 
could also alter expression of nAChRs.  To test this hypothesis, N2a cells were exposed to 
physiologically relevant levels of cotinine, ranging from 50 nM to 500 nM.  These values 
are centered around those matching the average reported values of cotinine in a smoker’s 
blood, urine, or brain [29, 241, 242].  Measuring SEP-labeled α4β2 nAChRs with TIRF 
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microscopy shows that cotinine upregulates the expression and distribution of α4β2 
towards the plasma membrane, as shown by an increase in PMID and % PM (Figure 4.2; 
P < 0.001).  The highest level of upregulation of α4β2 nAChRs is seen at a concentration 
of 1 μM cotinine, which corresponds to the average concentration of cotinine in the blood 
of a typical smoker [241]. Cotinine induces significant increases in both α4β2 PMID and 
% PM at as little as 100 nM. This suggests that cotinine could potentially contribute to 
α4β2 upregulation in smokers since brain concentrations of cotinine are estimated to be 
approximately 300 nM [26].  However, at higher concentrations of cotinine, this 
upregulation effect is lost.  This could be a result of overwhelming stress on the 
endoplasmic reticulum, given a significant increase in assembly and trafficking involving 
this organelle.  A recent functional study exposing α4β2 in oocytes to 10 μM cotinine for 
48 hours did not detect any differences in acetylcholine-evoked response at this 
concentration compared to control [243].  Since 10 μM cotinine did not alter the functional 
response of α4β2, it is likely that expression of α4β2 is unaltered as well at the higher 
concentration of cotinine used in that study. 
Recent studies to elucidate the mechanism of nicotine induced upregulation suggest 
nicotine acts intracellularly to increase maturational enhancement of subunits and 
pharmacologically chaperone nascent subunits, stabilizing subunit-subunit interactions in 
their lowest energy state [55, 97, 115, 123, 153].  This idea is supported by the fact 
upregulation occurs at low concentrations of nicotine, 100-200 nM, that remain in the brain 
of smokers at a steady state.  At these concentrations, few (α4)2(β2)3 are activated, while 
no low sensitivity (α4)3(β2)2 are activated [55], corresponding to the EC50 value for 
nicotine being 0.1 to 4.0 μM based on stoichiometry [80, 97-99].  Similarly, upregulation 
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of α4β2 occurs in the presence of as little as 100 nM cotinine.  This is well below the 
concentration of cotinine required to evoke dopamine release from rat striatal slices, with 
an EC50 value of 30 μM or higher reported [42, 240].  Since both nicotine and cotinine 
induce upregulation at concentrations below those required to induce a response, it is 
possible that both drugs are acting by a similar mechanism.  Both nicotine and cotinine are 
able to cross the blood-brain barrier [40, 244], and bind to nAChRs [41, 42].  Cotinine is 
also able to penetrate the cell membrane, given a log P value of -0.3 [245].  Nicotine and 
cotinine, as well as other upregulating ligands, likely permeate cell membranes, interact 
with intracellular receptors, and alter the expression of nAChRs internally. 
Nicotine also increases trafficking of α4β2 and insertion into the plasma membrane 
[198].  Since cotinine exposure increases the number of α4β2 receptors located on the 
plasma membrane, we hypothesized that the number of insertion events of α4β2 nAChR 
carrying vesicles could also be increased.  Using SEP-labeled α4β2, the number of nAChR 
carrying single vesicle insertion events were quantified in the presence of 1 μM cotinine.  
When cotinine is present, the number of α4-SEP/β2 single vesicle insertion events is 
increased.   This suggests that cotinine, similar to nicotine, increases the trafficking of α4β2 
from the endoplasmic reticulum to the plasma membrane.  Therefore, the higher PMID and 
% PM resulting from cotinine exposure are at least partially the result of an increased 
frequency of insertion of vesicles containing α4β2 receptors.   It is likely that the increase 
in trafficking is a result of increased assembly within the endoplasmic reticulum.  A higher 
number of assembled α4β2 nAChRs need to be trafficked out of the endoplasmic reticulum, 
leading to an increase in the number of trafficking vesicles to accommodate this increase.  
A higher number of trafficking vesicles are then inserted into the plasma membrane, 
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leading to an increase in expression on the PM.  Similar molecular consequences of 
physiologically relevant concentrations of nicotine and cotinine exposure, in terms of 
increased trafficking and expression of α4β2 on the plasma membrane, suggest cotinine 
could be partially responsible for physiological effects in nAChRs previously attributed to 
nicotine alone.  
In the case of nicotine, upregulation is subtype specific.  Incorporation of the α5 
subunit into the α4β2 pentamer results in a loss of both nicotine induced and cotinine 
induced upregulation.  Some studies suggest that the presence of this accessory α5 subunit 
alters the ability of the pentameric nAChR to be pharmacologically chaperoned by nicotine.  
Although α4β2 are believed to be chaperoned by nicotine, α4β2α5 may fail to undergo the 
same pharmacological chaperoning and therefore do not increase expression on the plasma 
membrane when a pharmacological chaperone is present [246, 247].  This is possibly due 
to subtle changes in ligand binding affinity between the two subtypes, which alters the 
ability to interact with nicotine as a chaperone [248, 249].  Since α4β2α5 also does not 
result in upregulation when exposed to cotinine, there is a potential that cotinine interacts 
with this subtype in the same way that nicotine does.   
The single nucleotide polymorphism in α5, resulting in a single amino acid change 
from aspartic acid to asparagine at position 398 (α5-D398N), has been connected to an 
increased risk of tobacco dependence in individuals with this allele [139-141]. When this 
accessory subunit is incorporated into the α4β2 pentamer, the resulting subtype α4β2α5-
D398N also fails to upregulate in the presence of nicotine or cotinine.  This is presumably 
due to the continued absence of a pharmacological chaperoning effect of nicotine, or 
cotinine, in this version of α5.  However, the SEP-based studied reveal that a higher ratio 
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of α4β2α5-D398N is located on the plasma membrane than in the peripheral endoplasmic 
reticulum, compared to the α4β2α5D version.  This redistribution of α4β2α5-D398N is 
independent of the presence of either nicotine or cotinine.   It is unclear if this increase in 
percentage of α4β2α5-D398N on the plasma membrane is due to an increase in trafficking 
towards the PM or a decrease in turnover once on the plasma membrane.  However, this 
difference in distribution between α4β2α5D and α4β2α5-D398N could lead to downstream 
consequences that result in an increased rate of smoking, particularly if the α4β2α5-D398N 
on the plasma membrane are functional. 
It appears that subtypes with a higher basal plasma membrane density are not 
subjected to nicotine induced upregulation at physiological concentrations, possibly 
because receptor transport is already efficient. For instance, basal levels of α3β4 nAChRs 
are three times higher than β2* containing nAChRs. Studies show that β4* nAChRs are 
exported from the endoplasmic reticulum to the plasma membrane more efficiently than 
β2* nAChRs [196, 198].  This increase in export efficiency can be attributed to the presence 
of trafficking motifs within the variable loop between TM3 and TM4 transmembrane 
regions.  The trafficking motifs are believed to control export of assembled pentameric 
receptors out of the endoplasmic reticulum [75, 76]. To date, it is known that export LXM 
motifs (where X is any amino acid), located in the TM3-TM4 loop of α4, α3, and β4 
subunits, govern trafficking out of the endoplasmic reticulum.  Also, a retention RXRR 
motif in the β2 subunit is associated with retention in the endoplasmic reticulum [76].  
Combinations of these subunits into pentamers result in combinations of trafficking motifs, 
potentially accounting for differences in subcellular location of subtypes of receptors.  The 
β2* nAChRs are inefficiently exported, while β4* are exported very efficiently.  When 
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both types of subunits in the pentamer contain the same export trafficking motif, such as 
in α3β4, it is believed that export is already at a maximum rate and therefore trafficking is 
not influenced by the presence of pharmacological chaperones [66, 76, 139].  This theory 
is supported by a lack of upregulation of α3β4 when exposed to physiologically relevant 
concentrations of nicotine [210, 250].  However, upregulation of α3β4 has been shown at 
much higher concentrations of nicotine (≥ 10 μM) [136].  Recent studies suggest nicotine 
increases the formation of additional exit sites within the endoplasmic reticulum (ERES) 
[196, 198].  It is possible that such high concentrations of nicotine increase the number of 
ERES in the endoplasmic reticulum to such an extent that α3β4 is able to upregulate.  In 
our SEP-based study, α3β4 was not upregulated at the physiologically relevant nicotine or 
cotinine concentrations used.  If cotinine affects nAChRs in a similar pharmacological 
chaperoning mechanism, α3β4 may not be upregulated by cotinine because of the already 
high levels of plasma membrane expression.  Likewise, incorporation of α5 or α5-D398N 
into α3β4 did not alter expression levels in the presence or absence of nicotine or cotinine.  
This suggests that addition of the accessory α5 subunit does not alter the interaction, or 
lack thereof, between α3β4 and nicotine or cotinine.  Unlike incorporation of α5-D398N 
into α4β2, addition of this accessory subunit did not increase the distribution of α3β4α5-
D398N towards the plasma membrane.  Presumably, this is due to the inherently higher 
levels of α3β4α5-D398N already on the plasma membrane.    
The idea of reaching a maximal level of expression on the plasma membrane may 
also explain why no additive effects are measured when cells expressing α4β2 are 
simultaneously exposed to both nicotine and cotinine.  No significant differences were 
detected in the α4β2 PMID or % PM of cells exposed to 300 nM, 1 μM, or 5 μM cotinine 
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in addition to 50 nM or 500 nM nicotine, although all values were significantly higher than 
those exposed to no drug (Figure 4.4; P < 0.001).  It is possible that an approximately 50% 
increase in PMID over the control is the maximum increase in α4β2 expression that can be 
achieved by pharmacological chaperoning at these physiologically relevant concentrations 
of nicotine and cotinine in this cell system, potentially because the two drugs are acting in 
the same way.  
Although α4β2 shows clear upregulation when exposed to nicotine, contradictory 
results have been reported for α6β2*, with claims of upregulation, downregulation, or no 
change when chronically exposed to nicotine [114, 251, 252].  Likewise, contradictory 
results have been reported for the ability of α6β2* to be chaperoned by nicotine.  Many 
reports suggest that nicotine fails to chaperone α6β2* [247, 253-255], while others suggest 
this subtype can be chaperoned when the accessory β3 subunit is present [115, 251].  These 
discrepancies may be due to the presence or absence of the accessory β3 subunit within 
different expression systems or concentrations of chaperoning ligand used.  In partial 
resolution of this inconsistency, a dose dependent response of α6β2β3 to nicotine has been 
measured [115].  Low concentrations of 50 nM nicotine are shown to upregulate α6β2β3, 
while higher concentrations of 500 nM nicotine downregulate α6β2β3.  In addition, α6β2β3 
expresses at higher levels on the plasma membrane than α6β2 alone [115].  Our data also 
show that the incorporation of a β3 accessory subunit resulted in higher levels of expression 
on the PM as compared to α6β2 alone, as well as a dose dependent downregulation of 
α6β2β3 in the presence of cotinine (Figure 4.13A; P < 0.05).  The concentrations of cotinine 
used here did not alter the distribution of α6β2 or α6β2β3 nAChRs between the plasma 
membrane and peripheral endoplasmic reticulum, evident by no significant changes in % 
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PM.  Recent evidence suggests a KKK motif within the TM3-TM4 loop of the β3 subunit 
plays a regulatory role in α6β2* expression when nicotine is present [115].  This motif is 
essential for nicotine induced upregulation of α6β2β3, possibly acting as a recognition site 
for COPI binding [115].  Cotinine potentially differs in its interaction with the KKK motif 
as compared to nicotine.  This suggests that nicotine is able to chaperone α6β2β3, at least 
at low concentrations, while cotinine is not.  Cotinine may also alter the likelihood of β3 
incorporation into the α6β2 pentamer.  It is feasible that at low concentrations of cotinine, 
500 nM, (α6)2(β2)3 or (α6)3(β2)2 is favored over α6β2β3, resulting in an apparent decrease 
in PMID levels that correspond to α6β2 alone.  Interestingly, another study has shown that 
cotinine only interacts with a subset of α6β2* nAChRs while the entire population is 
sensitive to nicotine [42]. The lack of cotinine-induced upregulation of α6β2β3 is 
potentially related to its action on only a portion of this receptor population.  This effect 
could also contribute to discrepancies between groups that detect upregulation [115, 251, 
252] or downregulation [253] in varying brain regions based on concentrations of nicotine, 
or cotinine, present.  
 
5.2   Cotinine Exposure Results in Preferential Assembly of (α4)2(β2)3 
 As a heteropentamer composed of two types of subunits, α4β2 can assemble with 
either (α4)3(β2)2 or (α4)2(β2)3 stoichiometry.  These isoforms of the same α4β2 subtype 
vary in sensitivity to agonists, calcium flux, and rates of desensitization [56, 80, 81].  It is 
well established that nicotine increases the expression of the high sensitivity (α4)2(β2)3 
isoform [85, 151, 154, 233, 256, 257], but the reason for this change has not been 
determined.  This observation is heavily based on bulk measurements and 
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electrophysiology studies.  Bulk studies use western blots to measure levels of protein 
based on binding of a subunit specific antibody or metabolic labeling of subunits.  
Typically, a ratio of expression of the α subunit versus the β subunit is calculated.  Changes 
in this ratio upon ligand exposure is attributed to changes in stoichiometry [136, 153, 154, 
258, 259].  The increase in (α4)2(β2)3 stoichiometry in the presence of nicotine is 
determined by an increase in amount of the β2 subunit compared to the α4 subunit detected.  
These measurements provide estimates of changes in levels of each subunit, but do not 
fully resolve any structural information about the present stoichiometry of each nAChR.  
Functional studies showing a biphasic response to nicotine, corresponding to (α4)3(β2)2 or 
(α4)2(β2)3 stoichiometry, were used to determine an increase in the high sensitivity version 
of α4β2 when nicotine is present [154, 167, 233, 234].  The EC50 values for the high 
sensitivity (α4)2(β2)3 and low sensitivity (α4)3(β2)2 are estimated to be 116 nM and 2700 
nM, respectively.  Since nicotine induces upregulation at concentrations lower than those 
required for activation, functional studies do not provide insight into the mechanism of an 
increase in the (α4)2(β2)3 isoform. 
Most studies agree that the increase in the high sensitivity (α4)2(β2)3 stoichiometry 
is the result of altered assembly of α4β2, rather than an altered binding affinity or functional 
state of an assembled nAChR.  However, direct structural studies of assembled nAChRs 
have primarily been limited to bulk fluorescence techniques [210, 260, 261].  One such 
technique is Förster resonance energy transfer (FRET), in which α4 and β2 subunits are 
labeled with donor and acceptor fluorescent proteins such as GFP and derivatives.   The 
efficiency of energy transfer from the donor to acceptor molecule is inversely proportional 
to the sixth power of the distance between the two fluorophores [151, 262].  A theoretical 
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FRET efficiency for (α4)3(β2)2 or (α4)2(β2)3 stoichiometry is calculated based on estimated 
differences between each isoform and compared to observed values to make conclusions 
about the predominate stoichiometry in the presence of a ligand [210].  This technique can 
detect general shifts in nAChRs assembly, but requires a range of assumptions about the 
geometry and distance between fluorophores in the structure. 
Single molecule fluorescence studies are ideally suited to reveal structural changes 
in nAChRs that cannot be resolved by ensemble techniques [263-266].  However, single 
molecule measurements are often obstructed by high background fluorescence or rely on 
purification of the protein outside of the cellular environment.  Measuring membrane 
proteins on a single molecule level is particularly challenging due to constant diffusion of 
proteins within a membrane and natural accumulation of membrane receptors on the 
plasma membrane [225, 267].  One of the few single molecule fluorescence studies capable 
of resolving structural assembly of nAChRs in a live cell use nanoscale plasmonic devices 
known as zero-mode waveguides [85].   Zero-mode waveguides are nanostructures with 
subwavelength wells constructed on a thin layer of aluminum.  The narrow width of the 
wells prevents the penetration of the beam of excitation, resulting in an attenuating 
evanescent field and reduction of background fluorescence from the whole cell.  The 
plasma membrane of N2a cells grown on top of the zero-mode waveguides are able to 
penetrate the wells, meaning only nAChRs within the wells are detected.  This prevents the 
lateral diffusion and aggregation of nAChRs, allowing isolated nAChRs to be evaluated on 
a single molecule level.  However, measurements are limited to nAChRs residing on the 
plasma membrane.  Also, the expression and trafficking of nAChRs isolated within this 
subwavelength size well may not reflect the population of the whole cell, or even typical 
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nAChR trafficking to the plasma membrane.  Even so, these experiments show single 
molecule fluorescence is capable of quantitatively determining the stoichiometry of 
individual α4β2 nAChRs isolated in a cellular environment. 
 Our lab recently developed a novel technique to spatially isolate nAChRs 
embedded in vesicles formed from endogenous cell membranes [228].  Upon 
fragmentation of membranes using nitrogen cavitation, single nAChRs become trapped in 
their membrane of origin.  This allows single nAChRs to be isolated in their endogenous 
cellular environment, without the use of artificial bilayers or detergents.   Once single 
nAChRs are isolated in cell membrane derived nanovesicles, single molecule 
photobleaching is used to determine subunit stoichiometry.  Vesicles were generated from 
cells expressing α4-GFP and β2-wt subunits. These vesicles containing α4-GFP/β2 were 
isolated on glass substrates, and visualized by TIRF microscopy.  Single step 
photobleaching of GFP molecules within α4 subunits was used to identify the number of 
α4-GFP subunits in each nAChR. The number of bleaching steps corresponds to the 
number of GFP-tagged subunits present and, therefore, indicates the stoichiometry of the 
receptor [85, 224].   Since the probability of GFP being in a fluorescent state is 90%, the 
number of counted one, two, or three bleaching steps was fit to a binomial distribution to 
quantify changes in assembly. 
Since cotinine alters the trafficking and expression of α4β2 in a similar way as 
nicotine, we hypothesized that cotinine could also alter the assembly of α4β2. In the 
absence of a pharmacological agent, the fifth position of the α4β2 pentamer slightly favors 
occupation by an α4 subunit fitting a binomial distribution of 40 ± 5% (α4)2(β2)3 and 60 ± 
4% (α4)3(β2)2 (Figure 4.21).  A higher ratio of α4β2 with (α4)3(β2)2 throughout the cell is 
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also measured with whole-cell electrophysiology [154, 167].  In the presence of cotinine 
or nicotine, α4β2 preferentially assembles in the high sensitivity, (α4)2(β2)3, stoichiometry.  
The distribution of α4β2 in the presence of nicotine fits a binomial of 65 ± 4% (α4)2(β2)3 
and 35 ± 6% (α4)3(β2)2, providing structural evidence to support results from other studies 
showing that nicotine exposure increases preferential assembly of high sensitivity α4β2 
nAChRs.  This alteration does not require surface receptor activating concentrations of 
nicotine, but is thought to be linked to the mechanism of nicotine addiction.  This study 
shows that the presence of cotinine also shifts the assembly of α4β2 to favor the high 
sensitivity version, fitting a binomial of 70 ± 4% (α4)2(β2)3 and 30 ± 6% (α4)3(β2)2.  Based 
on the 95% confidence intervals, both nicotine and cotinine distributions are different from 
the control distribution, although they are not different from each other (Figure 4.21; P < 
0.05).  This suggests that cotinine may be at least partially responsible for the increase in 
α4β2 sensitivity measured in other studies.  
As a control to verify our observations of nicotine and cotinine induced changes in 
α4β2 stoichiometry, biased transfections were performed with varying ratios of α4-GFP 
and β2 plasmid.  Previous studies have altered the primary stoichiometry of α4β2 expressed 
using biased transfections, with one subunit expressed at higher levels than the other [151, 
154, 191, 233, 234]. These types of studies have primarily used Xenopus oocyte expression 
systems with changes in stoichiometry determined from changes in the biphasic dose 
response based on whole cell current measurements.  Here biased transfection ratios of 
10:1, 4:1, 1:1, and 1:4 (α4:β2) were used to determine the stoichiometry of α4β2 nAChR 
in each condition.  A 1:10 transfection bias towards the β2 subunit was not viable in the 
HEK-293T clonal cell line used for these studies.  When an excess amount of the α4 subunit 
   
156 
 
is transfected, there is only a slight shift in assembly towards the (α4)3(β2)2 isoform.  As 
mentioned, equal amounts of α4 and β2 plasmid result in a distribution of 40 ± 4% 
(α4)2(β2)3 and 60 ± 5% (α4)3(β2)2.   A 10:1 (α4:β2) biased transfection shifts this 
distribution to 30 ± 7% (α4)2(β2)3 and 70 ± 7% (α4)3(β2)2, while the 4:1 transfection fit a 
binomial of 40 ± 7% (α4)2(β2)3 and 60 ± 4% (α4)3(β2)2, respectively.  On the converse, a 
1:4 biased transfection with an excess amount of the β2 subunit fits a distribution of 65 ± 
5% (α4)2(β2)3 and 35 ± 9% (α4)3(β2)2.  Based on the 95% confidence intervals, the fraction 
of (α4)3(β2)2 reduced and the fraction of (α4)2(β2)3 increased when higher levels of β2 
were transfected (1:4 (α4:β2)) (Figure 4.23).  However, over expression of the α4 subunit 
did not seem to significantly alter the assembly from the approximately 40:60 distribution 
seen in a 1:1 transfection.  This observation suggests there could be a natural bias, or higher 
amounts of α4 subunits, typically found in the endoplasmic reticulum.  This effect has also 
been observed in biased transfections for functional studies, showing higher levels of the 
(α4)3(β2)2 isoform [154].  One possibility for this effect is that unassembled β2 subunits 
are degraded more rapidly than α4 subunits within the endoplasmic reticulum [154, 191]. 
These studies show that nicotine’s primary metabolite, cotinine, has a similar effect 
on the trafficking and assembly of nAChRs as seen with nicotine. Cotinine has a longer 
half-life and higher sustained concentration than nicotine in the human body.  This means 
that cotinine may be at least partially responsible for physiological changes in nAChRs 
previously attributed to nicotine alone.  It is also possible that variations in the 
concentration of cotinine resulting from gene variation and clearance rates in different 
ethnicities could account for some differences in rates of nicotine addiction seen in these 
individuals.   
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5.3   nAChR Ligands Alter Expression, Trafficking, and Assembly of α4β2 
Most smoking cessation agents have targeted the α4β2* nAChR subtype.  Cytisine 
and varenicline, both partial agonists of α4β2, have previously been shown to increase the 
number of α4β2 nAChRs on the plasma membrane [176, 178, 210, 238, 258].  We 
hypothesized that cytisine and varenicline could also alter the distribution of α4β2 towards 
the plasma membrane, or alter the assembly of α4β2.  Using SEP-labeled α4β2, we show 
both of these drugs also increase the distribution of α4β2 towards the plasma membrane, 
as well as increase the integrated density on the plasma membrane.  This shows trafficking 
of α4β2 is increased in addition to expression on the plasma membrane.  These increases 
occur upon exposure to 500 nM of either drug.  This concentration is lower than the EC50 
values for cytisine and varenicline, which are both in the low micromolar range [177, 268].  
At a concentration of 500 nM, cytisine and varenicline both alter the assembly of α4β2.  
Previous studies have suggested cytisine exposure results in a preference for the low 
sensitivity, (α4)3(β2)2 isoform [85, 151].  This increase in (α4)3(β2)2 in the presence of 
cytisine has been primarily detected at the plasma membrane.  In contrast, the single 
molecule bleaching analysis of nAChRs isolated in cell-derived nanovesicles, developed 
in our lab, evaluates primarily intracellular nAChRs.  Using this method, we show a slight 
shift in the assembly to favor the (α4)2(β2)3 isoform in the presence of cytisine.  This 
difference is potentially the result of measuring stoichiometry of α4β2 in different 
subcellular regions.  Since SEP studies show cytisine increases the fraction of α4β2 
nAChRs that reside on the plasma membrane, (α4)3(β2)2 could be preferentially trafficked 
towards the plasma membrane when cytisine is present.  Varenicline exposure causes a 
pronounced shift towards the (α4)2(β2)3 isoform.  The partial agonists cytisine and 
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varenicline induce changes in trafficking, expression, and assembly of α4β2 at 
concentrations lower than those required for activation of these nAChRs.   
Bupropion, originally marketed as an antidepressant in 1989, has also been 
approved as a smoking cessation agent [180, 181].  As an antidepressant, bupropion acts 
as a norepinephrine and dopamine reuptake inhibitor, with no effect on serotonergic 
activity [180, 269, 270].  Recently, bupropion was also determined to act as a 
noncompetitive antagonist of α4β2, α3β4 and α7 nAChRs, with IC50 values ranging from 
0.4 to 60 μM [271, 272].  Photoaffinity labeling studies show bupropion has two distinct 
binding sites in the Torpedo nAChR transmembrane domain, one in each the resting state 
and desensitized state.  One high affinity site is found in the middle of the ion channel, 
within TM2.  Bupropion binds this site when the nAChR is in a resting state, or closed 
channel state.  Bupropion binds a second site near the extracellular end of TM1 within α 
subunits with three-fold higher affinity.  This binding occurs when the nAChR is in an 
agonist-induced desensitized state [181].  SEP-labeling of α4β2 nAChRs shows 500 nM 
bupropion upregulates the number of α4β2 nAChRs on the plasma membrane, and alters 
the distribution of these nAChRs towards the plasma membrane (Figure 4.26; P < 0.001).  
Although bupropion is not specific for nAChRs, it is able to upregulate the number of α4β2 
on the plasma membrane and affect the subcellular distribution.  Bupropion also alters the 
stoichiometric distribution of α4β2 nAChRs, as shown by single molecule analysis of GFP-
labeled α4 subunits in α4β2.  In the presence of 500 nM bupropion, the assembly is shifted 
towards the high sensitivity version of α4β2, fitting a binomial of 55 ± 2% (α4)2(β2)3 and 
45 ± 3% (α4)3(β2)2.  Based on the 95% confidence intervals, bupropion significantly shifts 
the assembly of α4β2 towards the high sensitivity version, from the 40 ± 4% (α4)2(β2)3 and 
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60 ± 5% (α4)3(β2)2 distribution when no drug is present (Figure 4.26; P < 0.05).  The 
increase in (α4)2(β2)3 in the presence of bupropion is likely the result of an altered assembly 
of α4β2, given that the majority of measured nAChRs originate from intracellular 
organelles in this study.  This gives rise to the potential that bupropion, a noncompetitive 
antagonist, also penetrates the cell membrane and interacts with nascent nAChRs as a 
pharmacological chaperone.  Unlike cytisine and varenicline, which are both partial 
agonists of α4β2, bupropion does not bind in the orthosteric ligand binding site of α4β2.  
However, bupropion still upregulates α4β2, in terms of increased expression on the plasma 
membrane, a change in distribution towards the plasma membrane, and preferential 
assembly of (α4)2(β2)3.  Other antagonists have also been shown to upregulate α4β2.  
Mecamylamine, a noncompetitive open channel blocker, increases [3H]-nicotine binding 
[150, 188, 273] and [125I]-epibatidine binding [274].  Dihydro-β-erythroidine (DhβE), a 
competitive antagonist, functionally upregulates α4β2 and increase the fraction of high 
affinity receptors [167], as well as increases  [125I]-epibatidine binding [274].  This further 
supports the idea that upregulation does not require surface activation.  It has been 
suggested that pharmacological chaperones stabilize an assembled pentameric nAChR, 
rather than unassembled subunits, in its most stable state within the endoplasmic reticulum.  
It is possible that intracellular binding and stabilization of nAChRs promotes upregulation.  
Overall, a variety of pharmacological agents with various binding properties induce 
upregulation or promote specific stoichiometries of nAChRs.  If these changes occur 
intracellularly, future therapeutically relevant pharmacological agents may be able to target 
intracellular processes. 
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5.4   Subcellular Differences in the Distribution of (α4)2(β2)3 versus (α4)3(β2)2 
 Although upregulation of α4β2 has been implicated in the addictive nature of 
nicotine, the actual mechanism of this upregulation remains elusive [6, 45, 46, 55, 64, 66, 
76, 151].  New evidence continues to converge on the idea that an intracellular mechanism 
is responsible for this effect.  Upregulation is currently considered an increase in nAChR 
number, as well as changes in trafficking and stoichiometric assembly.  As mentioned, 
nicotine increases the expression of the high sensitivity (α4)2(β2)3 isoform [85, 151, 154, 
233, 256, 257].  This suggests nicotine permeates cell membranes, interacts with 
intracellular subunits, and alters the expression of nAChRs internally to favor a high 
sensitivity (α4)2(β2)3 stoichiometry.  Despite the connection between α4β2 assembly and 
its role in nicotine addiction, evidence of changes in assembly distinctively within the 
endoplasmic reticulum had not been detected prior to this study.  This is primarily due to a 
lack of existing techniques that are capable of directly quantifying subcellular specific 
structural assembly of complex proteins in a cellular environment.  Prior to this research, 
direct structural studies had been limited to bulk fluorescence methods.  FRET, Förster 
resonance energy transfer, based studies show an increase in the number of α4 and β2 
subunits in close proximity within the whole-cell region measured, which includes the 
endoplasmic reticulum [115, 196, 197].  However, quantitatively determining the 
stoichiometry of individual α4β2 nAChRs isolated in native subcellular membranes can 
show exclusive localized changes in preferential assembly within the endoplasmic 
reticulum or plasma membrane. We hypothesized that nicotine alters the assembly of α4β2 
nAChRs within the endoplasmic reticulum, and this could be detected using single 
molecule analysis of GFP-labeled nAChRs embedded in cell-derived nanovesicles isolated 
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from specific subcellular regions.  To test this hypothesis, we developed a technique to 
separate nAChRs localized to the endoplasmic reticulum or plasma membrane using an 
system of gradient centrifugation.   
 Previously discussed changes in assembly upon exposure to nicotine, cotinine, 
cytisine, varenicline, and bupropion were measured for nAChRs isolated from membranes 
throughout the whole cell. These single molecule analysis studies with GFP-labeled 
subunits, discussed above, were expanded to detect organelle specific changes in nAChR 
stoichiometry.  Once vesicles containing α4β2 nAChRs are formed, an OptiPrep gradient 
is used to separate nanovesicles derived from the membranes of the endoplasmic reticulum 
and plasma membrane.  Density gradients have previously been used to separate these 
subcellular regions, but in much larger vesicles that are incompatible with single molecule 
studies [275-278].  Nanovesicles from the endoplasmic reticulum or plasma membrane 
were generated from cells expressing α4-GFP and β2-wt subunits at nitrogen cavitation 
pressures of 250 psi or 600 psi, respectively.  A cavitation pressure of 250 psi has been 
shown to form vesicles encapsulating a single nAChR [228].  At this pressure, a negligible 
number of nanovesicles were formed from the plasma membrane.  Large fragments of 
plasma membrane could be visualized by fluorescence microscopy in the whole cell lysate 
at 250 psi, and mostly localized to the bottom fraction of the column (Figure 4.27C).  
Although fraction 1 has a higher relative number of ER-derived nanovesicles, fraction 2 at 
250 psi is chosen to avoid contamination from dense species at the bottom of the column.  
To encourage the fragmentation of the plasma membrane, cells were swollen in a hypotonic 
solution [279] prior to nitrogen cavitation at a higher pressure of 600 psi.  At 600 psi, ER-
derived nanovesicles also localized to higher density fractions (Figure 4.29B).  At this 
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pressure, PMCA containing nanovesicles localize to lower density fractions of 5, 7, and 9.  
Fraction 7 is collected for plasma membrane specific studies, to avoid contamination from 
endoplasmic reticulum derived vesicles in denser fractions.  This method effectively allows 
the isolation of organelle specific vesicles originating from the endoplasmic reticulum or 
plasma membrane. 
 Endoplasmic reticulum and plasma membrane derived nanovesicles provide a 
snapshot of nAChR assembly in each location at the time of nitrogen cavitation.  Vesicles 
from each organelle are independently spatially isolated on a glass substrate.  The 
stoichiometry of α4β2 is determined by counting single molecule bleaching steps of the 
GFP-labeled alpha subunits.  By separating nAChRs based on the membrane of origin, 
structural differences between receptors located within the endoplasmic reticulum can be 
differentiated from those on the plasma membrane. This also provides a measure of 
preferential trafficking of one stoichiometry over the other.  In addition, organelle specific 
changes in structural assembly in the presence of nicotine can be determined.  
Understanding nicotine induced structural changes on a subcellular level is crucial to 
resolving the mechanism of nicotine addiction.  Detecting a shift towards the high 
sensitivity (α4)2(β2)3 isoform within the endoplasmic reticulum suggests nicotine acts 
internally.  
Endoplasmic reticulum specific vesicles expressing α4-GFP/β2 nAChRs were 
collected from fraction 2 of the OptiPrep gradient.  Purified fractions contained single 
nAChRs that were resident in the endoplasmic reticulum at the time of nitrogen cavitation, 
now encapsulated in nanovesicles.  In the absence of a pharmacological agent, α4β2 is 
predominately assembled as (α4)3(β2)2 in the endoplasmic reticulum.  The inherent α4β2 
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stoichiometry within the endoplasmic reticulum fits a distribution of 30 ± 4% (α4)2(β2)3 
and 70 ± 4% (α4)3(β2)2.  This roughly matches estimates based on whole cell functional 
measurements [154, 167, 233].  This is not surprising, since ligand binding studies have 
indicated 85% of [3H]-epibatidine binding sites are intracellular [195].  The higher ratio of 
α4β2 nAChRs with (α4)3(β2)2 within the endoplasmic reticulum could be related to a 
higher stability of α4 subunits compared to β2 subunits.  It has been proposed that 
unassembled β2 subunits are degraded more rapidly than α4 subunits within the 
endoplasmic reticulum [154]. 
Once cells are exposed to nicotine, single molecule bleaching step analysis shows 
this distribution is shifted to 55 ± 4% (α4)2(β2)3 and 45 ± 5% (α4)3(β2)2 within the 
endoplasmic reticulum.  Based on the 95% confidence intervals, the fraction of α4β2 
present in the high sensitivity (α4)2(β2)3 stoichiometry is significantly increased when 
nicotine is present.  This is the first structural evidence showing a distinct change in α4β2 
assembly to favor the (α4)2(β2)3 isoform directly within the endoplasmic reticulum.  This 
finding strongly supports the theory that nicotine acts as a pharmacological chaperone to 
stabilize the (α4)2(β2)3 version, as nicotine clearly causes an intracellular change in the 
assembly of α4β2.  Previous structural investigations have been limited to measuring α4 
and β2 subunits in close proximity by FRET [151].  This finding also correlates with bulk 
measurements detecting an increase in the amount of β2 subunit compared to α4 subunit 
[153, 154, 258, 259].  These single molecule bleaching step analysis studies directly 
measure a change in the assembly of pentameric nAChRs in the presence of nicotine for 
explicit structural determination of α4β2 within the endoplasmic reticulum for the first 
time.    
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Plasma membrane specific nanovesicles formed from cells expressing α4-GFP/β2 
were collected from fraction 7 of the OptiPrep gradient.  The purified fraction contains 
single α4β2 nAChRs encapsulated in nanovesicles formed from the plasma membrane at 
the time of nitrogen cavitation.  In the absence of a pharmacological agent, α4β2 on the 
plasma membrane slightly favors (α4)2(β2)3 stoichiometry.  The intrinsic α4β2 
stoichiometry on the plasma membrane fits a distribution of 56 ± 3% (α4)2(β2)3 and 44 ± 
4% (α4)3(β2)2.  This is the first study to show a distribution of α4β2 stoichiometry 
exclusively on the plasma membrane.  Based on 95% confidence intervals, this is a 
significantly different assembly than the inherent α4β2 distribution of 30 ± 4% (α4)2(β2)3 
and 70 ± 4% (α4)3(β2)2 within the endoplasmic reticulum.  This suggests that (α4)2(β2)3 is 
preferentially located on the plasma membrane.  Preferential trafficking of this isoform to 
the plasma membrane could account for this difference in subcellular localization.  Another 
possibility is an increased stability, or decreased internalization, of (α4)2(β2)3 on the plasma 
membrane. 
Upon exposure to nicotine, the distribution of α4β2 on the plasma membrane is 
shifted further towards the high sensitivity version.  When nicotine is present, plasma 
membrane resident α4β2 fits a 70 ± 2% (α4)2(β2)3 and 30 ± 4% (α4)3(β2)2 distribution.  This 
is a significant increase in (α4)2(β2)3 on the plasma membrane in the presence of nicotine 
compared to 56 ± 3% (α4)2(β2)3 and 44 ± 4% (α4)3(β2)2 in the absence of a 
pharmacological agent, based on the 95% confidence intervals.  This is the first structural 
study showing a distribution of α4β2 assembly favoring the (α4)2(β2)3 isoform exclusively 
on the plasma membrane upon exposure to nicotine.  The increase in (α4)2(β2)3 on the PM 
when nicotine is present is likely the result of an increase in this isoform within the ER, 
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combined with the increase in trafficking towards the PM.  However, this is significant 
because it shows a higher fraction of α4β2 on the plasma membrane will functionally 
respond to lower levels of nicotine, thus increasing α4β2 sensitivity.  A shift towards the 
high sensitivity (α4)2(β2)3 isoform on the plasma membrane may account for signaling 
changes measured in tobacco users. 
The increase in assembly of (α4)2(β2)3 within the endoplasmic reticulum provides 
a molecular basis for upregulation measured at the plasma membrane.  In the absence of a 
pharmacological agent, the majority of α4β2 nAChRs within the endoplasmic reticulum 
are assembled in the low sensitivity (α4)3(β2)2 version.  However, the high sensitivity 
(α4)2(β2)3 isoform is inherently preferentially trafficked to the plasma membrane.  Upon 
the addition of nicotine, the structural assembly of α4β2 is altered intracellularly within the 
endoplasmic reticulum to favor the high sensitivity (α4)2(β2)3 isoform.  Since this 
stoichiometry is intrinsically preferentially trafficked to the plasma membrane, the increase 
in (α4)2(β2)3 within the endoplasmic reticulum results in an increase in trafficking towards 
the plasma membrane.  The net result is an upregulation of (α4)2(β2)3, both within the 
endoplasmic reticulum and on the plasma membrane.  These shifts in stoichiometry within 
each subcellular location upon the addition of nicotine are summarized in Figure 5.1.  This 
is the first study to show subcellular differences in stoichiometry of α4β2, as well as a shift 
towards the high sensitivity version within the ER when nicotine is present. 
 
 
 
Copyright © Ashley Mae Loe 2016 
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Figure 5.1 Nicotine alters assembly within the ER and increases trafficking to the 
PM. When no nicotine is present, the α4β2 favors the (α4)3(β2)2 stoichiometry in the 
ER. However, the (α4)2(β2)3 version is preferentially trafficked to the PM. Upon 
exposure to nicotine, assembly is shifted within the ER towards (α4)2(β2)3 isoform.  
Increased trafficking when nicotine is present increases the fraction of (α4)2(β2)3 on 
the PM.  Error bars are 95% confidence intervals. 
   
167 
 
CHAPTER 6: CONCLUSION 
  
This dissertation exploits and expands novel fluorescence microscopy techniques 
to progress the understanding of the mechanism of nicotine induced upregulation in order 
to identify target nAChR structures for the development of smoking cessation therapeutics.   
Changes in nAChR number, stoichiometry, and trafficking are well-established 
consequences of exposure to nicotine [51, 55, 97, 161, 198], yet a full mechanism for this 
upregulation has not been determined.  An intracellular process is believed to be 
responsible for these changes in expression, but definitive evidence of a shift in assembly 
within the endoplasmic reticulum had not been detected prior to this study.   
In this work, cutting edge methodologies are developed and employed to pinpoint 
distinct changes in localization, assembly, export, vesicle trafficking and stoichiometry in 
order to further understand the physiology of these receptors.  In this work, drug induced 
changes in trafficking and expression of SEP-labeled nAChRs were measured using TIRF 
microscopy.  This technique is complementary to traditional methods of nAChR detection, 
offering particular advantages for analysis of receptors located near the plasma membrane. 
The majority of nAChR are thought to be intracellular [195], yet functional consequences 
of nAChR upregulation occur upon insertion into the plasma membrane.  Quantification of 
trafficking and distribution effects upon exposure to a ligand are made possible with this 
imaging technique.  A combination of pH sensitive fluorophores and TIRF microscopy 
enables the differentiation of nAChRs inserted into the plasma membrane, compared to 
those resident in the peripheral endoplasmic reticulum.  For this reason, relative numbers 
of nAChR located on the plasma membrane (PMID), as well as trafficking features such 
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as percentage of nAChRs on the plasma membrane (% PM) and single vesicle insertion 
events can be resolved.   
Although chronic nicotine exposure upregulates and alters the assembly of α4β2 
nAChRs [51, 97, 161, 235], the effects of nicotine metabolites on nAChR assembly and 
trafficking are not well studied.  In this work, N2a cells were exposed to physiologically 
relevant concentrations of cotinine, centered around the average reported concentrations of 
cotinine in the blood and brain of an average smoker [29, 241, 242].  Measuring α4-SEP/β2 
nAChRs with TIRF microscopy shows that cotinine upregulates the expression and 
distribution of α4β2 towards the plasma membrane.  This suggests that cotinine could 
potentially contribute to α4β2 upregulation measured in smokers, since this effect is seen 
at concentrations of cotinine even lower than estimated to be found in the brain [26].  
Cotinine also increases the number of insertion events of single vesicles carrying α4β2 
nAChRs.  The increase in insertion events, in addition to an increase in % PM, suggests 
that cotinine influences trafficking of α4β2.  Similar to nicotine, incorporation of α5 into 
the α4β2 pentamer results in a loss of cotinine induced upregulation.  However, the SEP-
based studies reveal that when α5 has a single nucleotide polymorphism, D398N, a higher 
percentage of α4β2α5-D398N are found on the plasma membrane compared to α4β2α5D.  
This increase is independent of either nicotine or cotinine exposure.  Neither drug appears 
to affect expression or trafficking of α3β4 upon exposure to physiologically relevant 
concentrations.  Interestingly, α6β2β3 shows a concentration dependent downregulation in 
the presence of 500 nM cotinine [227].  This is an opposite effect as seen with nicotine, 
which has been shown to upregulate α6β2β3 at low physiological concentrations (50 nM), 
while downregulating at higher concentrations (500 nM) [115]. 
   
169 
 
Our lab recently developed a novel technique to spatially isolate membrane proteins 
by encapsulation in vesicles formed from endogenous cell membranes [228].  This nitrogen 
cavitation based fragmentation method isolates single nAChRs in their endogenous cellular 
environment.  Individual nAChRs embedded in nanovesicles can then be spatially isolated 
on a glass surface and imaged with TIRF microscopy.  Single step photobleaching of GFP 
molecules within α4 subunits is used to identify the number of α4-GFP subunits in each 
nAChR, and thus the stoichiometry.  This novel method is used to determine that cotinine, 
the primary metabolite of nicotine, also shifts the assembly of α4β2.  Upon exposure to 1 
μM cotinine, the stoichiometry of α4β2 is shifted to favor the high sensitivity (α4)2(β2)3 
isoform.  Exposure to nicotine also favors this stoichiometry, causing an overall shift from 
the preferentially expressed low sensitivity version in the absence of a pharmacological 
agent.  This method primarily detects intracellular nAChRs, meaning these changes are 
likely to be internal. 
Parallel effects in the presence of cotinine and nicotine suggest it is possible that 
cotinine-induced upregulation of α4β2 results from a similar mechanism as nicotine, 
potentially acting inside the cell by binding immature subunits to enhance the maturation 
and stabilization of nAChRs [76, 160].  Cotinine increases expression and trafficking of 
α4β2, as well as alters the assembly to favor the high sensitivity (α4)2(β2)3 version.  
Cotinine has a longer half-life and higher sustained concentration than nicotine in the 
human body.  It is possible that variations in the concentration of cotinine resulting from 
gene variation and clearance rates in different ethnicities could account for some 
differences in rates of nicotine addiction.   
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Many current smoking cessation agents are typically ligands of the α4β2* nAChR 
subtype.  Cytisine and varenicline, both partial agonists of α4β2, have previously been 
shown to increase the number of α4β2 nAChRs on the plasma membrane [176, 178, 210, 
238, 258].  SEP-labeled α4β2 is used to show both of these drugs also increase the 
distribution of α4β2 towards the plasma membrane, as well as increase the integrated 
density on the plasma membrane.  This suggests trafficking of α4β2 is increased in addition 
to expression on the plasma membrane.   By encapsulating a single α4-GFP/β2 nAChR in 
a nanovesicle derived from a cell exposed to cytisine or varenticline, single molecule 
photobleaching is used to show both drugs alter the assembly of α4β2.  The effect of 
bupropion, a noncompetitive antagonist of α4β2, on expression is evaluated for the first 
time in this SEP-based study.  Bupropion is shown to upregulate the number of α4β2 
nAChRs on the plasma membrane, and alters the distribution of these nAChRs towards the 
plasma membrane.  Bupropion also alters the stoichiometric distribution of α4β2 nAChRs 
to favor the high sensitivity (α4)2(β2)3 version, as shown by single molecule analysis of 
GFP-labeled α4 subunits in α4β2.  Although bupropion is not specific for nAChRs, it is 
able to upregulate the number of α4β2 on the plasma membrane and affect the subcellular 
distribution.  Overall, a variety of pharmacological agents with various binding properties 
induce upregulation of nAChRs.  The shift in α4β2 assembly suggests these ligands 
penetrate the cell membrane and interact with nascent nAChRs, potentially as a 
pharmacological chaperone.  It is possible that intracellular binding and stabilization of 
nAChRs promotes upregulation.  On a broader scale, smoking cessation agents causing 
upregulation of α4β2, similar to nicotine, could explain why these agents have not been 
tremendously successful in aiding smoking cessation.  It is possible that current drugs only 
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maintain a steady upregulated expression of α4β2 as seen in tobacco users.  Understanding 
how existing therapeutics alter trafficking and structural assembly of α4β2 provides the 
framework required to develop more effective cessation therapeutics.  If these changes 
occur intracellularly, future therapeutically relevant pharmacological agents may be able 
to target intracellular processes. 
Nicotine and other ligands are thought to induce upregulation by permeating cell 
membranes and interacting with intracellular receptors.  However, a lack of existing 
techniques that are capable of directly quantifying subcellular specific structural assembly 
of nAChRs has prohibited the detection of these changes specifically within the 
endoplasmic reticulum.  In this work, a technique was developed to separate nAChRs 
localized to the endoplasmic reticulum from those localized to the plasma membrane.  
Individual nAChRs embedded in a nanoscale vesicle formed from the original ER or PM 
membranes are separated on a density gradient.  Endoplasmic reticulum and plasma 
membrane derived nanovesicles provide a snapshot of nAChR assembly in each location 
at the time of nitrogen cavitation.  In addition, organelle specific changes in structural 
assembly in the presence of nicotine can be determined.  Understanding nicotine induced 
structural changes on a subcellular level is crucial to resolving the mechanism of nicotine 
addiction.   
 ER-derived nanovesicles expressing α4-GFP/β2 are used to show that in the 
absence of a pharmacological agent, α4β2 is predominately assembled as (α4)3(β2)2 in the 
endoplasmic reticulum.  The higher ratio of α4β2 nAChRs with (α4)3(β2)2 within the ER 
could be related to a higher stability of α4 subunits compared to β2 subunits.  Once cells 
are exposed to nicotine, this distribution is shifted to favor the high sensitivity (α4)2(β2)3 
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isoform within the endoplasmic reticulum.  This is the first structural evidence showing a 
distinct change in α4β2 assembly to favor the (α4)2(β2)3 isoform directly within the 
endoplasmic reticulum.  This finding strongly supports the theory that nicotine acts as a 
pharmacological chaperone, as nicotine clearly causes an intracellular change in the 
assembly of α4β2.   
PM-derived vesicles reveal α4β2 slightly favors (α4)2(β2)3 stoichiometry on the 
plasma membrane, even in the absence of a pharmacological agent.  This is the first study 
to show a distribution of α4β2 stoichiometry exclusively on the plasma membrane.  This 
suggests that (α4)2(β2)3 is preferentially trafficked to the plasma membrane.  Upon addition 
of nicotine, the distribution of α4β2 on the plasma membrane is shifted further towards the 
high sensitivity isoform.  This is the first structural study showing a distribution of α4β2 
assembly favoring the (α4)2(β2)3 isoform on the plasma membrane in the presence of 
nicotine.  The significance of this finding lies in the possible functional consequences of 
an increase in α4β2 sensitivity on the plasma membrane when nicotine is present.  The 
increase in the high sensitivity (α4)2(β2)3 isoform on the plasma membrane could account 
for differences in nAChR activation measured in tobacco users. 
The work in this dissertation provides strong evidence that nicotine, and other 
upregulating ligands, induce intracellular changes in nAChRs.  Nicotine, and its primary 
metabolite cotinine, increase the distribution of α4β2 towards the plasma membrane and 
increase the number of vesicles carrying α4β2 being inserted into the plasma membrane. 
Both also increase the assembly of the (α4)2(β2)3 isoform throughout the cell.  Current 
smoking cessation agents acting as partial agonists or noncompetitive antagonists induce 
changes in expression, trafficking, and assembly of α4β2.  Organelle specific studies show 
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the shift in (α4)2(β2)3 assembly in the presence of nicotine occurs within the endoplasmic 
reticulum.  An increase in the ratio of α4β2 with (α4)2(β2)3 is also found on the plasma 
membrane when nicotine is present.   
These studies provide structural evidence for the pharmacological chaperoning 
theory of upregulation, suggesting a ligand permeates cell membranes and interacts with 
nAChRs within the endoplasmic reticulum to increase the stability and therefore assembly 
of nAChR pentamers.  An intracellular mechanism of upregulation has important 
implications in the discovery of therapeutics targeting nAChRs, since intracellular regions 
and processes can also be targeted instead of focusing solely on the plasma membrane.  
This is directly related to the development of more effective smoking cessation 
therapeutics.  An internal mechanism of upregulation could also explain an inverse 
correlation between the history of smoking and developing Parkinson’s disease [155, 196, 
280-282].  Understanding an intracellular mechanism for nicotine addiction level is 
important to the development of nAChRs as drug targets for a variety of neurological 
disorders including Alzheimer’s disease, Parkinson’s disease, ADHD, epilepsy, and 
schizophrenia, as well as tobacco addiction [59-65]. 
The technique developed in this dissertation to isolate endoplasmic reticulum and 
plasma membrane derived nanovesicles can be expanded to study assembly and trafficking 
in a variety of classes of membrane proteins.  For example, this technique is currently being 
employed in our lab to investigate changes in the trafficking of the cystic fibrosis 
transmembrane conductance regulator (CFTR) channel in the presence of current 
therapeutics.  Ideally, this technique will impact and advance research related to any 
   
174 
 
membrane protein that varies in expression between the endoplasmic reticulum and plasma 
membrane.  
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APPENDIX: LIST OF ABBREVIATIONS 
 
% PM – Percent Plasma Membrane 
ACh – Acetylcholine 
Bup – Bupropion  
Cot – Cotinine  
Cyt – Cytisine  
DPSS- Diode-Pumped Solid State  
EC50 – Half Maximal Effective Concentration 
ECS – Extracellular Solution  
EMCCD – Electron Multiplying Charge Transfer Device 
ER – Endoplasmic Reticulum 
ERES – Endoplasmic Reticulum Exit Site 
fMRI – Functional Magnetic Resonance Imaging 
FRET – Förster Resonance Energy Transfer 
GABA – γ-Aminobutryic Acid 
GFP – Green Fluorescent Protein 
HEK-293T – Human Embryonic Kidney-293T 
ID – Integrated Density 
N2a – Neuroblastoma 
nAChR – Nicotinic Acetylcholine Receptor 
Nic – Nicotine  
PBS – Phosphate Buffered Saline 
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PET – Positron Emission Tomography 
PM – Plasma Membrane  
PMCA – Plasma Membrane Calcium ATPase 
PMID – Plasma Membrane Integrated Density 
SNc – Substantia Nigra Pars Compacta 
SNr – Substantia Nigra Pars Reticulata 
SEM – Standard Error of the Mean 
SEP – Super-Ecliptic Phluorin 
TIRF – Total Internal Reflection Fluorescence 
TIRFM – Total Internal Reflection Fluorescence Microscopy 
TM – Transmembrane 
Var – Varenicline  
VTA – Ventral Tegmental Area 
Wt – wild type 
5-HT3 – 5-hydroxytryptamine 
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